Details of Disease

General Information of Disease (ID: DISN6V4S)

• Disease Name: Lymphoma
• Synonyms: MLYM; lymphoid cancer; lymphoma (Hodgkin and non-Hodgkin); lymphomatous; malignant lymphoma; lymphoma, malignant; lymphoma; lymphoma (Hodgkin's and non-Hodgkin's)
• Disease Class: 2A80-2A86: Lymphoma
• Definition: A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.|This is potentially too broad as well as overlaps with leukemia and should be obsoleted.
• Disease Hierarchy:
  DISSHRIL: Lymphoid hemopathy
  DIS9S8BC: Lymphoid neoplasm
  DISN6V4S: Lymphoma
• ICD Code:
  ICD-11: ICD-11: 2A80-2A86
  ICD-10: ICD-10: C81-C86
  ICD-9: ICD-9: 202
  Expand ICD-9: 202
• Disease Identifiers:
  MONDO ID: MONDO_0005062
  MESH ID: D008223
  UMLS CUI: C0024299
  MedGen ID: 44223
  HPO ID: HP:0002665
  Orphanet ID: 223735
  SNOMED CT ID: 1163043007

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 7 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
CDX-011	DM61FK3	Approved	NA	[1]
Cyclophosphamide	DM4O2Z7	Approved	Small molecular drug	[2]
Erdafitinib	DMI782S	Approved	NA	[3]
Pegfilgrastim	DM7UP8X	Approved	Small molecular drug	[4]
Ragweed allergy vaccine sublingual	DMMQIYX	Approved	NA	[5]
Ublituximab	DMHTY9W	Approved	Antibody	[6]
HIF-1alpha	DM4OQRD	Phase 4	Small molecular drug	[7]

This Disease is Treated as An Indication in 144 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Angiotensin-(1-7)	DM76GZ0	Phase 3	Small molecular drug	[8]
AT-406	DMVJW0S	Phase 3	Small molecular drug	[9]
Atacicept	DM8GFEV	Phase 3	NA	[10]
Dasiprotimut-T	DMN9VKM	Phase 3	NA	[11]
Fenretinide	DMRD5SP	Phase 3	Small molecular drug	[12]
INCB24360	DMIJGT9	Phase 3	Small molecular drug	[12]
ISS-1018	DMX3WN2	Phase 3	NA	[13]
PDR001	DM53J6B	Phase 3	Antibody	[14]
RRx-001	DMQM2FH	Phase 3	Small molecular drug	[15]
RUBOXISTAURIN HYDROCHLORIDE	DMQOCD8	Phase 3	NA	[16]
Toca 511/Toca FC	DM65FF6	Phase 3	NA	[12]
Zanolimumab	DMKB4ZY	Phase 3	Antibody	[17]
Ad-IFNg	DMF31GH	Phase 2	NA	[18]
ADCT-301	DMY78E0	Phase 2	NA	[14]
AFM13	DMN45IC	Phase 2	Antibody	[12]
ASN002	DM92X7N	Phase 2	NA	[12]
ASTX660	DMMKW8L	Phase 2	NA	[12]
Baltaleucel-T	DM3WCL4	Phase 2	NA	[14]
Birinapant	DM6PBUM	Phase 2	Small molecular drug	[19]
BMS-906024	DMEYR4K	Phase 2	Small molecular drug	[20]
CAR-T cells targeting CD22	DM6XN4C	Phase 2	CAR T Cell Therapy	[21]
CAR-T cells targeting CD30	DML0KWM	Phase 2	CAR T Cell Therapy	[21]
CC-90011	DM0EDHJ	Phase 2	Small molecular drug	[22]
CI-1033	DMSI8N3	Phase 2	Small molecular drug	[23]
CMD-003	DMLRIIP	Phase 2	NA	[24]
CP-724714	DMUJ0W7	Phase 2	Small molecular drug	[25]
CX-072	DMVZT2I	Phase 2	Antibody	[12]
EFT508	DMX6RZG	Phase 2	NA	[12]
ERC-1671	DMKJ7WA	Phase 2	NA	[26]
Galiximab	DMTXCUS	Phase 2	Antibody	[27]
GSK2141795	DMSHE70	Phase 2	Small molecular drug	[28]
INDISULAM	DM9SX6Y	Phase 2	Small molecular drug	[29]
Iratumumab	DMI874B	Phase 2	Antibody	[30]
L19-IL-2 fusion protein	DMI2XP1	Phase 2	Antibody	[31]
Lucatumumab	DMY2L7V	Phase 2	Monoclonal antibody	[32]
ME-401	DMK0UOY	Phase 2	Small molecular drug	[12]
Minjuvi	DMD725X	Phase 2	Antibody	[33]
Mitumprotimut-t	DM70117	Phase 2	NA	[34]
MK-1454	DMEDITW	Phase 2	NA	[12]
ONC201	DMM5SCF	Phase 2	NA	[12]
Pelitinib	DMIW453	Phase 2	Small molecular drug	[35]
SHAPE	DMIQB13	Phase 2	NA	[36]
Siplizumab	DM75RFJ	Phase 2	Antibody	[37]
TAK-850	DMYDAD6	Phase 2	NA	[38]
TRU-015	DMHEWT7	Phase 2	NA	[39]
Anti-BCMA-CAR-transduced T cells	DMZ18IO	Phase 1/2	CAR T Cell Therapy	[40]
Anti-CD19 CAR transduced T cells	DMHSLVJ	Phase 1/2	CAR T Cell Therapy	[41]
Anti-CD19 CAR-T cells	DM1EH9D	Phase 1/2	CAR T Cell Therapy	[42]
Anti-CD20-CAR-transduced T cells	DMXMK30	Phase 1/2	CAR T Cell Therapy	[43]
Anti-CD22 CAR-T cells	DMY6U8R	Phase 1/2	CAR T Cell Therapy	[42]
Anti-CD22-CAR-transduced T cells	DMTO9VF	Phase 1/2	CAR T Cell Therapy	[44]
Anti-CD30 CAR T cells	DM8139V	Phase 1/2	CAR T Cell Therapy	[45]
Anti-CD30-CAR-transduced T cells	DMTZSPJ	Phase 1/2	CAR T Cell Therapy	[46]
CAR-T cells targeting BCMA	DMENIQ7	Phase 1/2	CAR T Cell Therapy	[21]
CAR-T cells targeting CD19	DMIM9TZ	Phase 1/2	CAR T Cell Therapy	[21]
CAR-T cells targeting CLL1	DMCPM92	Phase 1/2	CAR T Cell Therapy	[21]
CAR.CD30 cells	DM6ZXWY	Phase 1/2	CAR T Cell Therapy	[47]
CD19 and CD22 CAR-T Cells	DM581CS	Phase 1/2	CAR T Cell Therapy	[48]
CD19-directed CAR-T cells	DMKQRUJ	Phase 1/2	CAR T Cell Therapy	[49]
CD20-Specific CAR T Cells	DMHPZ8G	Phase 1/2	CAR T Cell Therapy	[50]
CD22-Targeted CAR-T cells	DM61MBG	Phase 1/2	CAR T Cell Therapy	[51]
Chimeric Antigen Receptor Modified T cells Targeting CD19	DMHNFXR	Phase 1/2	CAR T Cell Therapy	[52]
CHR-3996	DMIXPNG	Phase 1/2	Small molecular drug	[53]
EBV CTLs	DMH2361	Phase 1/2	NA	[54]
EBV-targeted autologous T-cell therapy	DMUUWB9	Phase 1/2	NA	[55]
Ferritarg P	DMRHOFB	Phase 1/2	Antibody	[56]
G1	DMTV42K	Phase 1/2	Small molecular drug	[57]
HA20	DMDZO9Y	Phase 1/2	NA	[58]
INCB40093	DMED9QV	Phase 1/2	Small molecular drug	[59]
LY3039478	DMC5SAW	Phase 1/2	Small molecular drug	[60]
RGX-104	DM5AIKR	Phase 1/2	NA	[12]
SCRI-huCAR19v1	DMS1NMO	Phase 1/2	CAR T Cell Therapy	[61]
Tractinostat	DM8D2LC	Phase 1/2	NA	[12]
4SC-205	DMG75P3	Phase 1	NA	[62]
ABI-011	DM1KD7U	Phase 1	NA	[12]
AEZS-112	DMMNOR4	Phase 1	NA	[63]
AG-270	DMYTJG7	Phase 1	NA	[12]
Anti-BCMA CAR-T cells	DMK25QD	Phase 1	CAR T Cell Therapy	[64]
Anti-CD123 CAR-T cells	DMYIZFW	Phase 1	CAR T Cell Therapy	[64]
Anti-CD19 anti-CD20 Bispecific CAR-T	DMCABUR	Phase 1	CAR T Cell Therapy	[65]
Anti-CD19 CAR-T cell therapy	DMB7JS4	Phase 1	NA	[12]
Anti-CD19 CAR-T cells	DMUQ3C1	Phase 1	CAR T Cell Therapy	[64]
Anti-CD19-CAR T	DMMRANJ	Phase 1	CAR T Cell Therapy	[66]
Anti-CD30 CAR-T cells	DMTK78L	Phase 1	CAR T Cell Therapy	[64]
Anti-CD30-CAR T cells	DM2IEB7	Phase 1	CAR T Cell Therapy	[67]
Anti-CD45 mabs	DMZ2D0G	Phase 1	Antibody	[68]
Anti-CD7 CAR-T cells	DMMFL2P	Phase 1	CAR T Cell Therapy	[64]
AR-12	DM4RK6P	Phase 1	Small molecular drug	[69]
ARI-0001 cells	DMPLHBI	Phase 1	CAR T Cell Therapy	[70]
ATLCAR.CD30 cells	DMZI4UX	Phase 1	CAR T Cell Therapy	[71]
ATLCAR.CD30.CCR4 cells	DM3IPSX	Phase 1	CAR T Cell Therapy	[71]
Autologous cancer vaccine	DMVZ5VE	Phase 1	NA	[72]
Autologous idiotypic cancer vaccine	DMCYYYD	Phase 1	NA	[73]
AvidinOx	DMCM83R	Phase 1	NA	[12]
BAY1895344	DML781M	Phase 1	NA	[12]
CA-170	DMOUHR4	Phase 1	Small molecule immunotherapy	[12]
CA-4948	DMWV8C6	Phase 1	NA	[12]
CAR-T cells targeting CD19	DMJK1R0	Phase 1	CAR T Cell Therapy	[74]
CART-19 autologous T-cells	DMY218P	Phase 1	CAR T Cell Therapy	[75]
CC-122	DM0SRAN	Phase 1	Small molecular drug	[12]
CD19+ CAR T Cells	DMGUQ8V	Phase 1	CAR T Cell Therapy	[76]
CDX-1127	DMPVUGE	Phase 1	NA	[77]
CUDC427	DM2LNDV	Phase 1	NA	[78]
CYC065	DM9ODT6	Phase 1	NA	[12]
CZ-48	DMAY6X2	Phase 1	Small molecular drug	[12]
Daniquidone	DMWT5RS	Phase 1	Small molecular drug	[79]
DS-3078	DMG7I5J	Phase 1	NA	[80]
FF-10502-01	DMX5290	Phase 1	NA	[12]
FT596	DMINC05	Phase 1	Cell therapy	[81]
GDC-0425	DMDZ26X	Phase 1	NA	[82]
GS-9820	DMNX3US	Phase 1	NA	[83]
GSK2126458	DMM7ZXR	Phase 1	Small molecular drug	[84]
GWN323	DM2L2K0	Phase 1	NA	[12]
GZ17-6.02	DMVUZE6	Phase 1	NA	[85]
HMPL-689	DMEGN5I	Phase 1	Small molecular drug	[86]
HuCART19	DMNAR29	Phase 1	CAR T Cell Therapy	[87]
IC9-CAR19 T cells	DMNCBIU	Phase 1	CAR T Cell Therapy	[88]
IMC-002	DMWSI04	Phase 1	Antibody	[89]
L-778123	DMWSC5L	Phase 1	Small molecular drug	[90]
LMP-1/LMP-2 CTLs	DMZU2G1	Phase 1	NA	[91]
LMP400	DM4FW2E	Phase 1	Small molecular drug	[92]
MCLA-145	DM8CGUV	Phase 1	Antibody	[93]
MK-2118	DMKNH8B	Phase 1	Small molecular drug	[12]
mRNA-2416	DMFTAWU	Phase 1	mRNA therapy	[12]
OT-82	DMI24RF	Phase 1	Small molecular drug	[94]
Patient-derived CD19- and CD22 specific CAR	DMZSD3T	Phase 1	CAR T Cell Therapy	[95]
PG11047	DMXUU53	Phase 1	NA	[96]
RG7741	DMK6P9J	Phase 1	NA	[97]
RPTR-147	DMPCGY3	Phase 1	Cell therapy	[98]
SEA-CD40	DM9OVYK	Phase 1	NA	[12]
SGN-CD30C	DMKW10G	Phase 1	Antibody drug conjugate	[99]
SNX281	DMCGPU8	Phase 1	Small molecular drug	[100]
Sym021	DMVXLS5	Phase 1	Monoclonal antibody	[12]
Sym022	DMCK2YR	Phase 1	Antibody	[101]
Sym023	DMV3L62	Phase 1	Antibody	[102]
SYNB1891	DMZJNHM	Phase 1	NA	[103]
Teglarinad	DMJ3Y9A	Phase 1	Small molecular drug	[104]
TJC4	DMLUOVS	Phase 1	Antibody	[105]
TTI-622	DMOCQ4K	Phase 1	Recombinant protein	[106]
TTX-030	DM8H2AG	Phase 1	Antibody	[107]
UNBS-5162	DM4OS15	Phase 1	Small molecular drug	[108]
VMD-928	DM4AXPT	Phase 1	Small molecular drug	[109]
Xmab-2513	DM6V0KY	Phase 1	Antibody	[110]
CD19-targeted CAR-T cells	DMLPAFG	Clinical trial	CAR T Cell Therapy	[111]

This Disease is Treated as An Indication in 9 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
LymphoScan	DMH253M	Discontinued in Phase 3	Small molecular drug	[112]
IdioVax	DMJF1ZM	Discontinued in Phase 2	NA	[113]
IPH-1101	DMEKRVZ	Discontinued in Phase 2	NA	[114]
Beta LT	DM3U2DL	Discontinued in Phase 1/2	Small molecular drug	[115]
GSK1059615	DMI6KQM	Discontinued in Phase 1	Small molecular drug	[116]
LymphoRad-131	DMDUM0Z	Discontinued in Phase 1	NA	[117]
N-1177-inh	DMCJI5P	Discontinued in Phase 1	NA	[118]
RG7602	DMXJAFC	Discontinued in Phase 1	NA	[119]
FAV-201	DMFL3PB	Terminated	NA	[120]

This Disease is Treated as An Indication in 7 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Anti-CD20 engineered toxin bodies	DMEHRKA	Investigative	NA	[121]
BP-100-1.02	DMGEYFB	Investigative	Antisense drug	[122]
CEP-18050	DMCIOSM	Investigative	NA	[123]
ETI-210	DMZDW16	Investigative	NA	[124]
MKC-242844	DMUWSYR	Investigative	NA	[124]
MLN-0905	DMTU0IG	Investigative	Small molecular drug	[125]
NVP-TAE684	DMFZXI2	Investigative	Small molecular drug	[126]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 366 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
AICDA	TTKRTP6	Limited	Altered Expression	[128]
AMD1	TTBFROQ	Limited	Genetic Variation	[129]
ANXA8	TTSW16P	Limited	Altered Expression	[130]
APOBEC3G	TTP96KH	Limited	Altered Expression	[131]
ATIC	TT9NVXQ	Limited	Genetic Variation	[132]
BIRC3	TTAIWZN	Limited	Altered Expression	[133]
BTG1	TTL7N2W	Limited	Biomarker	[134]
BUB1	TT78309	Limited	Genetic Variation	[135]
CASP5	TTWR48J	Limited	Genetic Variation	[136]
CASP7	TTM7Y45	Limited	Genetic Variation	[137]
CCL17	TTMPHAE	Limited	Biomarker	[138]
CCR4	TT7HQD0	Limited	Genetic Variation	[139]
CCR6	TTFDB30	Limited	Altered Expression	[140]
CD19	TTW640A	Limited	Biomarker	[141]
CD3E	TTZAT79	Limited	Biomarker	[142]
CD3G	TTV3XPL	Limited	Genetic Variation	[143]
CD40	TT1ERKL	Limited	Altered Expression	[144]
CD52	TTQT5S9	Limited	Altered Expression	[145]
CDC25A	TTLZS4Q	Limited	Biomarker	[146]
CDK1	TTH6V3D	Limited	Biomarker	[147]
CDK9	TT1LVF2	Limited	Biomarker	[148]
CETP	TTFQAYR	Limited	Altered Expression	[149]
CR1	TTEA8OW	Limited	Biomarker	[150]
CSNK2A2	TT7GR5W	Limited	Biomarker	[151]
CTCFL	TTY0RZT	Limited	Genetic Variation	[152]
CXCL11	TTWG0RE	Limited	Biomarker	[153]
DNASE1	TTYWGOJ	Limited	Biomarker	[154]
EIF4EBP1	TTKGEBL	Limited	Biomarker	[155]
EIF5A	TTIVCNR	Limited	Biomarker	[129]
F9	TTFEZ5Q	Limited	Genetic Variation	[156]
FCGR2A	TTXT21W	Limited	Genetic Variation	[157]
FCGR2B	TT5RWKQ	Limited	Biomarker	[158]
FCGRT	TTKLPHO	Limited	Genetic Variation	[159]
FES	TTLBY21	Limited	Biomarker	[160]
FKBP1A	TTMW94E	Limited	Biomarker	[161]
FTH1	TT975ZT	Limited	Biomarker	[162]
FYN	TT2B9KF	Limited	Genetic Variation	[163]
GUCY2D	TTWNFC2	Limited	Biomarker	[164]
HBB	TTM6HK1	Limited	Biomarker	[165]
HEXA	TTJI5JW	Limited	Genetic Variation	[166]
HMBS	TTT0HW3	Limited	Genetic Variation	[143]
ID1	TTBXVDE	Limited	Altered Expression	[167]
IKZF2	TTKT5NV	Limited	Altered Expression	[168]
IKZF3	TTCZVFZ	Limited	Altered Expression	[168]
IL4	TTLGTKB	Limited	Biomarker	[169]
IL7	TT8FRMO	Limited	Biomarker	[170]
ITGAL	TT48WR6	Limited	Biomarker	[171]
JAK2	TTRMX3V	Limited	Biomarker	[172]
KCNA3	TTY3UE6	Limited	Biomarker	[173]
KDM4C	TTV8CRH	Limited	Biomarker	[174]
KLRC1	TTC4IMS	Limited	Genetic Variation	[175]
KRAS	TTM8FR7	Limited	Biomarker	[176]
LAMP1	TTC214J	Limited	Altered Expression	[177]
LCK	TT860QF	Limited	Biomarker	[178]
LMO2	TTFX379	Limited	Altered Expression	[179]
LYN	TT1RWNJ	Limited	Altered Expression	[180]
MALT1	TTCI81G	Limited	Altered Expression	[181]
MAP3K14	TT4LIAC	Limited	Biomarker	[182]
MAP3K19	TTRHJA3	Limited	Genetic Variation	[183]
MAP4K4	TT6NI13	Limited	Biomarker	[182]
MCL1	TTL53M6	Limited	Altered Expression	[184]
MDM2	TT9TE0O	Limited	Biomarker	[185]
MDM4	TT9OUDQ	Limited	Altered Expression	[186]
MLH1	TTISG27	Limited	Genetic Variation	[187]
MME	TT5TKPM	Limited	Biomarker	[188]
MPL	TTIHYA4	Limited	Altered Expression	[189]
MS4A1	TTUE541	Limited	Biomarker	[190]
MYB	TT8V13P	Limited	Biomarker	[191]
MYCBP	TTVW4XU	Limited	Biomarker	[192]
NEDD8	TTNDC4K	Limited	Biomarker	[193]
NELL1	TT7H4BF	Limited	Altered Expression	[194]
NR4A3	TTJQB49	Limited	Altered Expression	[195]
NRG4	TTWAGKJ	Limited	Altered Expression	[196]
PAK2	TT279WO	Limited	Biomarker	[197]
PAX5	TTA4REJ	Limited	Genetic Variation	[198]
PCSK1	TTED9LZ	Limited	Altered Expression	[199]
PCSK2	TT46F0P	Limited	Altered Expression	[199]
PDCD1LG2	TTW14O3	Limited	Biomarker	[172]
PDE4B	TTVIAT9	Limited	Biomarker	[200]
PIM1	TTTN5QW	Limited	Biomarker	[201]
PLD2	TTRLMKF	Limited	Altered Expression	[202]
PLK2	TT976FS	Limited	Posttranslational Modification	[203]
PMEL	TT8MK59	Limited	Genetic Variation	[204]
PSMB9	TTOUSTQ	Limited	Biomarker	[205]
PTGDR2	TTQDMX5	Limited	Biomarker	[206]
PTK6	TT6TH8V	Limited	Biomarker	[207]
RARA	TTW38KT	Limited	Biomarker	[208]
RHOA	TTP2U16	Limited	Genetic Variation	[209]
RICTOR	TT143WL	Limited	Biomarker	[210]
ROR1	TTDEJAU	Limited	Biomarker	[211]
RTN4R	TTVRZUO	Limited	Biomarker	[212]
RYR1	TTU5CIX	Limited	Altered Expression	[213]
SELE	TT1PL7M	Limited	Biomarker	[214]
SLAMF6	TTSIYJ6	Limited	Biomarker	[215]
SLC16A3	TTG6VD5	Limited	Altered Expression	[216]
SLC19A1	TT09I7D	Limited	Genetic Variation	[217]
SLC23A1	TT6XAGK	Limited	Biomarker	[218]
SLC23A2	TTOP832	Limited	Biomarker	[218]
SNAP25	TTYQWA0	Limited	Biomarker	[219]
SPN	TTOZAX0	Limited	Biomarker	[220]
STAB1	TTJFEOC	Limited	Altered Expression	[221]
SYK	TT2HUPM	Limited	Biomarker	[222]
TCF3	TTULOD8	Limited	Altered Expression	[223]
TERF2	TT5XSLT	Limited	Biomarker	[224]
TKTL1	TTNQ1J3	Limited	Altered Expression	[225]
TNFRSF10B	TTW20TU	Limited	Altered Expression	[226]
TNFRSF14	TTWGTC1	Limited	Biomarker	[227]
TNFRSF17	TTZ3P4W	Limited	Altered Expression	[228]
TOP1	TTGTQHC	Limited	Biomarker	[229]
TPX2	TT0PHL4	Limited	Genetic Variation	[204]
TRAF6	TTCDR6M	Limited	Biomarker	[230]
TSG101	TTHU7JA	Limited	Biomarker	[231]
VEGFD	TTOM5H4	Limited	Biomarker	[232]
WEE1	TTJFOAL	Limited	Biomarker	[233]
CD55	TT5Z9WY	Disputed	Biomarker	[234]
DCK	TTJOCE4	Disputed	Biomarker	[235]
MTAP	TTDBX7N	Disputed	Biomarker	[236]
SLC22A2	TT0XOJN	Disputed	Biomarker	[237]
SMC2	TTS8D17	Disputed	Genetic Variation	[238]
BCL2A1	TTGT9C7	moderate	Altered Expression	[239]
BTLA	TTER58P	moderate	Biomarker	[240]
CCL3	TT8I4WB	moderate	Altered Expression	[241]
CD38	TTPURFN	moderate	Altered Expression	[242]
CD46	TTMS7DF	moderate	Genetic Variation	[243]
CD5	TTEGYK1	moderate	Biomarker	[244]
CDC25B	TTR0SWN	moderate	Biomarker	[146]
CEBPA	TT5LWG1	moderate	Altered Expression	[245]
CMA1	TT8VUE0	moderate	Altered Expression	[246]
COPS5	TTSTNJR	moderate	Altered Expression	[247]
CX3CL1	TT1OFBQ	moderate	Biomarker	[248]
CXCL9	TTWE5PB	moderate	Biomarker	[249]
DLL1	TT9CFQD	moderate	Genetic Variation	[250]
EZH1	TTNJA0C	moderate	Biomarker	[251]
FCER2	TTCH6MU	moderate	Biomarker	[252]
GEM	TTAZF9M	moderate	Genetic Variation	[253]
HSP90B1	TTFPKXQ	moderate	Genetic Variation	[254]
IAPP	TTHN8EM	moderate	Biomarker	[255]
IL17D	TTC5LTG	moderate	Altered Expression	[256]
IL1R1	TTWOTEA	moderate	Biomarker	[257]
IL24	TT1EPXZ	moderate	Biomarker	[258]
INPP5D	TTTP2Z1	moderate	Biomarker	[259]
ITGA4	TTJMF9P	moderate	Biomarker	[260]
JAK3	TTT7PJU	moderate	Genetic Variation	[261]
JUN	TTS7IR5	moderate	Altered Expression	[262]
KIR2DS1	TTVWAGF	moderate	Genetic Variation	[263]
KIR3DL2	TTQH3N0	moderate	Genetic Variation	[263]
LAIR1	TTSI7A8	moderate	Biomarker	[264]
MTA1	TTO4HUS	moderate	Biomarker	[265]
MUC16	TTC1PS3	moderate	Altered Expression	[266]
NOTCH2	TT82FVD	moderate	Genetic Variation	[267]
ODC1	TTUMGNO	moderate	Genetic Variation	[268]
OGG1	TTRU01G	moderate	Therapeutic	[269]
PIM2	TT69J2Z	moderate	Biomarker	[270]
PLK1	TTH4IP0	moderate	Biomarker	[271]
PRLR	TTBPXMA	moderate	Biomarker	[272]
PSMB6	TT8EPLT	moderate	Genetic Variation	[250]
PTPRJ	TTWMKXP	moderate	Altered Expression	[273]
RTN4	TT7GXMU	moderate	Altered Expression	[274]
SATB1	TTLFRIC	moderate	Altered Expression	[275]
SLC16A1	TTN1J82	moderate	Biomarker	[276]
SOCS1	TT8COJM	moderate	Genetic Variation	[277]
SYVN1	TT8XKYM	moderate	Biomarker	[278]
UBC	TTBP3XA	moderate	Altered Expression	[279]
UCP1	TTI12YJ	moderate	Biomarker	[280]
ABCC1	TTOI92F	Strong	Biomarker	[281]
ACVRL1	TTGYPTC	Strong	Biomarker	[282]
ADA	TTLP57V	Strong	Altered Expression	[283]
AKT2	TTH24WI	Strong	Biomarker	[284]
ALOX12	TT12ABZ	Strong	Genetic Variation	[285]
ALPI	TTHYMUV	Strong	Biomarker	[286]
ANPEP	TTPHMWB	Strong	Biomarker	[287]
ASRGL1	TT4WT91	Strong	Biomarker	[288]
ATRAID	TTFLIKM	Strong	Biomarker	[289]
B2M	TTY7FKA	Strong	Biomarker	[290]
BAK1	TTFM7V0	Strong	Genetic Variation	[291]
BBC3	TT7JUKC	Strong	Biomarker	[292]
BCL11A	TTR61MW	Strong	Biomarker	[176]
BGN	TT0JPVF	Strong	Biomarker	[293]
BIRC2	TTQ5LRD	Strong	Biomarker	[294]
BMP6	TT07RIB	Strong	Posttranslational Modification	[295]
C1QBP	TTWTD7F	Strong	Biomarker	[296]
CAPN1	TT1WBIJ	Strong	Biomarker	[297]
CASR	TTBUYHA	Strong	Biomarker	[298]
CCND3	TT1JXNR	Strong	Altered Expression	[299]
CD14	TT6I7DC	Strong	Biomarker	[300]
CD22	TTM6QSK	Strong	Biomarker	[301]
CD27	TTDO1MV	Strong	Biomarker	[302]
CD28	TTQ13FT	Strong	Biomarker	[303]
CD33	TTJVYO3	Strong	Biomarker	[304]
CD37	TTFCW29	Strong	Altered Expression	[305]
CD40LG	TTIJP3Q	Strong	Biomarker	[306]
CD44	TTWFBT7	Strong	Biomarker	[307]
CD47	TT28S46	Strong	Biomarker	[308]
CD70	TTNCIE0	Strong	Biomarker	[302]
CD74	TTCMYP9	Strong	Altered Expression	[309]
CD79B	TTBN5I7	Strong	Genetic Variation	[310]
CD80	TT89Z17	Strong	Altered Expression	[311]
CD9	TTZEIBV	Strong	Biomarker	[312]
CDK2	TT7HF4W	Strong	Biomarker	[313]
CDK4	TT0PG8F	Strong	Altered Expression	[314]
CDK6	TTO0FDJ	Strong	Biomarker	[315]
CDK7	TTQYF7G	Strong	Biomarker	[316]
CDKN2C	TTBRUGA	Strong	Biomarker	[289]
CHEK1	TTTU902	Strong	Biomarker	[233]
CHEK2	TT9ABMF	Strong	Biomarker	[317]
CLEC4C	TT7YT06	Strong	Biomarker	[318]
CNTN2	TT2Z1WB	Strong	Biomarker	[319]
CR2	TT0HUN7	Strong	Biomarker	[320]
CREB1	TTH4AN3	Strong	Biomarker	[321]
CRTC2	TTFWETR	Strong	Biomarker	[321]
CSF1R	TT7MRDV	Strong	Altered Expression	[322]
CSNK2A1	TTER6YH	Strong	Biomarker	[151]
CTPS1	TTN12BZ	Strong	Biomarker	[302]
CXCL13	TT0NIZ1	Strong	Biomarker	[323]
CXCR4	TTBID49	Strong	Biomarker	[324]
DGKZ	TTSBBXL	Strong	Biomarker	[325]
EML4	TT92GY4	Strong	Genetic Variation	[326]
EP300	TTGH73N	Strong	Biomarker	[327]
EPHA4	TTG84D3	Strong	Altered Expression	[328]
EPHA7	TTAHTVG	Strong	Biomarker	[329]
ETS1	TTTGPSD	Strong	Altered Expression	[330]
EZH2	TT9MZCQ	Strong	Genetic Variation	[331]
F11R	TT3C8EG	Strong	Altered Expression	[332]
F8	TT1290U	Strong	Biomarker	[333]
FAS	TT7LTUJ	Strong	Biomarker	[334]
FBXW7	TT29KY7	Strong	Biomarker	[335]
FLT4	TTDCBX5	Strong	Biomarker	[336]
GBA	TT1B5PU	Strong	Biomarker	[337]
GLB1	TTNGJPH	Strong	Altered Expression	[338]
GPR34	TTVXSTQ	Strong	Altered Expression	[339]
GRB2	TTEYRJ9	Strong	Altered Expression	[340]
GSK3A	TTQWAU1	Strong	Altered Expression	[341]
HDAC6	TT5ZKDI	Strong	Altered Expression	[342]
HDAC7	TTMUEK1	Strong	Altered Expression	[343]
HDAC9	TT8M4E1	Strong	Biomarker	[344]
HLA-DQA1	TTU2I3J	Strong	Biomarker	[345]
HLA-G	TTLKFB3	Strong	Altered Expression	[346]
HMGA1	TTBA219	Strong	Altered Expression	[347]
HMGB2	TTA78JQ	Strong	Biomarker	[348]
HPSE	TTR7GJO	Strong	Biomarker	[349]
HSP90AA1	TT78R5H	Strong	Genetic Variation	[350]
HSPB8	TTY0OJN	Strong	Altered Expression	[351]
HTR1A	TTSQIFT	Strong	Biomarker	[352]
ICOS	TTE5VP6	Strong	Biomarker	[353]
IL12A	TTRTK6Y	Strong	Altered Expression	[354]
IL1RL1	TT4GZA4	Strong	Genetic Variation	[355]
IL2	TTF89GD	Strong	Altered Expression	[356]
IL21R	TTZO9B0	Strong	Altered Expression	[357]
IL25	TTVMO5W	Strong	Biomarker	[358]
IL5	TTPREZD	Strong	Biomarker	[359]
IL9	TT0JTFD	Strong	Biomarker	[360]
IRAK1	TTXAJWN	Strong	Genetic Variation	[361]
ITGAM	TTB69FJ	Strong	Altered Expression	[362]
ITGB2	TTIJWR7	Strong	Biomarker	[363]
ITK	TT3C80U	Strong	Biomarker	[302]
KAT6A	TT6O1J0	Strong	Genetic Variation	[364]
KIR2DS2	TTV3CFI	Strong	Genetic Variation	[263]
KMT2A	TT1GNDM	Strong	Biomarker	[365]
LGALS1	TTO3NYT	Strong	Biomarker	[366]
LONP1	TTM1VPZ	Strong	Biomarker	[201]
LY6K	TT5GKHN	Strong	Biomarker	[367]
MAD1L1	TTNE9U7	Strong	Genetic Variation	[368]
MAP3K20	TTTUZ3O	Strong	Biomarker	[369]
MAP3K7	TTJQT60	Strong	Biomarker	[370]
MLYCD	TT9Z4YD	Strong	Biomarker	[371]
MTHFR	TTQWOU1	Strong	Genetic Variation	[372]
MVD	TTE5J6X	Strong	Biomarker	[373]
MYCN	TT9JBY5	Strong	Altered Expression	[374]
MYD88	TTB6Q2O	Strong	Genetic Variation	[375]
NAPRT	TTVR1FW	Strong	Altered Expression	[376]
NCF1	TTZ4JC3	Strong	Biomarker	[377]
NCR1	TTQNRJM	Strong	Biomarker	[378]
NDUFA13	TTRU1NG	Strong	Altered Expression	[379]
NFKB2	TTKLNRV	Strong	Biomarker	[380]
NME1	TTDY8JH	Strong	Biomarker	[381]
NOTCH1	TTB1STW	Strong	Genetic Variation	[382]
NPR2	TTNB7IF	Strong	Biomarker	[337]
NR0B2	TT25A9Q	Strong	Posttranslational Modification	[383]
NR1I3	TTRANFM	Strong	Biomarker	[298]
NR4A1	TTMXE2Q	Strong	Biomarker	[384]
NRAS	TTW2R9X	Strong	Biomarker	[385]
PBK	TTMY6BZ	Strong	Altered Expression	[386]
PIM3	TTCGOIN	Strong	Altered Expression	[387]
PINX1	TT4FJ3A	Strong	Genetic Variation	[388]
PKD2L1	TTAHD89	Strong	Biomarker	[389]
PLK4	TTGPNZQ	Strong	Biomarker	[390]
PMS1	TTX1ISF	Strong	Altered Expression	[391]
PNP	TTMCF1Y	Strong	Biomarker	[392]
PON1	TT9LX82	Strong	Genetic Variation	[393]
PPID	TTNAFOU	Strong	Biomarker	[394]
PREP	TTNGKET	Strong	Genetic Variation	[395]
PRKAR1A	TTNAHEX	Strong	Biomarker	[298]
PRKCD	TT7A1BO	Strong	Genetic Variation	[396]
PRMT5	TTR1D7X	Strong	Altered Expression	[397]
PTGDR	TTNVEIR	Strong	Genetic Variation	[398]
PTGER4	TT79WV3	Strong	Therapeutic	[399]
PTK7	TTXH2ZN	Strong	Biomarker	[400]
PTP4A2	TT1MHKD	Strong	Altered Expression	[401]
PTPN1	TTELIN2	Strong	Genetic Variation	[402]
PTPN11	TT7WUAV	Strong	Biomarker	[403]
PTPN13	TT405FP	Strong	Posttranslational Modification	[404]
PTPN2	TTY8PUS	Strong	Biomarker	[405]
PTPN6	TT369M5	Strong	Posttranslational Modification	[383]
RAB7A	TTF6WAQ	Strong	Altered Expression	[406]
RIPK4	TTB4S01	Strong	Biomarker	[407]
RNF34	TTEWDK1	Strong	Biomarker	[408]
RORB	TTGB2LZ	Strong	Altered Expression	[409]
RPSA	TTLUW5B	Strong	Altered Expression	[410]
RUNX1	TTWIN3H	Strong	Biomarker	[411]
S100A9	TT0TMQG	Strong	Altered Expression	[412]
SENP1	TTW9HY5	Strong	Biomarker	[413]
SERPINC1	TT4QPUL	Strong	Biomarker	[414]
SERPING1	TTVQ6R9	Strong	Biomarker	[415]
SGPP1	TTN0VRB	Strong	Altered Expression	[416]
SKP2	TT5B2EO	Strong	Biomarker	[417]
SMYD2	TT7YJFO	Strong	Altered Expression	[418]
SPHK2	TTCN0M9	Strong	Biomarker	[419]
STAT6	TTWOE1T	Strong	Altered Expression	[420]
STK38	TT27XFN	Strong	Altered Expression	[421]
STK4	TTCPLVN	Strong	Biomarker	[422]
TBL1XR1	TTYXT16	Strong	Biomarker	[423]
TCL1A	TTUKRDV	Strong	Biomarker	[424]
TERF1	TT1Y6J2	Strong	Biomarker	[425]
TIAM1	TTNU6I5	Strong	Biomarker	[426]
TIRAP	TTKU0LS	Strong	Genetic Variation	[427]
TK1	TTP3QRF	Strong	Biomarker	[428]
TLR1	TTW14D0	Strong	Biomarker	[429]
TLR7	TTRJ1K4	Strong	Biomarker	[430]
TMEM97	TT9NXW4	Strong	Biomarker	[431]
TNFAIP3	TT5W0IO	Strong	Biomarker	[432]
TNFRSF10A	TT5WLRX	Strong	Genetic Variation	[433]
TNFRSF13B	TTL9OD4	Strong	Genetic Variation	[434]
TNFRSF13C	TT7NJSE	Strong	Biomarker	[435]
TNFRSF18	TTG6LA7	Strong	Biomarker	[436]
TNFRSF4	TTL31H0	Strong	Altered Expression	[437]
TNFRSF9	TTPW9LJ	Strong	Biomarker	[438]
TNFSF10	TTA5MS9	Strong	Altered Expression	[439]
TNFSF13	TTOI1RM	Strong	Biomarker	[440]
TNFSF13B	TTWMIDN	Strong	Genetic Variation	[441]
TNFSF14	TTKVENM	Strong	Biomarker	[442]
TRPV2	TTBECWA	Strong	Biomarker	[443]
TRPV6	TTBK14N	Strong	Biomarker	[444]
TTK	TTP7EGM	Strong	Genetic Variation	[445]
TYK2	TTBYWP2	Strong	Genetic Variation	[184]
TYRO3	TTIEMFN	Strong	Altered Expression	[446]
UCHL1	TTX9IFP	Strong	Biomarker	[337]
WAS	TTE8T73	Strong	Genetic Variation	[447]
WRN	TT2H5WQ	Strong	Genetic Variation	[448]
XIAP	TTK3WBU	Strong	Biomarker	[449]
XPA	TTGT87E	Strong	Genetic Variation	[450]
ZAP70	TTUMHT8	Strong	Altered Expression	[451]
ARRB1	TTMVD4A	Definitive	Biomarker	[452]
ARRB2	TT8SO2I	Definitive	Biomarker	[452]
BCL2L2	TTQ79W8	Definitive	Biomarker	[453]
CA12	TTSYM0R	Definitive	Altered Expression	[454]
CBX7	TTBN3HC	Definitive	Altered Expression	[455]
CXCR5	TTIW59R	Definitive	Altered Expression	[456]
DPP9	TTNDUL7	Definitive	Altered Expression	[457]
FMNL1	TTW20PQ	Definitive	Biomarker	[458]
GRIA3	TT82EZV	Definitive	Altered Expression	[459]
GRM3	TT8A9EF	Definitive	Altered Expression	[459]
IL3RA	TTENHJ0	Definitive	Biomarker	[460]
OPRK1	TTQW87Y	Definitive	Biomarker	[461]
S1PR1	TT9JZCK	Definitive	Altered Expression	[462]
TRB	TT84HCW	Definitive	Genetic Variation	[463]
VTCN1	TTCK85E	Definitive	Altered Expression	[464]

This Disease Is Related to 10 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC16A7	DTLT3UG	Limited	Altered Expression	[465]
SLC26A3	DTN1FMD	Limited	Genetic Variation	[466]
SLC43A1	DTBMSWG	Limited	Altered Expression	[467]
SLC7A6	DTTBSQG	Limited	Altered Expression	[467]
SLC7A7	DTE4HJ8	Limited	Altered Expression	[467]
ABCB5	DTKVEXO	Strong	Altered Expression	[468]
ABCB6	DTF9Y2V	Strong	Biomarker	[469]
SLC27A5	DT0TQS3	Strong	Genetic Variation	[470]
SLC35A2	DT0567K	Strong	Genetic Variation	[471]
SLC35B2	DT81RKJ	Strong	Altered Expression	[472]

This Disease Is Related to 9 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
UCK2	DETN1O0	Limited	Altered Expression	[473]
CES2	DETHCPD	Strong	Biomarker	[474]
EPHX1	DELB4KP	Strong	Biomarker	[475]
MGST1	DEAPJSO	Strong	Altered Expression	[476]
NAT1	DE7OAB3	Strong	Biomarker	[477]
NAT2	DER7TA0	Strong	Genetic Variation	[477]
PGPEP1	DEVDR46	Strong	Biomarker	[293]
SULT1E1	DESTKG6	Strong	Biomarker	[478]
THOP1	DE95LJC	Strong	Genetic Variation	[479]

This Disease Is Related to 474 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ACAP2	OTYNZPC4	Limited	Altered Expression	[480]
ADA2	OTGCV24S	Limited	Biomarker	[481]
ADAM28	OT3GBVHL	Limited	Biomarker	[482]
ALKBH1	OTADGU5D	Limited	Biomarker	[483]
ALLC	OTZE4XV7	Limited	Biomarker	[484]
AMELX	OTIN26MM	Limited	Biomarker	[485]
AMH	OT5FH4BD	Limited	Biomarker	[486]
AMT	OTQYEWZQ	Limited	Biomarker	[487]
APOBEC3B	OTHLNI51	Limited	Biomarker	[488]
ASCC2	OT3B204T	Limited	Genetic Variation	[204]
ASCL1	OTI4X44G	Limited	Altered Expression	[489]
ASS1	OT4ZMG0Q	Limited	Altered Expression	[490]
BMF	OT90NSLI	Limited	Biomarker	[491]
BTG2	OTZF6K1H	Limited	Biomarker	[134]
C10orf90	OT6DNZC4	Limited	Biomarker	[492]
C1orf56	OT0UYJMF	Limited	Altered Expression	[493]
CARD16	OT4NUHWB	Limited	Biomarker	[494]
CCDC34	OTZ3AGSQ	Limited	Altered Expression	[495]
CCL1	OT23NON8	Limited	Biomarker	[496]
CCNT1	OTDYVGCP	Limited	Altered Expression	[497]
CD8A	OTDWQJXK	Limited	Altered Expression	[498]
CD8B	OTMZ1T7J	Limited	Altered Expression	[498]
CDKN2D	OT2TTZPZ	Limited	Genetic Variation	[156]
CDO1	OTLG1P77	Limited	Posttranslational Modification	[499]
CENPM	OTYK9KOX	Limited	Biomarker	[500]
CIITA	OTRJNZFO	Limited	Altered Expression	[501]
CLEC4D	OTT7X1UC	Limited	Altered Expression	[502]
CLTA	OTLHOXMQ	Limited	Biomarker	[164]
CLTC	OTBFASMA	Limited	Genetic Variation	[503]
CNTNAP1	OT5Y03EU	Limited	Biomarker	[504]
COIL	OTP4I4DL	Limited	Genetic Variation	[505]
COL4A3	OT6SB8X5	Limited	Biomarker	[506]
CYP4V2	OTQKNK0D	Limited	Biomarker	[507]
DCTN3	OTQOSUES	Limited	Genetic Variation	[508]
DDX4	OTQOV093	Limited	Altered Expression	[509]
DDX6	OTKWXVDY	Limited	Genetic Variation	[183]
DERL3	OTRZRT6Q	Limited	Biomarker	[510]
DHX32	OTDYB66V	Limited	Altered Expression	[511]
DHX9	OT5AAOQI	Limited	Biomarker	[512]
DNASE1L3	OTEUIMC2	Limited	Biomarker	[513]
DNER	OT2GH2E5	Limited	Biomarker	[514]
DNTT	OTFSEF12	Limited	Biomarker	[515]
DPYSL3	OTINJV20	Limited	Posttranslational Modification	[516]
DYNC1H1	OTD1KRKO	Limited	Genetic Variation	[508]
EIF1AX	OTWG2LAB	Limited	Genetic Variation	[517]
EIF3K	OTGTKVGO	Limited	Biomarker	[518]
ELF3	OTUTLEQO	Limited	Altered Expression	[519]
ETV5	OTE2OBM4	Limited	Genetic Variation	[520]
ETV7	OTIAADPA	Limited	Biomarker	[521]
FCGR2C	OTNLMNYB	Limited	Biomarker	[158]
FCRL5	OTA7VHNE	Limited	Altered Expression	[522]
FH	OTEQWU6Q	Limited	Altered Expression	[502]
FOSB	OTW6C05J	Limited	Altered Expression	[262]
FRS2	OTDMD800	Limited	Biomarker	[523]
GCSH	OTNC1OKA	Limited	Biomarker	[487]
GFI1B	OTRDW8YO	Limited	Altered Expression	[223]
GH2	OT32TR4C	Limited	Biomarker	[524]
GNLY	OTZJKA8C	Limited	Altered Expression	[525]
GPC5	OT8NR7GC	Limited	Altered Expression	[526]
HCCS	OTQE88BE	Limited	Biomarker	[527]
HERPUD1	OT9EROL6	Limited	Biomarker	[219]
HMMR	OT4M0JTZ	Limited	Biomarker	[528]
HPR	OTXSC9UB	Limited	Altered Expression	[529]
HSH2D	OTOGB2BR	Limited	Biomarker	[530]
HYAL2	OTTVINXW	Limited	Altered Expression	[531]
ID4	OTPMJ39I	Limited	Altered Expression	[532]
IGF2BP1	OT9G360P	Limited	Altered Expression	[533]
IGF2BP2	OT4ZSEEE	Limited	Altered Expression	[533]
IGF2BP3	OTB97VIK	Limited	Altered Expression	[533]
IGLL5	OT9XQFL5	Limited	Altered Expression	[534]
INSM1	OTG8RV8E	Limited	Biomarker	[535]
INSM2	OTNMQUZV	Limited	Biomarker	[536]
ISCU	OTSW6DQP	Limited	Biomarker	[537]
KDM6A	OTZM3MJJ	Limited	Genetic Variation	[538]
KLRD1	OTMYLOV4	Limited	Genetic Variation	[175]
LGALS9	OT7MF91K	Limited	Biomarker	[539]
MAD2L1	OTXNGZCG	Limited	Biomarker	[291]
MARCKSL1	OT13J2FM	Limited	Biomarker	[281]
MCM3AP	OT895FEC	Limited	Altered Expression	[540]
MCTS1	OT7SAOJP	Limited	Altered Expression	[246]
MOS	OTNMQPFJ	Limited	Biomarker	[541]
MTX1	OTLSDNZO	Limited	Genetic Variation	[542]
MYBL1	OTBJMC2P	Limited	Biomarker	[543]
NDUFAB1	OTF906UR	Limited	Biomarker	[485]
NFATC2	OTK5T6HZ	Limited	Altered Expression	[544]
NKX2-3	OTF4IL5J	Limited	Altered Expression	[545]
NLRP2	OTJA81JU	Limited	Posttranslational Modification	[546]
NOL3	OT1K0L0D	Limited	Biomarker	[547]
NUTM1	OTONYC08	Limited	Genetic Variation	[548]
NXF1	OTEFHXG6	Limited	Altered Expression	[549]
OAS3	OT6E5FYS	Limited	Genetic Variation	[204]
OTUD4	OT7U62SW	Limited	Posttranslational Modification	[550]
PARP4	OTXBK59G	Limited	Posttranslational Modification	[551]
PARP9	OT7K4494	Limited	Genetic Variation	[470]
PASD1	OTZZWR7L	Limited	Biomarker	[552]
PATZ1	OT0X9WGR	Limited	Biomarker	[553]
PBX1	OTORABGO	Limited	Genetic Variation	[554]
PCBP4	OTDLL4NB	Limited	Biomarker	[555]
PCDH10	OT2GIT0E	Limited	Posttranslational Modification	[556]
PCM1	OTFM133C	Limited	Biomarker	[557]
PFDN5	OTTKPTUP	Limited	Biomarker	[192]
PGP	OT6QQ7OR	Limited	Altered Expression	[558]
PIAS2	OTJLSC3V	Limited	Genetic Variation	[559]
PLCG2	OTGVC9MY	Limited	Biomarker	[560]
PLEKHA2	OTY2AP6T	Limited	Biomarker	[561]
PLK3	OT19CT2Z	Limited	Posttranslational Modification	[203]
PLOD3	OTT00T7Q	Limited	Biomarker	[150]
PPP1R14A	OTQODWZB	Limited	Biomarker	[562]
PPP1R3A	OTJL9VYP	Limited	Genetic Variation	[563]
PRC1	OTHD0XS0	Limited	Biomarker	[564]
PRDM15	OTYTP3SU	Limited	Altered Expression	[565]
PRPF6	OT3U0ABN	Limited	Biomarker	[566]
PTPRA	OTZA82J1	Limited	Biomarker	[567]
PTPRO	OTFLKWOY	Limited	Altered Expression	[568]
RAB40B	OTCA9ZF5	Limited	Genetic Variation	[569]
RASSF7	OT0V4EIZ	Limited	Genetic Variation	[570]
RB1	OT9VMY7B	Limited	Altered Expression	[571]
RBL2	OTBQSOE6	Limited	Altered Expression	[572]
RBM38	OTPO8EXU	Limited	Altered Expression	[573]
RBP1	OTRP1MFC	Limited	Biomarker	[574]
RCAN1	OT1MVXC7	Limited	Biomarker	[575]
RHEB	OTFLTSEC	Limited	Altered Expression	[576]
RHOF	OTPA3F8Q	Limited	Altered Expression	[577]
RHOJ	OTWI65OA	Limited	Biomarker	[578]
RIOX2	OT2YFPI2	Limited	Altered Expression	[579]
RIT1	OTVNOGOH	Limited	Altered Expression	[580]
RNF2	OTFPLOIN	Limited	Altered Expression	[564]
SART3	OTC1AM7S	Limited	Genetic Variation	[204]
SCGB3A1	OTIR98RB	Limited	Posttranslational Modification	[550]
SEC31A	OT2U42AC	Limited	Genetic Variation	[581]
SEL1L	OTC0FB7T	Limited	Biomarker	[582]
SGCE	OT9F17JB	Limited	Altered Expression	[583]
SHMT1	OTIINA3J	Limited	Genetic Variation	[584]
SIRT7	OT5M4OT4	Limited	Genetic Variation	[585]
SKI	OT4KJ8F6	Limited	Biomarker	[586]
SLAMF1	OTBTT3ZQ	Limited	Altered Expression	[587]
SLC16A4	OT1YXBKC	Limited	Altered Expression	[216]
SLC7A4	OTAVC6QS	Limited	Biomarker	[588]
SMOC2	OTK1EQ49	Limited	Biomarker	[589]
SND1	OTT734JN	Limited	Genetic Variation	[204]
SOX30	OTGT38E3	Limited	Biomarker	[590]
SPTA1	OT1YMP65	Limited	Biomarker	[591]
SRI	OT4R3EAC	Limited	Altered Expression	[592]
ST6GALNAC5	OTH91ETM	Limited	Biomarker	[593]
STING1	OTDAP4G0	Limited	Biomarker	[436]
SUMO1	OTJFD4P5	Limited	Altered Expression	[594]
SUMO2	OT1Y5IKN	Limited	Biomarker	[594]
SUMO3	OTTUJQJ1	Limited	Biomarker	[594]
TAT	OT2CJ91O	Limited	Altered Expression	[595]
TELO2	OT2YQ9L8	Limited	Biomarker	[521]
TFAM	OTXXV5V7	Limited	Biomarker	[596]
TLE2	OT2KSZ9B	Limited	Altered Expression	[583]
TLE3	OTR9PH95	Limited	Altered Expression	[583]
TLE4	OT4QEH6T	Limited	Altered Expression	[583]
TP53BP2	OTOWJ2Y4	Limited	Altered Expression	[597]
TRAF2	OT1MEZZN	Limited	Posttranslational Modification	[598]
TRIM11	OTMD6IM2	Limited	Biomarker	[599]
TSPYL2	OTGGW2EF	Limited	Biomarker	[600]
CORO1A	OTVAZOHC	Disputed	Altered Expression	[601]
LPXN	OTUNV3CK	Disputed	Altered Expression	[602]
NT5DC3	OTRHBVM5	Disputed	Genetic Variation	[254]
POU2F2	OTPV0J0C	Disputed	Biomarker	[237]
RGS1	OTGXJYMG	Disputed	Altered Expression	[603]
RGS13	OTPAMQ18	Disputed	Altered Expression	[603]
RHOH	OT1J9SEB	Disputed	Altered Expression	[602]
SMC4	OTEJE6AG	Disputed	Genetic Variation	[238]
ACSBG1	OTM040MW	moderate	Altered Expression	[604]
BACH2	OT17GS18	moderate	Altered Expression	[424]
BATF3	OTI61WXQ	moderate	Biomarker	[605]
BCL3	OT1M5B95	moderate	Altered Expression	[606]
BCOR	OTG013AX	moderate	Genetic Variation	[607]
BLNK	OTSSPF6F	moderate	Biomarker	[608]
CALM2	OTNYA92F	moderate	Biomarker	[609]
CASZ1	OTWJ2OR8	moderate	Biomarker	[610]
CCL4	OT6B8P25	moderate	Altered Expression	[611]
CD247	OT45FGUX	moderate	Biomarker	[612]
CDKN2B	OTAG24N1	moderate	Genetic Variation	[613]
CKS1B	OTNUPLUJ	moderate	Biomarker	[614]
CLEC10A	OTD8HQT6	moderate	Biomarker	[615]
CTCF	OT8ZB70U	moderate	Genetic Variation	[152]
DLC1	OTP8LMCR	moderate	Biomarker	[616]
DLEC1	OTMKKBUW	moderate	Posttranslational Modification	[617]
DLX5	OTEEFBEU	moderate	Biomarker	[618]
DYNLL1	OTR69LHT	moderate	Altered Expression	[619]
ERCC5	OTQAKFJM	moderate	Genetic Variation	[620]
GNL3	OTILGYO4	moderate	Biomarker	[621]
HLA-DPB1	OTW8JHU2	moderate	Biomarker	[622]
IKZF1	OTCW1FKL	moderate	Altered Expression	[168]
IL10RA	OTOX3D1D	moderate	Genetic Variation	[623]
IRF5	OT8SIIAP	moderate	Biomarker	[624]
IRF7	OTC1A2PQ	moderate	Biomarker	[625]
KIR2DL4	OTXN18OA	moderate	Biomarker	[626]
LBR	OT1HG3HG	moderate	Biomarker	[627]
LGALS7	OTMSVI7R	moderate	Altered Expression	[628]
LIMD1	OTN1CG6R	moderate	Altered Expression	[629]
LXN	OTZQ2M6Y	moderate	Biomarker	[630]
MAGT1	OTQSAV5C	moderate	Biomarker	[302]
MCAT	OTH07FIW	moderate	Altered Expression	[246]
MCM2	OTGGORIQ	moderate	Altered Expression	[631]
MLLT10	OTURMDV7	moderate	Genetic Variation	[632]
MNDA	OTCTKR47	moderate	Altered Expression	[633]
NFATC1	OT4TMERS	moderate	Biomarker	[634]
NINL	OTWIK6HT	moderate	Biomarker	[635]
OPCML	OT93PQ6Y	moderate	Biomarker	[636]
PAG1	OTFOJUIQ	moderate	Biomarker	[555]
PLSCR4	OT2AMYLY	moderate	Genetic Variation	[254]
POLM	OT0SRIP4	moderate	Biomarker	[637]
RAPH1	OTMQXW7S	moderate	Altered Expression	[604]
RASGRF1	OTNWJ7EN	moderate	Biomarker	[426]
RPS27A	OTIIGGZ2	moderate	Altered Expression	[279]
SERPINA5	OTTZXPGD	moderate	Biomarker	[260]
SERPINA9	OT0OIZH1	moderate	Altered Expression	[638]
SOS1	OTTCWXC3	moderate	Biomarker	[426]
STAT4	OTAK3VFR	moderate	Altered Expression	[639]
TCHH	OT4J7EFT	moderate	Biomarker	[640]
THY1	OTVONVTB	moderate	Biomarker	[362]
TLE1	OT50MRZ1	moderate	Biomarker	[641]
TNFRSF6B	OTKAN9G7	moderate	Altered Expression	[642]
TPM3	OT5RU5G6	moderate	Biomarker	[643]
ABCE1	OTH19LOA	Strong	Biomarker	[644]
ABRAXAS1	OT1K4J80	Strong	Genetic Variation	[210]
ACOX1	OTM0A0DY	Strong	Biomarker	[645]
ACSF3	OT3WZW8S	Strong	Genetic Variation	[646]
ADAM19	OTH88TXU	Strong	Genetic Variation	[398]
ADGRG7	OT4IPNZC	Strong	Biomarker	[647]
AHI1	OT8K2YWY	Strong	Biomarker	[648]
AHRR	OTSJ12W6	Strong	Biomarker	[649]
AIP	OTDJ3OSV	Strong	Altered Expression	[650]
AKIRIN2	OTQ6WSKW	Strong	Altered Expression	[651]
ANP32B	OT3SQMLU	Strong	Biomarker	[440]
ARID3A	OTZZ4SFP	Strong	Biomarker	[652]
ARR3	OTRZ00CH	Strong	Biomarker	[298]
ASPG	OT5E2EKR	Strong	Biomarker	[653]
ATF2	OTNIZPEA	Strong	Genetic Variation	[654]
ATF7	OTM8T3OD	Strong	Biomarker	[654]
ATF7IP	OTU6ZA7F	Strong	Biomarker	[655]
ATMIN	OTEADE76	Strong	Altered Expression	[619]
BCL11B	OT8KKCVJ	Strong	Biomarker	[656]
BCL2L11	OTNQQWFJ	Strong	Biomarker	[657]
BIK	OTTH1T3D	Strong	Genetic Variation	[658]
BLM	OTEJOAJX	Strong	Biomarker	[659]
CACUL1	OT6P1ZVP	Strong	Biomarker	[193]
CAMKMT	OTLJBRUW	Strong	Biomarker	[609]
CARD11	OTRCTLYC	Strong	Biomarker	[375]
CARTPT	OTTE4V9S	Strong	Genetic Variation	[660]
CBFA2T3	OTOJ10S1	Strong	Genetic Variation	[646]
CBLL2	OTB4AD3V	Strong	Altered Expression	[342]
CCAR1	OTUXLQZZ	Strong	Biomarker	[408]
CCDC51	OTOJNHNA	Strong	Biomarker	[661]
CCL19	OTQ2UJMH	Strong	Biomarker	[662]
CD1D	OT3ROU4J	Strong	Biomarker	[663]
CD2AP	OTC76KQM	Strong	Biomarker	[664]
CD48	OT83ZNPP	Strong	Biomarker	[665]
CD79A	OTOJC8DV	Strong	Genetic Variation	[375]
CD99	OTPUZ5DE	Strong	Altered Expression	[666]
CDC42BPB	OTO6NT7Q	Strong	Genetic Variation	[667]
CDCA7	OT12HDZY	Strong	Biomarker	[668]
CDK2AP2	OTR99SJ8	Strong	Altered Expression	[412]
CFDP1	OTXY7J96	Strong	Altered Expression	[669]
CFL1	OTT6D5MH	Strong	Biomarker	[289]
CHD1	OT9R9G0H	Strong	Genetic Variation	[670]
CHP1	OTHTXN1A	Strong	Biomarker	[312]
CMTM1	OTKN7E89	Strong	Biomarker	[671]
CNOT2	OT98OJ42	Strong	Genetic Variation	[672]
CREBZF	OTO3TOEU	Strong	Biomarker	[673]
CXADR	OT9ZP02A	Strong	Biomarker	[298]
DAP	OT5YLL7E	Strong	Posttranslational Modification	[674]
DAPK1	OTNCNUCO	Strong	Posttranslational Modification	[675]
DCLRE1C	OTW3KB1I	Strong	Biomarker	[676]
DDIT3	OTI8YKKE	Strong	Genetic Variation	[677]
DDX53	OTHK3EGZ	Strong	Genetic Variation	[678]
DIXDC1	OT87DXEG	Strong	Biomarker	[679]
DOHH	OTDRAT3F	Strong	Biomarker	[680]
DUSP22	OTEZ3U85	Strong	Biomarker	[209]
E2F8	OTQKZGFP	Strong	Biomarker	[681]
EEF1E1	OTRA6XOB	Strong	Biomarker	[289]
EGR3	OTGPJIRA	Strong	Altered Expression	[682]
EIF4A1	OTMTBX6N	Strong	Biomarker	[683]
EIF4A2	OT08H03R	Strong	Biomarker	[683]
EIF4G2	OTEO98CR	Strong	Altered Expression	[669]
EIF6	OTEXMUED	Strong	Biomarker	[684]
ELF4	OT167PR5	Strong	Altered Expression	[685]
ELL3	OTALC1YD	Strong	Biomarker	[686]
ENO2	OTRODL0T	Strong	Biomarker	[687]
ENOSF1	OT65D3ZK	Strong	Biomarker	[688]
EPM2A	OTJU4IAG	Strong	Altered Expression	[689]
ERVW-1	OTWV8DXJ	Strong	Biomarker	[690]
FAM72A	OTBZYSR3	Strong	Genetic Variation	[691]
FAM72B	OT6AOG64	Strong	Genetic Variation	[691]
FAU	OTGTVOWK	Strong	Biomarker	[692]
FCRL4	OT3DVTRV	Strong	Altered Expression	[693]
FGF6	OTRJ679P	Strong	Biomarker	[694]
FIP1L1	OTF91GTL	Strong	Biomarker	[695]
FLI1	OT0EV3LX	Strong	Biomarker	[696]
FLII	OT7G9JG6	Strong	Biomarker	[696]
FMOD	OT9EJ5H8	Strong	Biomarker	[697]
FOXO4	OT90X9LN	Strong	Biomarker	[698]
FOXP2	OTVX6A59	Strong	Biomarker	[699]
GCSAM	OTZNOPYK	Strong	Altered Expression	[700]
GEMIN4	OTX7402E	Strong	Altered Expression	[669]
GFI1	OT9HB9H8	Strong	Biomarker	[701]
GLIS2	OTOUUV1X	Strong	Biomarker	[702]
GNA13	OTVDL515	Strong	Biomarker	[703]
GOT2	OT6XBWN0	Strong	Altered Expression	[704]
GPR65	OTCF5O4G	Strong	Biomarker	[705]
GPX4	OTRAFFX2	Strong	Altered Expression	[706]
H4C1	OTB71W46	Strong	Genetic Variation	[707]
HACE1	OTEZULKD	Strong	Altered Expression	[708]
HBZ	OTMHGFSS	Strong	Altered Expression	[709]
HCST	OTILCB4K	Strong	Biomarker	[710]
HLA-DQB1	OTVVI3UI	Strong	Altered Expression	[711]
HNRNPK	OTNPRM8U	Strong	Altered Expression	[712]
HRK	OTR4GWJ0	Strong	Altered Expression	[713]
HS3ST2	OTWFA0GJ	Strong	Biomarker	[694]
HSPA1L	OTC2V1K6	Strong	Biomarker	[714]
HSPH1	OTVRR73T	Strong	Altered Expression	[680]
HVCN1	OT4ALYU4	Strong	Genetic Variation	[715]
IBTK	OTB2GM4G	Strong	Biomarker	[716]
ICAM3	OTTZ5A5D	Strong	Genetic Variation	[398]
ID3	OTUULW5Z	Strong	Genetic Variation	[717]
IL12RB1	OTM1IJO2	Strong	Genetic Variation	[434]
IL17RB	OT0KDNSF	Strong	Biomarker	[358]
IL34	OTZ15VVK	Strong	Biomarker	[718]
IL9R	OTILCLXA	Strong	Altered Expression	[719]
INAFM2	OT2H4HAP	Strong	Biomarker	[720]
INPP4B	OTLROA7G	Strong	Biomarker	[210]
ISG20	OTCWRJJW	Strong	Biomarker	[721]
ISL1	OTVNVKAX	Strong	Altered Expression	[722]
ITM2B	OTMXEPXB	Strong	Biomarker	[723]
JUNB	OTG2JXV5	Strong	Altered Expression	[262]
JUND	OTNKACJD	Strong	Altered Expression	[262]
KAT5	OTL7257A	Strong	Biomarker	[724]
KCNRG	OTXHYFOD	Strong	Altered Expression	[725]
KIR3DL1	OTPOSXFX	Strong	Genetic Variation	[726]
KLHDC8B	OTKP6LCR	Strong	Biomarker	[727]
KMT2D	OTTVHCLY	Strong	Altered Expression	[728]
KRT20	OT4RB40L	Strong	Biomarker	[190]
KRT222	OTTK7M0R	Strong	Biomarker	[729]
LAMTOR1	OTIBJBW9	Strong	Biomarker	[289]
LAMTOR2	OTHEDISB	Strong	Altered Expression	[412]
LAPTM5	OT2XI2JG	Strong	Biomarker	[730]
LAT	OTZC1XZ1	Strong	Genetic Variation	[731]
LIG4	OT40DNXU	Strong	Biomarker	[659]
LNX2	OT3I0A91	Strong	Genetic Variation	[667]
LRP12	OTRT1UJ7	Strong	Posttranslational Modification	[732]
MAFB	OTH2N3T8	Strong	Biomarker	[733]
MAFK	OTZJUE4P	Strong	Biomarker	[289]
MLKL	OTDSLC81	Strong	Altered Expression	[734]
MRPL28	OT4LUTZU	Strong	Biomarker	[735]
MSH6	OT46FP09	Strong	Biomarker	[317]
MTG1	OTC9U1LI	Strong	Genetic Variation	[447]
MTSS1	OT5DTDO2	Strong	Altered Expression	[736]
MUL1	OT2JC9YR	Strong	Altered Expression	[342]
MVP	OTJGHJRB	Strong	Altered Expression	[737]
MYCL	OT1MFQ5U	Strong	Biomarker	[738]
MYDGF	OT9HRPL6	Strong	Biomarker	[358]
MYH14	OT1TZEJK	Strong	Biomarker	[700]
NAPSA	OT6F8IAL	Strong	Biomarker	[739]
NBN	OT73B5MD	Strong	Biomarker	[740]
NCR3	OT20M764	Strong	Biomarker	[741]
NCR3LG1	OT15YWU7	Strong	Altered Expression	[742]
NFE2L3	OT1MGXT0	Strong	Biomarker	[743]
NOCT	OTVSYP2D	Strong	Genetic Variation	[744]
NOMO1	OTIALEI1	Strong	Genetic Variation	[745]
NRSN1	OT1KKXC8	Strong	Biomarker	[312]
NXT1	OT0VO6AY	Strong	Biomarker	[735]
ODF1	OTTSURLA	Strong	Altered Expression	[746]
P3H3	OTRC8QCM	Strong	Altered Expression	[747]
PDLIM7	OTAZVODU	Strong	Biomarker	[748]
PER2	OTU2B1DJ	Strong	Genetic Variation	[749]
PHB2	OTCAX3AW	Strong	Altered Expression	[750]
PHLPP1	OTIFXW8D	Strong	Altered Expression	[751]
PICALM	OTQVRPMQ	Strong	Genetic Variation	[752]
PIGK	OTAFSYLD	Strong	Altered Expression	[753]
PKNOX1	OTUDMNHX	Strong	Genetic Variation	[754]
PLEKHO1	OTMVUQ9W	Strong	Altered Expression	[755]
PMS2	OTNLWTMI	Strong	Biomarker	[756]
POLE3	OTOELRF6	Strong	Genetic Variation	[691]
POU2AF1	OTOO6WHL	Strong	Genetic Variation	[757]
PPP1R15A	OTYG179K	Strong	Biomarker	[758]
PRDM1	OTQLSVBS	Strong	Altered Expression	[759]
PRF1	OTFVXD7H	Strong	Genetic Variation	[760]
PRKN	OTJBN41W	Strong	Altered Expression	[342]
PSMD2	OT6HZHN7	Strong	Altered Expression	[669]
PWWP3A	OTXQVL4U	Strong	Altered Expression	[761]
RAB7B	OT60A0E9	Strong	Altered Expression	[406]
RAC2	OTAOHFNH	Strong	Biomarker	[762]
RAD23B	OT0PGOG3	Strong	Altered Expression	[342]
RAD54B	OTMWB2P2	Strong	Altered Expression	[763]
RAE1	OT54OKC3	Strong	Biomarker	[764]
RAG1	OTV131E4	Strong	Biomarker	[765]
RAG2	OTG9UYTW	Strong	Biomarker	[766]
RASGRP1	OTX9WN2E	Strong	Biomarker	[302]
RCOR1	OTREADPC	Strong	Biomarker	[767]
RDH11	OTIND43N	Strong	Altered Expression	[768]
RECQL4	OT59LSW7	Strong	Biomarker	[688]
RELB	OTU3QYEF	Strong	Biomarker	[769]
RFC1	OT3L5PK3	Strong	Genetic Variation	[770]
RNASE7	OTIXO0Z4	Strong	Biomarker	[764]
RPP14	OT4OYFSK	Strong	Altered Expression	[412]
RRAS2	OT83NCEB	Strong	Altered Expression	[771]
RTEL1	OTI3PJCT	Strong	Biomarker	[772]
RTL10	OTHGB81W	Strong	Biomarker	[773]
SET	OTGYYQJO	Strong	Altered Expression	[774]
SETD3	OTO5RAU2	Strong	Altered Expression	[774]
SETX	OTG3JNOQ	Strong	Biomarker	[775]
SF3B6	OTPRKS6S	Strong	Altered Expression	[412]
SH3BP4	OTVIRKW7	Strong	Biomarker	[776]
SLPI	OTUNFUU8	Strong	Biomarker	[282]
SMAD5	OTQNSVCQ	Strong	Biomarker	[777]
SMARCAL1	OTTKXLUZ	Strong	Altered Expression	[778]
SMC3	OTWGFRHD	Strong	Biomarker	[657]
SMCHD1	OTBV52DR	Strong	Altered Expression	[779]
SNAP91	OTE3EXWZ	Strong	Genetic Variation	[752]
SNRPN	OTQB1ID1	Strong	Biomarker	[694]
SOAT1	OTB4Y5RJ	Strong	Biomarker	[704]
SPART	OTIVOS2I	Strong	Biomarker	[780]
SPATA2	OTOA45GL	Strong	Biomarker	[710]
SPG7	OT8OY9ST	Strong	Biomarker	[298]
SPIB	OTO4YKYI	Strong	Altered Expression	[781]
SPINK1	OTSUVAL2	Strong	Altered Expression	[782]
SPINK2	OTSFBT0G	Strong	Altered Expression	[783]
SSB	OTCCTPBR	Strong	Genetic Variation	[784]
SSX2	OT2Z6RLL	Strong	Genetic Variation	[785]
STAT2	OTO9G2RZ	Strong	Biomarker	[665]
STAT5A	OTBSJGN3	Strong	Biomarker	[786]
STAT5B	OTZVPEBT	Strong	Biomarker	[786]
STXBP2	OTX8GUC4	Strong	Biomarker	[787]
SUB1	OTK71JYU	Strong	Altered Expression	[412]
SUV39H2	OTU0F4LL	Strong	Altered Expression	[788]
TCL1B	OT4CSO39	Strong	Biomarker	[424]
TCP1	OT1MGUX9	Strong	Biomarker	[789]
TFG	OT2KJENI	Strong	Biomarker	[647]
TIGAR	OTR7NMRJ	Strong	Altered Expression	[709]
TINF2	OT861N2N	Strong	Biomarker	[425]
TJP1	OTBDCUPK	Strong	Biomarker	[790]
TLX1	OTVN0MNW	Strong	Biomarker	[791]
TLX2	OTPFAUM8	Strong	Biomarker	[792]
TMED2	OTBLO7RW	Strong	Biomarker	[312]
TMEM176A	OTOZDWXX	Strong	Altered Expression	[793]
TMTC3	OTMTTDYG	Strong	Biomarker	[673]
TNFRSF10C	OTVHOL9B	Strong	Posttranslational Modification	[794]
TNFSF8	OTDYGDJ3	Strong	Biomarker	[795]
TNFSF9	OTV9L89D	Strong	Genetic Variation	[796]
TP53INP2	OT0GTBXO	Strong	Altered Expression	[753]
TP63	OT0WOOKQ	Strong	Altered Expression	[797]
TPPP	OTCFMSUF	Strong	Biomarker	[312]
TPPP2	OTI3WA6X	Strong	Biomarker	[289]
TRAF1	OTTLM5RU	Strong	Biomarker	[798]
TRAF3	OT5TQBGV	Strong	Biomarker	[799]
TREX1	OTQG7K12	Strong	Genetic Variation	[800]
TRIM13	OTQIUACB	Strong	Biomarker	[298]
TRIM65	OTSQTK3A	Strong	Biomarker	[801]
TRRAP	OT68OI2Y	Strong	Biomarker	[802]
TSN	OTOFAQ2Z	Strong	Altered Expression	[768]
TSPAN33	OTH6C0WU	Strong	Altered Expression	[803]
AIRE	OTA7G1Y1	Definitive	Biomarker	[353]
APAF1	OTJWIVY0	Definitive	Biomarker	[804]
CAMLG	OTTSRY39	Definitive	Altered Expression	[805]
GNA12	OT3IRZH3	Definitive	Altered Expression	[806]
HOXC5	OTPQTLKZ	Definitive	Altered Expression	[807]
KLF2	OTIP1UFX	Definitive	Altered Expression	[462]
LYL1	OTCNOV1M	Definitive	Biomarker	[808]
MIXL1	OT584VOQ	Definitive	Altered Expression	[809]
NR2C2	OTDZWVOJ	Definitive	Biomarker	[370]
NSF	OTKRJ2ZT	Definitive	Biomarker	[810]
PALB2	OT6DNDBG	Definitive	Biomarker	[811]
PIMREG	OTKC8T3E	Definitive	Altered Expression	[812]
RBM14	OTO9GMBD	Definitive	Genetic Variation	[813]
RC3H1	OTCU6CYA	Definitive	Biomarker	[353]
RPL22	OTVCN8K0	Definitive	Altered Expression	[462]
RRBP1	OT4ZTPTM	Definitive	Biomarker	[814]
SPRY2	OTH0CRCZ	Definitive	Posttranslational Modification	[815]
TAL1	OTX4K6QZ	Definitive	Altered Expression	[816]

References

• [1] 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
• [2] Cyclophosphamide FDA Label
• [3] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036975)
• [4] Feasibility and efficacy of low-dose pegfilgrastim for CD34(+) cell mobilization in lymphoma. J Clin Apher. 2020 Sep;35(5):413-419.
• [5] Clinical pipeline report, company report or official report of Merck.
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] ClinicalTrials.gov (NCT00880672) Effect of Dutasteride on HIF-1alpha and VEGF in the Prostate. U.S. National Institutes of Health.
• [8] ClinicalTrials.gov (NCT01121120) Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients. U.S. National Institutes of Health.
• [9] ClinicalTrials.gov (NCT02022098) Debio 1143-201 Dose-finding and Efficacy Phase I/II Trial. U.S. National Institutes of Health.
• [10] Atacicept: a new B lymphocyte-targeted therapy for multiple sclerosis. Nervenarzt. 2009 Dec;80(12):1462-72.
• [11] ClinicalTrials.gov (NCT00091676) Study of the BiovaxId Tumor Derived Idiotype Vaccine in Patients With Follicular Lymphoma. U.S. National Institutes of Health.
• [12] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [13] Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov. 2006 Jun;5(6):471-84.
• [14] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [15] ClinicalTrials.gov (NCT02452970) RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy.
• [16] Ruboxistaurin: LY 333531. Drugs R D. 2007;8(3):193-9.
• [17] ClinicalTrials.gov (NCT00127881) Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome. U.S. National Institutes of Health.
• [18] TG1042 (Adenovirus-interferon-gamma) in primary cutaneous B-cell lymphomas: a phase II clinical trial. PLoS One. 2014 Feb 24;9(2):e83670.
• [19] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7432).
• [20] ClinicalTrials.gov (NCT01292655) Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors. U.S. National Institutes of Health.
• [21] ClinicalTrials.gov (NCT03312205) CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
• [22] ClinicalTrials.gov (NCT02875223) A Safety and Efficacy Study of CC-90011 in Subjects With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas. U.S. National Institutes of Health.
• [23] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5675).
• [24] ClinicalTrials.gov (NCT01948180) Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma. U.S. National Institutes of Health.
• [25] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7883).
• [26] ClinicalTrials.gov (NCT01903330) ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme. U.S. National Institutes of Health.
• [27] ClinicalTrials.gov (NCT00516217) Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma. U.S. National Institutes of Health.
• [28] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7902).
• [29] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7046).
• [30] ClinicalTrials.gov (NCT00284804) A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's Disease. U.S. National Institutes of Health.
• [31] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026492)
• [32] ClinicalTrials.gov (NCT00231166) Safety, Efficacy, Dose-finding Study of a Monoclonal Antibody in Patients With Multiple Myeloma. U.S. National Institutes of Health.
• [33] ClinicalTrials.gov (NCT05626322) A PHASE 1b/2 STUDY OF PF-07901801, A CD47 BLOCKING AGENT, WITH TAFASITAMAB AND LENALIDOMIDE FOR PARTICIPANTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA NOT ELIGIBLE FOR STEM CELL TRANSPLANTATION. U.S.National Institutes of Health.
• [34] ClinicalTrials.gov (NCT01426828) Id-KLH Vaccine + T Cells. U.S. National Institutes of Health.
• [35] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7644).
• [36] Clinical pipeline report, company report or official report of Tetralogic pharmaceuticals.
• [37] Safety profile of intravenous and subcutaneous siplizumab, an anti-CD2 monoclonal antibody, for the treatment of plaque psoriasis: results of two randomized, double-blind, placebo-controlled studies.Int J Dermatol. 2010 Jul;49(7):818-28.
• [38] ClinicalTrials.gov (NCT02555618) A Phase 2 Study of Trivalent Inactivated Influenza Vaccine (TIV), TAK-850 (Cell-culture Derived) Compared to TIV (Egg-derived) in Adults.
• [39] ClinicalTrials.gov (NCT00634933) Study Evaluating 2 Dosing Regimens Of TRU-015 In Rheumatoid Arthritis. U.S. National Institutes of Health.
• [40] ClinicalTrials.gov (NCT02954445) A Clinical Research of BCMA-Targeted CAR-T in B Cell Malignancies
• [41] ClinicalTrials.gov (NCT03191773) A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies
• [42] ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
• [43] ClinicalTrials.gov (NCT02710149) A Clinical Research of CD20-Targeted CAR-T in B Cell Malignancies
• [44] ClinicalTrials.gov (NCT03262298) Anti-CD22 CAR-T Cell Therapy Targeting B Cell Malignancies
• [45] ClinicalTrials.gov (NCT02274584) CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273)
• [46] ClinicalTrials.gov (NCT02958410) A Clinical Research of CD30-Targeted CAR-T in Lymphocyte Malignancies
• [47] ClinicalTrials.gov (NCT02663297) Administration of T Lymphocytes for Prevention of Relapse of Lymphomas
• [48] ClinicalTrials.gov (NCT03468153) Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Relapsed and Refractory Lymphoma
• [49] ClinicalTrials.gov (NCT02537977) CD19-directed CAR T Cells Therapy in Relapsed/Refractory B Cell Malignancy
• [50] ClinicalTrials.gov (NCT03277729) A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
• [51] ClinicalTrials.gov (NCT02935153) A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies
• [52] ClinicalTrials.gov (NCT02349698) A Clinical Research of CAR T Cells Targeting CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma
• [53] ClinicalTrials.gov (NCT03397706) Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV-Associated Lymphoid Malignancies. U.S. National Institutes of Health.
• [54] T-cell therapy using a bank of EBV-specific cytotoxic T cells: lessons from a phase I/II feasibility and safety study. J Immunother. 2014 Apr;37(3):170-9.
• [55] Clinical pipeline report, company report or official report of Queensland Institute of Medical Research.
• [56] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019964)
• [57] ClinicalTrials.gov (NCT04130516) Phase 1 Study to Determine the MTD, Safety, Tolerability, PK and Preliminary Anti-tumor Effects of LNS8801alone and in Combination With Pembrolizumab. U.S. National Institutes of Health.
• [58] Clinical pipeline report, company report or official report of Immunomedics.
• [59] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800038471)
• [60] ClinicalTrials.gov (NCT01695005) A Study of LY3039478 in Participants With Advanced Cancer. U.S. National Institutes of Health.
• [61] ClinicalTrials.gov (NCT03684889) CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma
• [62] 2011 Pipeline of 4SC AG.
• [63] Tubulin inhibitor AEZS 112 inhibits the growth of experimental human ovarian and endometrial cancers irrespective of caspase inhibition. Oncol Rep. 2009 Aug;22(2):361-7.
• [64] ClinicalTrials.gov (NCT03121625) CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
• [65] ClinicalTrials.gov (NCT03271515) Immunotherapy With Bispecific CAR-T Cells for B-Cell Lymphoma, ALL and CLL
• [66] ClinicalTrials.gov (NCT02546739) Immunotherapy With CD19 CAR T-cells for B-Cell Lymphoma, ALL and CLL
• [67] ClinicalTrials.gov (NCT03049449) T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas
• [68] ClinicalTrials.gov (NCT00078546) EBV-Specific CTLs Following CD45 Antibody to Patients With Epstein-Barr Virus (EBV) + Nasopharyngeal Carcinoma (NPC). U.S. National Institutes of Health.
• [69] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8005).
• [70] ClinicalTrials.gov (NCT03144583) Pilot Study on the Infusion of ARI-0001 Cells in Patients With CD19+ Leukemia or Lymphoma Refractory to Therapy
• [71] ClinicalTrials.gov (NCT03602157) Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and NHL
• [72] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032956)
• [73] Biologics Research Pushing Frontiers of Science With More Than 900 Medicines and Vaccines in Development. Pharmaceutical Research and Manufacturers of America report. 2013.
• [74] ClinicalTrials.gov (NCT03086954) Study Evaluating the Efficacy and Safety With CAR-T Immunotherapy for CD19 Positive Lymphoma
• [75] ClinicalTrials.gov (NCT02476734) FDG-PET/CT Imaging as Early Predictor of DP
• [76] ClinicalTrials.gov (NCT02529813) CD19+ CAR T Cells for Lymphoid Malignancies
• [77] ClinicalTrials.gov (NCT02284971) Pilot Study of SBRT and CDX-1127 in Prostate Cancer. U.S. National Institutes of Health.
• [78] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033081)
• [79] ClinicalTrials.gov (NCT00450502) Safety of Batracylin in Patients With Solid Tumors and Lymphomas. U.S. National Institutes of Health.
• [80] ClinicalTrials.gov (NCT01588678) A Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas. U.S. National Institutes of Health.
• [81] ClinicalTrials.gov (NCT04245722) FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies. U.S. National Institutes of Health.
• [82] ClinicalTrials.gov (NCT01359696) A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma. U.S. National Institutes of Health.
• [83] Clinical pipeline report, company report or official report of Gilead.
• [84] Dual PI3K/mTOR inhibitors, GSK2126458 and PKI-587, suppress tumor progression and increase radiosensitivity in nasopharyngeal carcinoma. Mol Cancer Ther. 2015 Feb;14(2):429-39.
• [85] ClinicalTrials.gov (NCT03775525) Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or Lymphoma (GEN602). U.S. National Institutes of Health.
• [86] ClinicalTrials.gov (NCT03786926) Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas. U.S. National Institutes of Health.
• [87] ClinicalTrials.gov (NCT02374333) Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy
• [88] ClinicalTrials.gov (NCT03696784) Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma
• [89] ClinicalTrials.gov (NCT04306224) A Study of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas. U.S. National Institutes of Health.
• [90] ClinicalTrials.gov (NCT00003430) L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors. U.S. National Institutes of Health.
• [91] ClinicalTrials.gov (NCT00062868) LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma. U.S. National Institutes of Health.
• [92] ClinicalTrials.gov (NCT01794104) Indenoisoquinoline LMP400 for Advanced Solid Tumors and Lymphomas. U.S. National Institutes of Health.
• [93] ClinicalTrials.gov (NCT03922204) A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies. U.S. National Institutes of Health.
• [94] ClinicalTrials.gov (NCT03921879) Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma. U.S. National Institutes of Health.
• [95] ClinicalTrials.gov (NCT03330691) A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia and Lymphoma
• [96] ClinicalTrials.gov (NCT00705653) Study of CGC-11047 (PG-11047) in Subjects With Advanced Refractory Solid Tumors. U.S. National Institutes of Health.
• [97] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034037)
• [98] ClinicalTrials.gov (NCT03815682) RPTR-147 in Patients With Selected Solid Tumors and Lymphomas. U.S. National Institutes of Health.
• [99] Clinical pipeline report, company report or official report of Seagen.
• [100] ClinicalTrials.gov (NCT04609579) Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma. U.S. National Institutes of Health.
• [101] ClinicalTrials.gov (NCT03489369) Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas. U.S. National Institutes of Health.
• [102] ClinicalTrials.gov (NCT03489343) Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas. U.S. National Institutes of Health.
• [103] ClinicalTrials.gov (NCT04167137) Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Subjects. U.S. National Institutes of Health.
• [104] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026283)
• [105] Clinical pipeline report, company report or official report of I-MAB Biopharma.
• [106] ClinicalTrials.gov (NCT03530683) A Trial of TTI-622 in Patients With Advanced Relapsed or Refractory Lymphoma or Myeloma (TTI-622-01). U.S. National Institutes of Health.
• [107] ClinicalTrials.gov (NCT03884556) TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers. U.S. National Institutes of Health.
• [108] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027062)
• [109] ClinicalTrials.gov (NCT03556228) Oral TrkA Inhibitor VMD-928 for Treatment of Advanced Adult Solid Tumors or Lymphoma. U.S. National Institutes of Health.
• [110] ClinicalTrials.gov (NCT00606645) Safety Study of XmAb2513 to Treat Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma. U.S. National Institutes of Health.
• [111] ClinicalTrials.gov (NCT02728882) Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Diffuse Large B Cell Lymphoma
• [112] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007040)
• [113] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016388)
• [114] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016977)
• [115] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010099)
• [116] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028447)
• [117] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016875)
• [118] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015744)
• [119] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034639)
• [120] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020641)
• [121] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2628).
• [122] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2844).
• [123] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1839).
• [124] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [125] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2168).
• [126] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5714).
• [127] ClinicalTrials.gov (NCT00486759) A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma. U.S. National Institutes of Health.
• [128] AICDA drives epigenetic heterogeneity and accelerates germinal center-derived lymphomagenesis.Nat Commun. 2018 Jan 15;9(1):222. doi: 10.1038/s41467-017-02595-w.
• [129] A tumour suppressor network relying on the polyamine-hypusine axis.Nature. 2012 Jul 12;487(7406):244-8. doi: 10.1038/nature11126.
• [130] Expression and modulation of annexin VIII in human leukemia-lymphoma cell lines.Leuk Res. 1993 Nov;17(11):949-57. doi: 10.1016/0145-2126(93)90042-j.
• [131] Mitochondrial hypoxic stress induces widespread RNA editing by APOBEC3G in natural killer cells.Genome Biol. 2019 Feb 21;20(1):37. doi: 10.1186/s13059-019-1651-1.
• [132] Inv(2)(p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis.Blood. 2000 Mar 15;95(6):2144-9.
• [133] CIAP2 inhibits anigen receptor signaling by targeting Bcl10 for degredation.Cell Cycle. 2006 Jul;5(13):1438-42. doi: 10.4161/cc.5.13.2866. Epub 2006 Jul 1.
• [134] Tumor suppressors BTG1 and BTG2: Beyond growth control.J Cell Physiol. 2019 May;234(5):5379-5389. doi: 10.1002/jcp.27407. Epub 2018 Oct 23.
• [135] hBUB1 defects in leukemia and lymphoma cells.Oncogene. 2002 Jul 11;21(30):4673-9. doi: 10.1038/sj.onc.1205585.
• [136] Frameshift mutations in caspase-5 and other target genes in leukemia and lymphoma cell lines having microsatellite instability.Leuk Res. 2003 Apr;27(4):359-61. doi: 10.1016/s0145-2126(02)00215-1.
• [137] Absence of CASP7 and CASP8 mutation in gastrointestinal lymphomas.Eur J Haematol. 2007 Jul;79(1):86-7. doi: 10.1111/j.1600-0609.2007.00865.x. Epub 2007 May 28.
• [138] RNA Aptamers Recognizing Murine CCL17 Inhibit T Cell Chemotaxis and Reduce Contact Hypersensitivity InVivo.Mol Ther. 2018 Jan 3;26(1):95-104. doi: 10.1016/j.ymthe.2017.10.005. Epub 2017 Oct 13.
• [139] CCR4 is rarely expressed in CCR4-mutated T/NK-cell lymphomas other than adult T-cell leukemia/lymphoma.Int J Hematol. 2019 Oct;110(4):389-392. doi: 10.1007/s12185-019-02728-5. Epub 2019 Aug 29.
• [140] Circulating Tfh1 (cTfh1) cell numbers and PD1 expression are elevated in low-grade B-cell non-Hodgkin's lymphoma and cTfh gene expression is perturbed in marginal zone lymphoma.PLoS One. 2018 Jan 2;13(1):e0190468. doi: 10.1371/journal.pone.0190468. eCollection 2018.
• [141] Early and late hematologic toxicity following CD19 CAR-T cells.Bone Marrow Transplant. 2019 Oct;54(10):1643-1650. doi: 10.1038/s41409-019-0487-3. Epub 2019 Feb 26.
• [142] Prosthetic Antigen Receptors.J Am Chem Soc. 2015 Aug 19;137(32):10108-11. doi: 10.1021/jacs.5b06166. Epub 2015 Aug 6.
• [143] Distinct breakpoints in band 11q23 of the t(4;11) and t(11;14) associated with leukocyte malignancy.Genes Chromosomes Cancer. 1992 Jul;5(1):50-6. doi: 10.1002/gcc.2870050108.
• [144] Pre-clinical blocking of PD-L1 molecule, which expression is down regulated by NF-B, JAK1/JAK2 and BTK inhibitors, induces regression of activated B-cell lymphoma.Cell Commun Signal. 2019 Aug 5;17(1):89. doi: 10.1186/s12964-019-0391-x.
• [145] Assessment of CD52 expression in "double-hit" and "double-expressor" lymphomas: Implications for clinical trial eligibility.PLoS One. 2018 Jul 18;13(7):e0199708. doi: 10.1371/journal.pone.0199708. eCollection 2018.
• [146] Cdc25A and cdc25B expression in malignant lymphoma of the thyroid: correlation with histological subtypes and cell proliferation.Int J Mol Med. 2004 Mar;13(3):431-5.
• [147] Study of the mechanism by which dinaciclib induces apoptosis and cell cycle arrest of lymphoma Raji cells through a CDK1-involved pathway.Cancer Med. 2019 Aug;8(9):4348-4358. doi: 10.1002/cam4.2324. Epub 2019 Jun 17.
• [148] A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies.Leukemia. 2020 Jun;34(6):1646-1657. doi: 10.1038/s41375-019-0652-0. Epub 2019 Dec 11.
• [149] Expression of cholesteryl ester transfer protein (CETP) in germinal centre B cells and their neoplastic counterparts.Histopathology. 2004 Jul;45(1):73-81. doi: 10.1111/j.1365-2559.2004.01905.x.
• [150] Localization of collagen modifying enzymes on fibroblastic reticular cells and follicular dendritic cells in non-neoplastic and neoplastic lymphoid tissues.Leuk Lymphoma. 2016 Jul;57(7):1687-96. doi: 10.3109/10428194.2015.1107907. Epub 2015 Dec 24.
• [151] Lentivirus-mediated down-regulation of CK2 inhibits proliferation and induces apoptosis of malignant lymphoma and leukemia cells.Biochem Cell Biol. 2018 Dec;96(6):786-796. doi: 10.1139/bcb-2017-0345. Epub 2018 May 17.
• [152] Role of chromosomal architecture in germinal center B cells and lymphomagenesis.Curr Opin Hematol. 2019 Jul;26(4):294-302. doi: 10.1097/MOH.0000000000000505.
• [153] EBV microRNAs in primary lymphomas and targeting of CXCL-11 by ebv-mir-BHRF1-3.Cancer Res. 2008 Mar 1;68(5):1436-42. doi: 10.1158/0008-5472.CAN-07-5126.
• [154] Sequence-specific interactions of nuclear factors with conserved sequences of human class II major histocompatibility complex genes.Proc Natl Acad Sci U S A. 1987 Jul;84(14):4939-43. doi: 10.1073/pnas.84.14.4939.
• [155] Pleiotropic antitumor effects of the pan-HDAC inhibitor ITF2357 against c-Myc-overexpressing human B-cell non-Hodgkin lymphomas.Int J Cancer. 2014 Nov 1;135(9):2034-45. doi: 10.1002/ijc.28852. Epub 2014 Mar 26.
• [156] Alterations of the cyclin-dependent kinase inhibitor p19 (INK4D) is rare in hematopoietic malignancies.Leukemia. 1996 Dec;10(12):1897-900.
• [157] FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia.Blood. 2005 Jan 1;105(1):289-91. doi: 10.1182/blood-2004-02-0651. Epub 2004 Jun 24.
• [158] Follicular colonization in B-cell lymphoma of mucosa-associated lymphoid tissue.Am J Surg Pathol. 1991 Sep;15(9):819-28. doi: 10.1097/00000478-199109000-00001.
• [159] Gene for alpha-chain of human T-cell receptor: location on chromosome 14 region involved in T-cell neoplasms.Science. 1985 Mar 1;227(4690):1044-7. doi: 10.1126/science.3919442.
• [160] Expression of truncated transcripts of the proto-oncogene c-fps/fes in human lymphoma and lymphoid leukemia cell lines.Oncogene. 1992 May;7(5):943-52.
• [161] Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells.J Biol Chem. 1995 Jan 13;270(2):815-22. doi: 10.1074/jbc.270.2.815.
• [162] Inhibition of constitutively activated nuclear factor-kappaB induces reactive oxygen species- and iron-dependent cell death in cutaneous T-cell lymphoma.Cancer Res. 2009 Mar 15;69(6):2365-74. doi: 10.1158/0008-5472.CAN-08-3221. Epub 2009 Mar 3.
• [163] Inhibition of DNA methyltransferase activity upregulates Fyn tyrosine kinase expression in Hut-78 T-lymphoma cells.Biomed Pharmacother. 2008 Dec;62(10):672-6. doi: 10.1016/j.biopha.2008.01.011. Epub 2008 Feb 20.
• [164] Cutaneous spindled follicle center cell lymphoma with abundant mucin: A diagnostic pitfall.J Cutan Pathol. 2020 Apr;47(4):394-397. doi: 10.1111/cup.13609. Epub 2019 Nov 27.
• [165] Eradication of Borrelia burgdorferi infection in primary marginal zone B-cell lymphoma of the skin.Hum Pathol. 2000 Feb;31(2):263-8. doi: 10.1016/s0046-8177(00)80233-6.
• [166] Medical conditions in Ashkenazi schizophrenic pedigrees.Schizophr Bull. 1994;20(3):507-17. doi: 10.1093/schbul/20.3.507.
• [167] Inhibitor of differentiation 1 transcription factor promotes metabolic reprogramming in hepatocellular carcinoma cells.FASEB J. 2016 Jan;30(1):262-75. doi: 10.1096/fj.15-277749. Epub 2015 Sep 1.
• [168] Aberrant Ikaros, Aiolos, and Helios expression in Hodgkin and non-Hodgkin lymphoma.Blood. 2008 Mar 15;111(6):3296-7. doi: 10.1182/blood-2007-12-125682.
• [169] Intracellular BH3 Profiling Reveals Shifts in Antiapoptotic Dependency in Human B Cell Maturation and Mitogen-Stimulated Proliferation.J Immunol. 2018 Mar 1;200(5):1727-1736. doi: 10.4049/jimmunol.1701473. Epub 2018 Jan 22.
• [170] The Potential Role of a Soluble -Chain Cytokine Receptor as a Regulator of IL-7-Induced Lymphoproliferative Disorders.Int J Mol Sci. 2018 Oct 28;19(11):3375. doi: 10.3390/ijms19113375.
• [171] Proliferation and apoptosis-related gene expression in experimental acquired immunodeficiency syndrome-related simian lymphoma.Blood. 1999 Feb 15;93(4):1364-71.
• [172] Genetic alterations of 9p24 in lymphomas and their impact for cancer (immuno-)therapy.Virchows Arch. 2019 Apr;474(4):497-509. doi: 10.1007/s00428-018-2438-6. Epub 2018 Aug 21.
• [173] Colocalization and nonrandom distribution of Kv1.3 potassium channels and CD3 molecules in the plasma membrane of human T lymphocytes.Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2592-7. doi: 10.1073/pnas.0438057100. Epub 2003 Feb 25.
• [174] Cooperative epigenetic modulation by cancer amplicon genes.Cancer Cell. 2010 Dec 14;18(6):590-605. doi: 10.1016/j.ccr.2010.11.013.
• [175] A case of lymphoblastoid natural killer (NK)-cell lymphoma: association with the NK-cell receptor complex CD94/NKG2 and TP53 intragenic deletion.Br J Dermatol. 2002 Jan;146(1):148-53. doi: 10.1046/j.0007-0963.2001.04571.x.
• [176] High-resolution genomic profiling reveals clonal evolution and competition in gastrointestinal marginal zone B-cell lymphoma and its large cell variant.Int J Cancer. 2013 Feb 1;132(3):E116-27. doi: 10.1002/ijc.27774. Epub 2012 Sep 1.
• [177] CD56dimCD16neg cells are responsible for natural cytotoxicity against tumor targets.Leukemia. 2005 May;19(5):835-40. doi: 10.1038/sj.leu.2403704.
• [178] Localization of a lymphocyte-specific protein tyrosine kinase gene (lck) at a site of frequent chromosomal abnormalities in human lymphomas.Proc Natl Acad Sci U S A. 1986 Oct;83(19):7400-4. doi: 10.1073/pnas.83.19.7400.
• [179] A combination of LMO2 negative and CD38 positive is useful for the diagnosis of Burkitt lymphoma.Diagn Pathol. 2019 Sep 4;14(1):100. doi: 10.1186/s13000-019-0876-3.
• [180] Oncogenic association of the Cbp/PAG adaptor protein with the Lyn tyrosine kinase in human B-NHL rafts.Blood. 2008 Feb 15;111(4):2310-20. doi: 10.1182/blood-2007-05-090985. Epub 2007 Dec 10.
• [181] MALT1 Proteolytic Activity Suppresses Autoimmunity in a T Cell Intrinsic Manner.Front Immunol. 2019 Aug 14;10:1898. doi: 10.3389/fimmu.2019.01898. eCollection 2019.
• [182] Pharmacological and genomic profiling identifies NF-B-targeted treatment strategies for mantle cell lymphoma.Nat Med. 2014 Jan;20(1):87-92. doi: 10.1038/nm.3435. Epub 2013 Dec 22.
• [183] Cloning and expression of a murine cDNA homologous to the human RCK/P54, a lymphoma-linked chromosomal translocation junction gene on 11q23.Gene. 1995 Dec 12;166(2):293-6. doi: 10.1016/0378-1119(95)00559-5.
• [184] Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma.Leukemia. 2019 Mar;33(3):696-709. doi: 10.1038/s41375-018-0239-1. Epub 2018 Aug 21.
• [185] Lymphomas driven by Epstein-Barr virus nuclear antigen-1 (EBNA1) are dependant upon Mdm2.Oncogene. 2018 Jul;37(29):3998-4012. doi: 10.1038/s41388-018-0147-x. Epub 2018 Apr 25.
• [186] The p53 inhibitor Mdm4 cooperates with multiple genetic lesions in tumourigenesis.J Pathol. 2017 Mar;241(4):501-510. doi: 10.1002/path.4854. Epub 2017 Jan 6.
• [187] Mutational landscape of T-cell lymphoma in mice lacking the DNA mismatch repair gene Mlh1: no synergism with ionizing radiation.Carcinogenesis. 2019 Apr 29;40(2):216-224. doi: 10.1093/carcin/bgz013.
• [188] Flow Cytometry in the Differential Diagnosis of CD10-Positive Nodal Lymphomas.Lab Med. 2020 Jul 8;51(4):385-393. doi: 10.1093/labmed/lmz085.
• [189] Expression of thrombopoietin and thrombopoietin receptor MPL in human leukemia-lymphoma and solid tumor cell lines.Leuk Res. 1996 Oct;20(10):831-8. doi: 10.1016/s0145-2126(96)00057-4.
• [190] Two cases of aquaporin-4 positive neuromyelitis optica associated with T-cell lymphoma.J Neuroimmunol. 2020 Jan 15;338:577092. doi: 10.1016/j.jneuroim.2019.577092. Epub 2019 Oct 30.
• [191] GFI1B, EVI5, MYB--additional genes that cooperate with the human BCL6 gene to promote the development of lymphomas.Blood Cells Mol Dis. 2014 Jan;52(1):68-75. doi: 10.1016/j.bcmd.2013.07.003. Epub 2013 Jul 30.
• [192] MM-1, a c-Myc-binding protein, is a candidate for a tumor suppressor in leukemia/lymphoma and tongue cancer.J Biol Chem. 2001 Nov 30;276(48):45137-44. doi: 10.1074/jbc.M106127200. Epub 2001 Sep 20.
• [193] CRL4(DCAF2) negatively regulates IL-23 production in dendritic cells and limits the development of psoriasis.J Exp Med. 2018 Aug 6;215(8):1999-2017. doi: 10.1084/jem.20180210. Epub 2018 Jul 17.
• [194] Expression and clinical significance of neuropilin-1 in Epstein-Barr virus-associated lymphomas.Cancer Biomark. 2019;25(3):259-273. doi: 10.3233/CBM-192437.
• [195] NR4A3 Suppresses Lymphomagenesis through Induction of Proapoptotic Genes.Cancer Res. 2017 May 1;77(9):2375-2386. doi: 10.1158/0008-5472.CAN-16-2320. Epub 2017 Mar 1.
• [196] The role of neuregulin4 and HER4 in gastrointestinal malignant lymphoma.Mol Med Rep. 2011 Nov-Dec;4(6):1151-5. doi: 10.3892/mmr.2011.542. Epub 2011 Jul 26.
• [197] Expansion of BCR/ABL1(+) cells requires PAK2 but not PAK1.Br J Haematol. 2017 Oct;179(2):229-241. doi: 10.1111/bjh.14833. Epub 2017 Jul 14.
• [198] Tumor protein 53 mutations are enriched in diffuse large B-cell lymphoma with irregular CD19 marker expression.Sci Rep. 2017 May 8;7(1):1566. doi: 10.1038/s41598-017-01800-6.
• [199] Comparative tissue distribution of the processing enzymes "prohormone thiol protease," and prohormone convertases 1 and 2, in human PTHrP-producing cell lines and mammalian neuroendocrine tissues.Endocrine. 2001 Jul;15(2):217-24. doi: 10.1385/endo:15:2:217.
• [200] A phosphodiesterase 4B-dependent interplay between tumor cells and the microenvironment regulates angiogenesis in B-cell lymphoma.Leukemia. 2016 Mar;30(3):617-626. doi: 10.1038/leu.2015.302. Epub 2015 Oct 27.
• [201] Understanding PIM-1 kinase inhibitor interactions with free energy simulation.Phys Chem Chem Phys. 2019 Apr 3;21(14):7544-7558. doi: 10.1039/c9cp00070d.
• [202] Effects of active and inactive phospholipase D2 on signal transduction, adhesion, migration, invasion, and metastasis in EL4 lymphoma cells.Mol Pharmacol. 2008 Sep;74(3):574-84. doi: 10.1124/mol.107.040105. Epub 2008 Jun 3.
• [203] Epigenetic inactivation implies a tumor suppressor function in hematologic malignancies for Polo-like kinase 2 but not Polo-like kinase 3.Cell Cycle. 2006 Jun;5(12):1262-4. doi: 10.4161/cc.5.12.2813.
• [204] Transcriptional regulatory effects of lymphoma-associated NFKB2/lyt10 protooncogenes.Oncogene. 2000 Mar 2;19(10):1334-45. doi: 10.1038/sj.onc.1203432.
• [205] EBV-Directed T Cell Therapeutics for EBV-Associated Lymphomas.Methods Mol Biol. 2017;1532:255-265. doi: 10.1007/978-1-4939-6655-4_19.
• [206] Chemoattractant receptor-homologous molecule expressed on Th2 cells activation in vivo increases blood leukocyte counts and its blockade abrogates 13,14-dihydro-15-keto-prostaglandin D2-induced eosinophilia in rats.J Pharmacol Exp Ther. 2003 Nov;307(2):518-25. doi: 10.1124/jpet.103.055442. Epub 2003 Sep 15.
• [207] Expression and oncogenic role of Brk (PTK6/Sik) protein tyrosine kinase in lymphocytes.Am J Pathol. 2006 May;168(5):1631-41. doi: 10.2353/ajpath.2006.050521.
• [208] Induction of murine leukemia and lymphoma by dominant negative retinoic acid receptor alpha.Mol Carcinog. 2005 Dec;44(4):252-61. doi: 10.1002/mc.20144.
• [209] Defining signatures of peripheral T-cell lymphoma with a targeted 20-marker gene expression profiling assay.Haematologica. 2020 Jun;105(6):1582-1592. doi: 10.3324/haematol.2019.226647. Epub 2019 Sep 5.
• [210] Kaposi Sarcoma in Association With an Extracavitary Primary Effusion Lymphoma Showing Unusual Intravascular Involvement: Report of a Case Harboring a FAM175A Germline Mutation.Am J Dermatopathol. 2020 Jan;42(1):55-60. doi: 10.1097/DAD.0000000000001491.
• [211] ROR1 associates unfavorable prognosis and promotes lymphoma growth in DLBCL by affecting PI3K/Akt/mTOR signaling pathway.Biofactors. 2019 May;45(3):416-426. doi: 10.1002/biof.1498. Epub 2019 Feb 24.
• [212] Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13).Nat Biotechnol. 2000 Nov;18(11):1185-90. doi: 10.1038/81183.
• [213] Activation of ryanodine receptor/Ca2+ release channels downregulates CD38 in the Namalwa B lymphoma.FEBS Lett. 2003 Nov 6;554(1-2):133-7. doi: 10.1016/s0014-5793(03)01122-0.
• [214] p38 and JNK pathways control E-selectin-dependent extravasation of colon cancer cells by modulating miR-31 transcription.Oncotarget. 2017 Jan 3;8(1):1678-1687. doi: 10.18632/oncotarget.13779.
• [215] SLAMF6 as a Regulator of Exhausted CD8(+) T Cells in Cancer.Cancer Immunol Res. 2019 Sep;7(9):1485-1496. doi: 10.1158/2326-6066.CIR-18-0664. Epub 2019 Jul 17.
• [216] Inhibition of monocarboxyate transporter 1 by AZD3965 as a novel therapeutic approach for diffuse large B-cell lymphoma and Burkitt lymphoma.Haematologica. 2017 Jul;102(7):1247-1257. doi: 10.3324/haematol.2016.163030. Epub 2017 Apr 6.
• [217] Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma.Eur J Clin Pharmacol. 2011 Oct;67(10):993-1006. doi: 10.1007/s00228-011-1046-z. Epub 2011 Apr 21.
• [218] Polymorphisms in the estrogen receptor 1 and vitamin C and matrix metalloproteinase gene families are associated with susceptibility to lymphoma.PLoS One. 2008 Jun 30;3(7):e2816. doi: 10.1371/journal.pone.0002816.
• [219] Chemical evaluation and cytotoxic mechanism investigation of Clinacanthus nutans extract in lymphoma SUP-T1 cells.Environ Toxicol. 2018 Dec;33(12):1229-1236. doi: 10.1002/tox.22629. Epub 2018 Sep 6.
• [220] Pulmonary malignant lymphoma of mucosa-associated lymphoid tissue (MALT) arising in a pediatric HIV-positive patient.Am J Surg Pathol. 1995 Mar;19(3):357-63. doi: 10.1097/00000478-199503000-00014.
• [221] Stabilin-1 is expressed in human breast cancer and supports tumor growth in mammary adenocarcinoma mouse model. Oncotarget. 2016 May 24;7(21):31097-110.
• [222] SYK regulates mTOR signaling in AML.Leukemia. 2013 Nov;27(11):2118-28. doi: 10.1038/leu.2013.89. Epub 2013 Mar 28.
• [223] Growth factor independent 1B (Gfi1b) is an E2A target gene that modulates Gata3 in T-cell lymphomas.Blood. 2007 May 15;109(10):4406-14. doi: 10.1182/blood-2006-08-043331. Epub 2007 Feb 1.
• [224] Telomerase activity in B-cell non-Hodgkin lymphomas is regulated by hTERT transcription and correlated with telomere-binding protein expression but uncoupled from proliferation.Br J Cancer. 2003 Aug 18;89(4):713-9. doi: 10.1038/sj.bjc.6601112.
• [225] Enhanced TKTL1 expression in malignant tumors of the ocular adnexa predicts clinical outcome.Ophthalmology. 2012 Sep;119(9):1924-9. doi: 10.1016/j.ophtha.2012.03.037. Epub 2012 Jun 1.
• [226] Relationship between the agonist activity of synthetic ligands of TRAIL-R2 and their cell surface binding modes.Oncotarget. 2018 Feb 17;9(21):15566-15578. doi: 10.18632/oncotarget.24526. eCollection 2018 Mar 20.
• [227] The HVEM-BTLA Axis Restrains T Cell Help to Germinal Center B Cells and Functions as a Cell-Extrinsic Suppressor in Lymphomagenesis.Immunity. 2019 Aug 20;51(2):310-323.e7. doi: 10.1016/j.immuni.2019.05.022. Epub 2019 Jun 13.
• [228] Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.Hum Gene Ther. 2018 May;29(5):585-601. doi: 10.1089/hum.2018.001.
• [229] Herbal Medicines for Irinotecan-Induced Diarrhea.Front Pharmacol. 2019 Mar 29;10:182. doi: 10.3389/fphar.2019.00182. eCollection 2019.
• [230] Smoothened stabilizes and protects TRAF6 from degradation: A novel non-canonical role of smoothened with implications in lymphoma biology.Cancer Lett. 2018 Nov 1;436:149-158. doi: 10.1016/j.canlet.2018.08.020. Epub 2018 Aug 27.
• [231] Truncated TSG101 transcripts in human leukemia and lymphoma cell lines.J Cancer Res Clin Oncol. 2000 Feb;126(2):79-84.
• [232] VEGF-D is expressed in activated lymphoid cells and in tumors of hematopoietic and lymphoid tissues.Leuk Lymphoma. 2007 Oct;48(10):2014-21. doi: 10.1080/10428190701540975.
• [233] DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas.Mol Cancer Ther. 2019 Jul;18(7):1255-1264. doi: 10.1158/1535-7163.MCT-18-0919. Epub 2019 May 7.
• [234] Blockade of bulky lymphoma-associated CD55 expression by RNA interference overcomes resistance to complement-dependent cytotoxicity with rituximab.Cancer Sci. 2006 Jan;97(1):72-9. doi: 10.1111/j.1349-7006.2006.00139.x.
• [235] Study of the efficacy of a pronucleotide of 2-chloro-2'-deoxyadenosine in deoxycytidine kinase-deficient lymphoma cells.Nucleosides Nucleotides Nucleic Acids. 2006;25(9-11):997-1000. doi: 10.1080/15257770600889444.
• [236] Lack of expression of MTAP in uncommon T-cell lymphomas.Clin Lymphoma Myeloma Leuk. 2012 Oct;12(5):306-9. doi: 10.1016/j.clml.2012.07.001.
• [237] Oct transcription factors mediate t(14;18) lymphoma cell survival by directly regulating bcl-2 expression.Oncogene. 2006 Feb 9;25(6):888-98. doi: 10.1038/sj.onc.1209127.
• [238] Condensin mutations and abnormal chromosomal structures in pyothorax-associated lymphoma.Cancer Sci. 2007 Jul;98(7):1041-7. doi: 10.1111/j.1349-7006.2007.00500.x. Epub 2007 May 4.
• [239] The novel double-hit, t(8;22)(q24;q11)/MYC-IGL and t(14;15)(q32;q24)/IGH-BCL2A1, in diffuse large B-cell lymphoma.Cancer Genet. 2017 Aug;214-215:26-31. doi: 10.1016/j.cancergen.2017.03.009. Epub 2017 Apr 4.
• [240] Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells.Cell. 2016 Oct 6;167(2):405-418.e13. doi: 10.1016/j.cell.2016.08.032. Epub 2016 Sep 29.
• [241] Proinflammatory chemokine gene expression influences survival of patients with non-Hodgkin's lymphoma.Folia Histochem Cytobiol. 2011;49(2):240-7. doi: 10.5603/fhc.2011.0033.
• [242] Bright CD38 Expression by Flow Cytometric Analysis Is a Biomarker for Double/Triple Hit Lymphomas with a Moderate Sensitivity and High Specificity.Cytometry B Clin Cytom. 2019 Sep;96(5):368-374. doi: 10.1002/cyto.b.21770. Epub 2019 Feb 7.
• [243] A comprehensive evaluation of the role of genetic variation in follicular lymphoma survival.BMC Med Genet. 2014 Oct 8;15:113. doi: 10.1186/s12881-014-0113-6.
• [244] Analysis of chromosomal imbalances in de novo CD5-positive diffuse large-B-cell lymphoma detected by comparative genomic hybridization.Genes Chromosomes Cancer. 2004 Jan;39(1):77-81. doi: 10.1002/gcc.10298.
• [245] Transcription factor CCAAT/enhancer-binding protein alpha and critical circadian clock downstream target gene PER2 are highly deregulated in diffuse large B-cell lymphoma.Leuk Lymphoma. 2012 Aug;53(8):1577-85. doi: 10.3109/10428194.2012.658792. Epub 2012 Feb 21.
• [246] PKC inhibition of sotrastaurin has antitumor activity in diffuse large B-cell lymphoma via regulating the expression of MCT-1.Acta Biochim Biophys Sin (Shanghai). 2018 Apr 1;50(4):399-407. doi: 10.1093/abbs/gmy021.
• [247] Jun activation domain-binding protein 1 negatively regulate p27 kip1 in non-Hodgkin's lymphomas.Cancer Biol Ther. 2008 Mar;7(3):460-7. doi: 10.4161/cbt.7.3.5456. Epub 2007 Dec 21.
• [248] B cell lymphomas express CX3CR1 a non-B cell lineage adhesion molecule.Cancer Lett. 2008 Feb 8;259(2):138-45. doi: 10.1016/j.canlet.2007.10.031. Epub 2007 Dec 3.
• [249] Increased T-cell activation and Th1 cytokine concentrations prior to the diagnosis of B-cell lymphoma in HIV infected patients.J Clin Immunol. 2013 Jan;33(1):22-9. doi: 10.1007/s10875-012-9766-0. Epub 2012 Aug 23.
• [250] Rapid detection of clonality in patients with acute lymphoblastic leukemia.Haematologica. 2001 Apr;86(4):382-5.
• [251] Targeting Excessive EZH1 and EZH2 Activities for Abnormal Histone Methylation and Transcription Network in Malignant Lymphomas.Cell Rep. 2019 Nov 19;29(8):2321-2337.e7. doi: 10.1016/j.celrep.2019.10.083.
• [252] Blastic marginal zone lymphoma: a clinical and pathological study of 8 cases and review of the literature.Am J Dermatopathol. 2013 May;35(3):319-26. doi: 10.1097/DAD.0b013e318267495f.
• [253] KIR Genes and Patterns Given by the A Priori Algorithm: Immunity for Haematological Malignancies.Comput Math Methods Med. 2015;2015:141363. doi: 10.1155/2015/141363. Epub 2015 Sep 30.
• [254] The common viral insertion site Evi12 is located in the 5'-noncoding region of Gnn, a novel gene with enhanced expression in two subclasses of human acute myeloid leukemia.J Virol. 2005 May;79(9):5249-58. doi: 10.1128/JVI.79.9.5249-5258.2005.
• [255] IAPP-driven metabolic reprogramming induces regression of p53-deficient tumours in vivo.Nature. 2015 Jan 29;517(7536):626-30. doi: 10.1038/nature13910. Epub 2014 Nov 17.
• [256] An IL-27/Stat3 axis induces expression of programmed cell death 1 ligands (PD-L1/2) on infiltrating macrophages in lymphoma.Cancer Sci. 2016 Nov;107(11):1696-1704. doi: 10.1111/cas.13065.
• [257] Joint effect between regular use of non-steroidal anti-inflammatory drugs, variants in inflammatory genes and risk of lymphoma.Cancer Causes Control. 2008 Mar;19(2):163-73. doi: 10.1007/s10552-007-9082-9. Epub 2007 Nov 24.
• [258] Mda?/IL?4 induces the differentiation of Bcell lymphoma via activation of the P38 mitogen activated protein kinase signaling pathway.Mol Med Rep. 2017 Oct;16(4):5633-5642. doi: 10.3892/mmr.2017.7306. Epub 2017 Aug 21.
• [259] Dual enhancement of T and NK cell function by pulsatile inhibition of SHIP1 improves antitumor immunity and survival.Sci Signal. 2017 Oct 10;10(500):eaam5353. doi: 10.1126/scisignal.aam5353.
• [260] The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia.Blood. 2012 Mar 15;119(11):2590-4. doi: 10.1182/blood-2011-11-390989. Epub 2012 Jan 25.
• [261] Hyperactivation of Oncogenic JAK3 Mutants Depend on ATP Binding to the Pseudokinase Domain.Front Oncol. 2018 Dec 3;8:560. doi: 10.3389/fonc.2018.00560. eCollection 2018.
• [262] The Role of Activator Protein-1 (AP-1) Family Members in CD30-Positive Lymphomas.Cancers (Basel). 2018 Mar 28;10(4):93. doi: 10.3390/cancers10040093.
• [263] Natural killer-cell receptor polymorphisms and posttransplantation non-Hodgkin lymphoma.Blood. 2010 May 13;115(19):3960-5. doi: 10.1182/blood-2009-10-250134. Epub 2010 Mar 5.
• [264] Vaccination with immunoglobulin frame region-derived nonapeptide elicits cellular immune response against lymphoma in human leukocyte antigen-A2.1 transgenic mice.Leuk Lymphoma. 2011 Sep;52(9):1795-802. doi: 10.3109/10428194.2011.577257. Epub 2011 Jun 10.
• [265] Identification of Pax5 as a target of MTA1 in B-cell lymphomas.Cancer Res. 2007 Aug 1;67(15):7132-8. doi: 10.1158/0008-5472.CAN-07-0750.
• [266] CA125 expression in patients with non-Hodgkin's lymphoma.Leuk Lymphoma. 2006 Jul;47(7):1322-6. doi: 10.1080/10428190600580882.
• [267] Clinical and experimental aspects of notch receptor signaling: Hajdu-Cheney syndrome and related disorders.Metabolism. 2018 Mar;80:48-56. doi: 10.1016/j.metabol.2017.08.002. Epub 2017 Aug 24.
• [268] Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma.Cancer Res. 2009 Jan 15;69(2):547-53. doi: 10.1158/0008-5472.CAN-08-2968.
• [269] Carcinogenicity of dimethylarsinic acid in Ogg1-deficient mice.Cancer Sci. 2007 Jun;98(6):803-14. doi: 10.1111/j.1349-7006.2007.00475.x. Epub 2007 Apr 18.
• [270] Pim2 cooperates with PML-RARalpha to induce acute myeloid leukemia in a bone marrow transplantation model.Blood. 2010 Jun 3;115(22):4507-16. doi: 10.1182/blood-2009-03-210070. Epub 2010 Mar 9.
• [271] The role of aurora A and polo-like kinases in high-risk lymphomas.Blood Adv. 2019 Jun 11;3(11):1778-1787. doi: 10.1182/bloodadvances.2019000232.
• [272] Prolactin suppresses a progestin-induced CK5-positive cell population in luminal breast cancer through inhibition of progestin-driven BCL6 expression.Oncogene. 2014 Apr 24;33(17):2215-24. doi: 10.1038/onc.2013.172. Epub 2013 May 27.
• [273] CD148 and CD27 are expressed in B cell lymphomas derived from both memory and nave B cells.Leuk Lymphoma. 2002 Sep;43(9):1855-8. doi: 10.1080/1042819021000006385.
• [274] Down-regulation of ASY/Nogo transcription associated with progression of adult T-cell leukemia/lymphoma.Int J Cancer. 2006 Oct 1;119(7):1648-53. doi: 10.1002/ijc.22011.
• [275] The Role of SATB1 in Tumour Progression and Metastasis.Int J Mol Sci. 2019 Aug 25;20(17):4156. doi: 10.3390/ijms20174156.
• [276] Development and validation of a liquid chromatography tandem mass spectrometry assay for AZD3965 in mouse plasma and tumor tissue: Application to pharmacokinetic and breast tumor xenograft studies.J Pharm Biomed Anal. 2018 Jun 5;155:270-275. doi: 10.1016/j.jpba.2018.03.061. Epub 2018 Mar 31.
• [277] SOCS1 mutation subtypes predict divergent outcomes in diffuse large B-Cell lymphoma (DLBCL) patients.Oncotarget. 2013 Jan;4(1):35-47. doi: 10.18632/oncotarget.774.
• [278] HSP70-Hrd1 axis precludes the oncorepressor potential of N-terminal misfolded Blimp-1s in lymphoma cells.Nat Commun. 2017 Aug 25;8(1):363. doi: 10.1038/s41467-017-00476-w.
• [279] Cyclin D1 expression in B-cell lymphomas.Exp Hematol. 2010 Nov;38(11):1047-57. doi: 10.1016/j.exphem.2010.08.002. Epub 2010 Aug 18.
• [280] Respiratory uncoupling in skeletal muscle delays death and diminishes age-related disease.Cell Metab. 2007 Dec;6(6):497-505. doi: 10.1016/j.cmet.2007.10.010.
• [281] Expression of the MDR1 and MRP genes in patients with lymphoma with primary bone marrow involvement.Nucleosides Nucleotides Nucleic Acids. 2004 Oct;23(6-7):843-7. doi: 10.1081/NCN-200026029.
• [282] Cutaneous anaplastic large-cell lymphoma should be evaluated for systemic involvement regardless of ALK-1 status: case reports and review of literature.Am J Clin Dermatol. 2011 Jun 1;12(3):203-9. doi: 10.2165/11537520-000000000-00000.
• [283] Differential diagnosis between lymphoma-associated malignant pleural effusion and tuberculous pleural effusion.Ann Transl Med. 2019 Aug;7(16):373. doi: 10.21037/atm.2019.07.17.
• [284] Recurrent chromosomal rearrangements implicate oncogenes contributing to T-cell lymphomagenesis in Lck-MyrAkt2 transgenic mice.Genes Chromosomes Cancer. 2009 Sep;48(9):786-94. doi: 10.1002/gcc.20683.
• [285] ALOX12 is required for p53-mediated tumour suppression through a distinct ferroptosis pathway.Nat Cell Biol. 2019 May;21(5):579-591. doi: 10.1038/s41556-019-0305-6. Epub 2019 Apr 8.
• [286] Inhibitor of Apoptosis (IAP) proteins in hematological malignancies: molecular mechanisms and therapeutic opportunities.Leukemia. 2014 Jul;28(7):1414-22. doi: 10.1038/leu.2014.56. Epub 2014 Feb 3.
• [287] CD13+ anaplastic large cell lymphoma with leukemic presentation and additional chromosomal abnormality.Diagn Cytopathol. 2010 Feb;38(2):141-6. doi: 10.1002/dc.21170.
• [288] Insights into the Microbial L-Asparaginases: from Production to Practical Applications.Curr Protein Pept Sci. 2019;20(5):452-464. doi: 10.2174/1389203720666181114111035.
• [289] Analysis of the novel cyclin-dependent kinase 4 and 6 inhibitor gene p18 in lymphoma and leukemia cell lines.Leuk Res. 1996 Feb;20(2):197-200. doi: 10.1016/0145-2126(95)00137-9.
• [290] The incidence and risk factors of thrombosis and the need for thromboprophylaxis in lymphoma and leukemia patients: A 9-year single-center experience.J Oncol Pharm Pract. 2020 Mar;26(2):386-396. doi: 10.1177/1078155219851540. Epub 2019 Jun 2.
• [291] Mitotic slippage: an old tale with a new twist.Cell Cycle. 2019 Jan;18(1):7-15. doi: 10.1080/15384101.2018.1559557. Epub 2019 Jan 2.
• [292] Therapeutic Response to Non-genotoxic Activation of p53 by Nutlin3a Is Driven by PUMA-Mediated Apoptosis in Lymphoma Cells.Cell Rep. 2016 Mar 1;14(8):1858-66. doi: 10.1016/j.celrep.2016.01.059. Epub 2016 Feb 18.
• [293] Increased expression of the spindle checkpoint protein BubR1 is associated with high cell proliferation in primary gastrointestinal diffuse large B cell lymphoma.Cell Biochem Biophys. 2013 Jul;66(3):747-52. doi: 10.1007/s12013-013-9519-6.
• [294] Antagonist of cIAP1/2 and XIAP enhances anti-tumor immunity when combined with radiation and PD-1 blockade in a syngeneic model of head and neck cancer.Oncoimmunology. 2018 Aug 1;7(9):e1471440. doi: 10.1080/2162402X.2018.1471440. eCollection 2018.
• [295] Promoter methylation of the bone morphogenetic protein-6 gene in association with adult T-cell leukemia.Int J Cancer. 2008 Oct 15;123(8):1824-31. doi: 10.1002/ijc.23749.
• [296] Systematic Multiomics Analysis of Alterations in C1QBP mRNA Expression and Relevance for Clinical Outcomes in Cancers.J Clin Med. 2019 Apr 15;8(4):513. doi: 10.3390/jcm8040513.
• [297] Induction of apoptosis in E-myc lymphoma cells in vitro and in vivo through calpain inhibition.Exp Hematol. 2012 Jul;40(7):548-563.e2. doi: 10.1016/j.exphem.2012.02.002. Epub 2012 Feb 23.
• [298] Challenges of driving CD30-directed CAR-T cells to the clinic.BMC Cancer. 2019 Mar 6;19(1):203. doi: 10.1186/s12885-019-5415-9.
• [299] Expression of D-type cyclins in mantle cell and diffuse large B-cell lymphomas.Oncol Rep. 2016 May;35(5):2673-80. doi: 10.3892/or.2016.4658. Epub 2016 Mar 7.
• [300] CD14(+) HLA-DR low/(-) monocytes as indicator of disease aggressiveness in B-cell non-Hodgkin lymphoma.Int J Lab Hematol. 2014 Dec;36(6):650-5. doi: 10.1111/ijlh.12203. Epub 2014 Mar 17.
• [301] CAR T cell therapy: A new era for cancer treatment (Review).Oncol Rep. 2019 Dec;42(6):2183-2195. doi: 10.3892/or.2019.7335. Epub 2019 Sep 24.
• [302] Signaling pathways involved in the T-cell-mediated immunity against Epstein-Barr virus: Lessons from genetic diseases.Immunol Rev. 2019 Sep;291(1):174-189. doi: 10.1111/imr.12791.
• [303] During acute graft versus host disease CD28 deletion in donor CD8(+) , but not CD4(+) , Tcells maintain antileukemia responses in mice.Eur J Immunol. 2018 Dec;48(12):2055-2067. doi: 10.1002/eji.201847669. Epub 2018 Nov 14.
• [304] Development of A Chimeric Antigen Receptor Targeting C-Type Lectin-Like Molecule-1 for Human Acute Myeloid Leukemia.Int J Mol Sci. 2017 Oct 27;18(11):2259. doi: 10.3390/ijms18112259.
• [305] High frequency of inactivating tetraspanin C D37 mutations in diffuse large B-cell lymphoma at immune-privileged sites.Blood. 2019 Sep 19;134(12):946-950. doi: 10.1182/blood.2019001185. Epub 2019 Jul 31.
• [306] CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response.Cancer Cell. 2019 Mar 18;35(3):473-488.e6. doi: 10.1016/j.ccell.2019.02.006.
• [307] Epigenetic regulation of CD44 in Hodgkin and non-Hodgkin lymphoma.BMC Cancer. 2010 Sep 29;10:517. doi: 10.1186/1471-2407-10-517.
• [308] CD47/SIRP blocking enhances CD19/CD3-bispecific T cell engager antibody-mediated lysis of B cell malignancies.Biochem Biophys Res Commun. 2019 Feb 12;509(3):739-745. doi: 10.1016/j.bbrc.2018.12.175. Epub 2019 Jan 3.
• [309] CD74 interferes with the expression of fas receptor on the surface of lymphoma cells.J Exp Clin Cancer Res. 2014 Oct 10;33(1):80. doi: 10.1186/s13046-014-0080-y.
• [310] CD79B mutations in primary vitreoretinal lymphoma: Diagnostic and prognostic potential.Eur J Haematol. 2019 Feb;102(2):191-196. doi: 10.1111/ejh.13191. Epub 2018 Nov 23.
• [311] Evaluation of costimulatory molecules in dogs with B cell high grade lymphoma.PLoS One. 2018 Jul 24;13(7):e0201222. doi: 10.1371/journal.pone.0201222. eCollection 2018.
• [312] HIV-associated benign lymphoepithelial cysts of the parotid glands confirmed by HIV-1 p24 antigen immunostaining.BMJ Case Rep. 2017 Sep 28;2017:bcr2017221869. doi: 10.1136/bcr-2017-221869.
• [313] Study on the role of G1 cyclins in Epstein-Barr virus-associated human lymphomas maintained in severe combined immune deficiency (SCID) mice.Int J Cancer. 2001 Apr 15;92(2):232-9. doi: 10.1002/1097-0215(200102)9999:9999<::aid-ijc1171>3.0.co;2-r.
• [314] Hedyotisdiffusa Willd inhibits proliferation and induces apoptosis of 5FU resistant colorectal cancer cells by regulating the PI3K/AKT signaling pathway.Mol Med Rep. 2018 Jan;17(1):358-365. doi: 10.3892/mmr.2017.7903. Epub 2017 Oct 26.
• [315] Expression of cyclin-dependent kinase 6 (cdk6) and frequent loss of CD44 in nasal-nasopharyngeal NK/T-cell lymphomas: comparison with CD56-negative peripheral T-cell lymphomas.Lab Invest. 2000 Jun;80(6):893-900. doi: 10.1038/labinvest.3780093.
• [316] Efficacy of the novel CDK7 inhibitor QS1189 in mantle cell lymphoma.Sci Rep. 2019 May 10;9(1):7193. doi: 10.1038/s41598-019-43760-z.
• [317] Genes Associated with Human Cancers: Their Expressions, Features, Functions, and Significance.Crit Rev Eukaryot Gene Expr. 2015;25(3):209-38. doi: 10.1615/critreveukaryotgeneexpr.2015013893.
• [318] Clinicopathological analysis of 46 cases with CD4(+) and/or CD56(+) immature haematolymphoid malignancy: reappraisal of blastic plasmacytoid dendritic cell and related neoplasms.Histopathology. 2017 Dec;71(6):972-984. doi: 10.1111/his.13340. Epub 2017 Oct 10.
• [319] Detection of Tax-specific CTLs in lymph nodes of adult T-cell leukemia/lymphoma patients and its association with Foxp3 positivity of regulatory T-cell function.Oncol Lett. 2017 Jun;13(6):4611-4618. doi: 10.3892/ol.2017.6067. Epub 2017 Apr 21.
• [320] Clinical significance of co-expression of CD21 and LFA-1 in B-cell lymphoma.Int J Hematol. 2009 May;89(4):497-507. doi: 10.1007/s12185-009-0303-8. Epub 2009 Apr 11.
• [321] The CREB Coactivator CRTC2 Is a Lymphoma Tumor Suppressor that Preserves Genome Integrity through Transcription of DNA Mismatch Repair Genes.Cell Rep. 2015 Jun 9;11(9):1350-7. doi: 10.1016/j.celrep.2015.04.052. Epub 2015 May 21.
• [322] CSF1R Protein Expression in Reactive Lymphoid Tissues and Lymphoma: Its Relevance in Classical Hodgkin Lymphoma.PLoS One. 2015 Jun 12;10(6):e0125203. doi: 10.1371/journal.pone.0125203. eCollection 2015.
• [323] Biomarker Dynamics in B-cell Lymphoma: A Longitudinal Prospective Study of Plasma Samples Up to 25 Years before Diagnosis.Cancer Res. 2017 Mar 15;77(6):1408-1415. doi: 10.1158/0008-5472.CAN-16-2345. Epub 2017 Jan 20.
• [324] A CXCR4-targeted nanocarrier achieves highly selective tumor uptake in diffuse large B-cell lymphoma mouse models.Haematologica. 2020 Mar;105(3):741-753. doi: 10.3324/haematol.2018.211490. Epub 2019 Jun 27.
• [325] Diacylglycerol Kinase Limits Cytokine-dependent Expansion of CD8(+) T Cells with Broad Antitumor Capacity.EBioMedicine. 2017 May;19:39-48. doi: 10.1016/j.ebiom.2017.04.024. Epub 2017 Apr 14.
• [326] The EML4-ALK transcript but not the fusion protein can be expressed in reactive and neoplastic lymphoid tissues.Haematologica. 2009 Sep;94(9):1307-11. doi: 10.3324/haematol.2009.008045.
• [327] Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas.Clin Cancer Res. 2019 Sep 1;25(17):5271-5283. doi: 10.1158/1078-0432.CCR-18-3989. Epub 2019 Apr 12.
• [328] Regulation of EBV LMP1-triggered EphA4 downregulation in EBV-associated B lymphoma and its impact on patients' survival.Blood. 2016 Sep 22;128(12):1578-89. doi: 10.1182/blood-2016-02-702530. Epub 2016 Jun 23.
• [329] Functional genomics lead to new therapies in follicular lymphoma.Ann N Y Acad Sci. 2013 Jul;1293:18-24. doi: 10.1111/nyas.12120. Epub 2013 May 15.
• [330] Insertional mutagenesis using the Sleeping Beauty transposon system identifies drivers of erythroleukemia in mice.Sci Rep. 2019 Apr 2;9(1):5488. doi: 10.1038/s41598-019-41805-x.
• [331] Global characterization of proteome and lysine methylome features in EZH2 wild-type and mutant lymphoma cell lines.J Proteomics. 2020 Feb 20;213:103614. doi: 10.1016/j.jprot.2019.103614. Epub 2019 Dec 14.
• [332] JAM-A overexpression is related to disease progression in diffuse large B-cell lymphoma and downregulated by lenalidomide.Sci Rep. 2017 Aug 7;7(1):7433. doi: 10.1038/s41598-017-07964-5.
• [333] High coagulation factor VIII and von Willebrand factor in patients with lymphoma and leukemia.Int J Hematol. 2016 Feb;103(2):189-95. doi: 10.1007/s12185-015-1913-y. Epub 2015 Nov 26.
• [334] Differential regulation of miR-146a/FAS and miR-21/FASLG axes in autoimmune lymphoproliferative syndrome due to FAS mutation (ALPS-FAS).Clin Exp Immunol. 2016 Aug;185(2):148-53. doi: 10.1111/cei.12800. Epub 2016 May 24.
• [335] Np63/DGCR8-Dependent MicroRNAs Mediate Therapeutic Efficacy of HDAC Inhibitors in Cancer.Cancer Cell. 2016 Jun 13;29(6):874-888. doi: 10.1016/j.ccell.2016.04.016.
• [336] Lymphangiogenesis is a feature of acute GVHD, and VEGFR-3 inhibition protects against experimental GVHD.Blood. 2017 Mar 30;129(13):1865-1875. doi: 10.1182/blood-2016-08-734210. Epub 2017 Jan 17.
• [337] UCH-L1 is induced in germinal center B cells and identifies patients with aggressive germinal center diffuse large B-cell lymphoma.Blood. 2016 Mar 24;127(12):1564-74. doi: 10.1182/blood-2015-07-656678. Epub 2015 Dec 23.
• [338] Efficient transduction of murine B lymphocytes and B lymphoma lines by modified adenoviral vectors: enhancement via targeting to FcR and heparan-containing proteins.Gene Ther. 2001 Jun;8(12):938-45. doi: 10.1038/sj.gt.3301487.
• [339] t(X;14)(p11;q32) in MALT lymphoma involving GPR34 reveals a role for GPR34 in tumor cell growth.Blood. 2012 Nov 8;120(19):3949-57. doi: 10.1182/blood-2011-11-389908. Epub 2012 Sep 10.
• [340] Interplay between HGAL and Grb2 proteins regulates B-cell receptor signaling.Blood Adv. 2019 Aug 13;3(15):2286-2297. doi: 10.1182/bloodadvances.2018016162.
• [341] Small-Molecule Inhibition of PD-1 Transcription Is an Effective Alternative to Antibody Blockade in Cancer Therapy.Cancer Res. 2018 Feb 1;78(3):706-717. doi: 10.1158/0008-5472.CAN-17-0491. Epub 2017 Oct 20.
• [342] Activation of MET signaling by HDAC6 offers a rationale for a novel ricolinostat and crizotinib combinatorial therapeutic strategy in diffuse large B-cell lymphoma.J Pathol. 2018 Oct;246(2):141-153. doi: 10.1002/path.5108. Epub 2018 Aug 20.
• [343] The transcriptional repressor HDAC7 promotes apoptosis and c-Myc downregulation in particular types of leukemia and lymphoma.Cell Death Dis. 2015 Feb 12;6(2):e1635. doi: 10.1038/cddis.2014.594.
• [344] Correction: Predictive biomarkers for disease sensitivity in lymphoma - the holy grail for HDAC inhibitors?.Oncotarget. 2019 Feb 26;10(17):1661. doi: 10.18632/oncotarget.26767. eCollection 2019 Feb 26.
• [345] HLA-DQA1*0103-DQB1*0601 haplotype and Helicobacter pylori-positive gastric mucosa-associated lymphoid tissue lymphoma.Clin Gastroenterol Hepatol. 2005 Sep;3(9):865-8. doi: 10.1016/s1542-3565(05)00185-0.
• [346] HLA-G expression in hematologic malignancies.Expert Rev Hematol. 2010 Feb;3(1):67-80. doi: 10.1586/ehm.09.72.
• [347] High mobility group A1 protein acts as a new target of Notch1 signaling and regulates cell proliferation in T leukemia cells.Mol Cell Biochem. 2013 Feb;374(1-2):173-80. doi: 10.1007/s11010-012-1517-2. Epub 2012 Nov 16.
• [348] Coexpression of B-lymphoma Moloney murine leukemia virus insertion region-1 and sex-determining region of Y chromosome-related high mobility group box-2 in cervical carcinogenesis.Hum Pathol. 2013 Feb;44(2):208-17. doi: 10.1016/j.humpath.2012.02.020. Epub 2012 Aug 3.
• [349] The heparanase inhibitor PG545 is a potent anti-lymphoma drug: Mode of action.Matrix Biol. 2019 Apr;77:58-72. doi: 10.1016/j.matbio.2018.08.005. Epub 2018 Aug 7.
• [350] Ganetespib synergizes with cyclophosphamide to improve survival of mice with autochthonous tumors in a mutant p53-dependent manner.Cell Death Dis. 2017 Mar 16;8(3):e2683. doi: 10.1038/cddis.2017.108.
• [351] HSPB8 is methylated in hematopoietic malignancies and overexpression of HSPB8 exhibits antileukemia effect.Exp Hematol. 2012 Jan;40(1):14-21. doi: 10.1016/j.exphem.2011.09.004. Epub 2011 Sep 10.
• [352] Growth-inhibition of cell lines derived from B cell lymphomas through antagonism of serotonin receptor signaling.Sci Rep. 2019 Mar 12;9(1):4276. doi: 10.1038/s41598-019-40825-x.
• [353] T-cell regulation by casitas B-lineage lymphoma (Cblb) is a critical failsafe against autoimmune disease due to autoimmune regulator (Aire) deficiency.Proc Natl Acad Sci U S A. 2010 Aug 17;107(33):14709-14. doi: 10.1073/pnas.1009209107. Epub 2010 Jul 28.
• [354] The interleukin-12 and interleukin-12 receptor system in normal and transformed human B lymphocytes.Haematologica. 2002 Apr;87(4):434-42.
• [355] Chromosome analyses in chronic lymphocytic leukemia and related B-cell neoplasms.Cancer Genet Cytogenet. 1991 Aug;55(1):49-56. doi: 10.1016/0165-4608(91)90234-l.
• [356] Structural and diffusion weighted MRI demonstrates responses to ibrutinib in a mouse model of follicular helper (Tfh) T-cell lymphoma.PLoS One. 2019 Apr 23;14(4):e0215765. doi: 10.1371/journal.pone.0215765. eCollection 2019.
• [357] Absence of Grail promotes CD8(+) T cell anti-tumour activity.Nat Commun. 2017 Aug 10;8(1):239. doi: 10.1038/s41467-017-00252-w.
• [358] Interleukin-25 Axis Is Involved in the Pathogenesis of Human Primary and Experimental Murine Sjgren's Syndrome.Arthritis Rheumatol. 2018 Aug;70(8):1265-1275. doi: 10.1002/art.40500. Epub 2018 Jun 27.
• [359] The hypereosinophilic syndromes: current concepts and treatments.Br J Haematol. 2009 May;145(3):271-85. doi: 10.1111/j.1365-2141.2009.07599.x.
• [360] The role of interleukin-9 in lymphoma.Leuk Lymphoma. 2013 Jul;54(7):1367-72. doi: 10.3109/10428194.2012.745072. Epub 2012 Dec 5.
• [361] Interleukin 1 receptor-associated kinase 1 (IRAK1) mutation is a common, essential driver for Kaposi sarcoma herpesvirus lymphoma.Proc Natl Acad Sci U S A. 2014 Nov 4;111(44):E4762-8. doi: 10.1073/pnas.1405423111. Epub 2014 Oct 23.
• [362] Early Generated B-1-Derived B Cells Have the Capacity To Progress To Become Mantle Cell Lymphoma-like Neoplasia in Aged Mice.J Immunol. 2018 Jul 15;201(2):804-813. doi: 10.4049/jimmunol.1800400. Epub 2018 Jun 13.
• [363] Th17 cytokine differentiation and loss of plasticity after SOCS1 inactivation in a cutaneous T-cell lymphoma.Oncotarget. 2016 Jun 7;7(23):34201-16. doi: 10.18632/oncotarget.9077.
• [364] Inhibitors of histone acetyltransferases KAT6A/B induce senescence and arrest tumour growth.Nature. 2018 Aug;560(7717):253-257. doi: 10.1038/s41586-018-0387-5. Epub 2018 Aug 1.
• [365] Low concentrations of permethrin and malathion induce numerical and structural abnormalities in KMT2A and IGH genes in vitro.J Appl Toxicol. 2018 Sep;38(9):1262-1270. doi: 10.1002/jat.3638. Epub 2018 May 9.
• [366] High intratumoural galectin-1 expression predicts adverse outcome in ALK(-) ALCL and CD30(+) PTCL-NOS.Hematol Oncol. 2020 Feb;38(1):59-66. doi: 10.1002/hon.2702. Epub 2020 Jan 1.
• [367] Outcomes for HIV-associated diffuse large B-cell lymphoma in the modern combined antiretroviral therapy era.AIDS. 2017 Nov 28;31(18):2493-2501. doi: 10.1097/QAD.0000000000001652.
• [368] Mutations in the mitotic check point gene, MAD1L1, in human cancers.Oncogene. 2001 May 31;20(25):3301-5. doi: 10.1038/sj.onc.1204421.
• [369] Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy.Lancet. 2001 Jan 6;357(9249):39-40. doi: 10.1016/S0140-6736(00)03571-6.
• [370] Novel phosphorylated TAK1 species with functional impact on NF-B and -catenin signaling in human Cutaneous T-cell lymphoma.Leukemia. 2018 Oct;32(10):2211-2223. doi: 10.1038/s41375-018-0066-4. Epub 2018 Feb 22.
• [371] Relapse of HHV8-positive multicentric Castleman disease following rituximab-based therapy in HIV-positive patients.Blood. 2017 Apr 13;129(15):2143-2147. doi: 10.1182/blood-2016-10-747477. Epub 2017 Jan 31.
• [372] Association between the MTHFR A1298C polymorphism and risk of cancer: evidence from 265 case-control studies.Mol Genet Genomics. 2016 Feb;291(1):51-63. doi: 10.1007/s00438-015-1082-y. Epub 2015 Jul 9.
• [373] The anti-invasive role of novel synthesized pyridazine hydrazide appended phenoxy acetic acid against neoplastic development targeting matrix metallo proteases.Biomed Pharmacother. 2017 Nov;95:375-386. doi: 10.1016/j.biopha.2017.08.105. Epub 2017 Sep 12.
• [374] Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas.Blood. 2008 Jun 15;111(12):5683-90. doi: 10.1182/blood-2007-10-118794. Epub 2008 Apr 7.
• [375] Immunohistochemical distinction of ABC and GCB in extranodal DLBCL is not reflected in mutation patterns.Leuk Res. 2019 Jan;76:107-111. doi: 10.1016/j.leukres.2018.10.003. Epub 2018 Oct 10.
• [376] Expression patterns of nicotinamide phosphoribosyltransferase and nicotinic acid phosphoribosyltransferase in human malignant lymphomas.APMIS. 2011 Apr;119(4-5):296-303. doi: 10.1111/j.1600-0463.2011.02733.x. Epub 2011 Mar 25.
• [377] Hodgkin-Reed-Sternberg cells in classical Hodgkin lymphoma show alterations of genes encoding the NADPH oxidase complex and impaired reactive oxygen species synthesis capacity.PLoS One. 2013 Dec 23;8(12):e84928. doi: 10.1371/journal.pone.0084928. eCollection 2013.
• [378] Discovery of a novel natural killer cell line with distinct immunostimulatory and proliferative potential as an alternative platform for cancer immunotherapy.J Immunother Cancer. 2019 May 24;7(1):138. doi: 10.1186/s40425-019-0612-2.
• [379] Enhanced antitumor effect of cisplatin in human oral squamous cell carcinoma cells by tumor suppressor GRIM?9.Mol Med Rep. 2015 Dec;12(6):8185-92. doi: 10.3892/mmr.2015.4423. Epub 2015 Oct 9.
• [380] Myc suppression of Nfkb2 accelerates lymphomagenesis.BMC Cancer. 2010 Jul 2;10:348. doi: 10.1186/1471-2407-10-348.
• [381] NDPKA is not just a metastasis suppressor - be aware of its metastasis-promoting role in neuroblastoma.Lab Invest. 2018 Feb;98(2):219-227. doi: 10.1038/labinvest.2017.105. Epub 2017 Oct 9.
• [382] The frequency of NOTCH1 variants in T-acute lymphoblastic leukemia/lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma among Jordanian patients.Ann Diagn Pathol. 2019 Apr;39:53-58. doi: 10.1016/j.anndiagpath.2019.01.004. Epub 2019 Jan 24.
• [383] SHP-1 promoter 2 methylation in normal epithelial tissues and demethylation in psoriasis.J Mol Med (Berl). 2006 Feb;84(2):175-82. doi: 10.1007/s00109-005-0020-6. Epub 2005 Dec 31.
• [384] Cytoplasmic location of NR4A1 in aggressive lymphomas is associated with a favourable cancer specific survival.Sci Rep. 2018 Sep 28;8(1):14528. doi: 10.1038/s41598-018-32972-4.
• [385] Genetic alterations of p53 and ras genes in 1,3-butadiene- and 2',3'-dideoxycytidine-induced lymphomas.Cancer Res. 1997 Jul 1;57(13):2710-4.
• [386] PBK/TOPK is a novel mitotic kinase which is upregulated in Burkitt's lymphoma and other highly proliferative malignant cells.Blood Cells Mol Dis. 2001 Sep-Oct;27(5):825-9. doi: 10.1006/bcmd.2001.0452.
• [387] The direct Myc target Pim3 cooperates with other Pim kinases in supporting viability of Myc-induced B-cell lymphomas.Oncotarget. 2011 Jun;2(6):448-60. doi: 10.18632/oncotarget.283.
• [388] The telomerase inhibitor PinX1 is a major haploinsufficient tumor suppressor essential for chromosome stability in mice.J Clin Invest. 2011 Apr;121(4):1266-82. doi: 10.1172/JCI43452. Epub 2011 Mar 23.
• [389] EBV lymphoproliferative-associated disease and primary cardiac T-cell lymphoma in a STK4 deficient patient: A case report.Medicine (Baltimore). 2017 Dec;96(48):e8852. doi: 10.1097/MD.0000000000008852.
• [390] The deregulated promoter methylation of the Polo-like kinases as a potential biomarker in hematological malignancies.Leuk Lymphoma. 2015 Jul;56(7):2123-33. doi: 10.3109/10428194.2014.971407. Epub 2015 Jan 24.
• [391] Mismatch repair gene expression in malignant lymphoproliferative disorders of B-cell origin.Leuk Lymphoma. 2002 Feb;43(2):393-9. doi: 10.1080/10428190290006215.
• [392] Mantle cell lymphoma salvage regimen: synergy between a reprogrammed oncolytic virus and two chemotherapeutics.Gene Ther. 2010 Dec;17(12):1506-16. doi: 10.1038/gt.2010.103. Epub 2010 Aug 5.
• [393] Paraoxonase 1 (PON1) Q192R Gene Polymorphism and Cancer Risk: A Meta-Analysis Based on 30 Publications.Asian Pac J Cancer Prev. 2015;16(10):4457-63. doi: 10.7314/apjcp.2015.16.10.4457.
• [394] The heat shock protein-90 co-chaperone, Cyclophilin 40, promotes ALK-positive, anaplastic large cell lymphoma viability and its expression is regulated by the NPM-ALK oncoprotein.BMC Cancer. 2012 Jun 8;12:229. doi: 10.1186/1471-2407-12-229.
• [395] Metronomic therapy for refractory/relapsed lymphoma: the PEP-C low-dose oral combination chemotherapy regimen.Hematology. 2012 Apr;17 Suppl 1:S90-2. doi: 10.1179/102453312X13336169155970.
• [396] Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas.Clin Cancer Res. 2015 Sep 1;21(17):3986-94. doi: 10.1158/1078-0432.CCR-14-2116. Epub 2015 May 19.
• [397] Protein arginine methyltransferase 5 (PRMT5) promotes survival of lymphoma cells via activation of WNT/-catenin and AKT/GSK3 proliferative signaling.J Biol Chem. 2019 May 10;294(19):7692-7710. doi: 10.1074/jbc.RA119.007640. Epub 2019 Mar 18.
• [398] Polymorphisms in integrin genes and lymphoma risk.Leuk Res. 2011 Jul;35(7):968-70. doi: 10.1016/j.leukres.2010.12.012. Epub 2011 Jan 15.
• [399] Prostaglandin E2 regulates B cell proliferation through a candidate tumor suppressor, Ptger4.J Exp Med. 2008 Dec 22;205(13):3091-103. doi: 10.1084/jem.20081163. Epub 2008 Dec 15.
• [400] Development of new PTK7-targeting aptamer-fluorescent and -radiolabelled probes for evaluation as molecular imaging agents: Lymphoma and melanoma in vivo proof of concept.Bioorg Med Chem. 2017 Feb 1;25(3):1163-1171. doi: 10.1016/j.bmc.2016.12.026. Epub 2016 Dec 24.
• [401] PRL-2 increases Epo and IL-3 responses in hematopoietic cells.Blood Cells Mol Dis. 2010 Apr 15;44(4):209-14. doi: 10.1016/j.bcmd.2010.02.013. Epub 2010 Mar 11.
• [402] TC-PTP and PTP1B: Regulating JAK-STAT signaling, controlling lymphoid malignancies.Cytokine. 2016 Jun;82:52-7. doi: 10.1016/j.cyto.2015.12.025. Epub 2016 Jan 23.
• [403] Critical role of SHP2 (PTPN11) signaling in germinal center-derived lymphoma.Haematologica. 2014 Dec;99(12):1834-45. doi: 10.3324/haematol.2014.106401. Epub 2014 Sep 5.
• [404] 5-Azacitidine induces demethylation of PTPL1 and inhibits growth in non-Hodgkin lymphoma.Int J Mol Med. 2015 Sep;36(3):698-704. doi: 10.3892/ijmm.2015.2269. Epub 2015 Jul 1.
• [405] Benzoquinone, a leukemogenic metabolite of benzene, catalytically inhibits the protein tyrosine phosphatase PTPN2 and alters STAT1 signaling.J Biol Chem. 2019 Aug 16;294(33):12483-12494. doi: 10.1074/jbc.RA119.008666. Epub 2019 Jun 27.
• [406] EBV and KSHV Infection Dysregulates Autophagy to Optimize Viral Replication, Prevent Immune Recognition and Promote Tumorigenesis.Viruses. 2018 Oct 31;10(11):599. doi: 10.3390/v10110599.
• [407] PKK deficiency in B cells prevents lupus development in Sle lupus mice.Immunol Lett. 2017 May;185:1-11. doi: 10.1016/j.imlet.2017.03.002. Epub 2017 Mar 6.
• [408] Cell cycle and apoptosis regulatory protein (CARP)-1 is a novel, adriamycin-inducible, diffuse large B-cell lymphoma (DLBL) growth suppressor.Cancer Chemother Pharmacol. 2011 Jun;67(6):1401-13. doi: 10.1007/s00280-010-1442-6. Epub 2010 Aug 31.
• [409] Retinoic Acid Receptor-Related Orphan Receptors: Critical Roles in Tumorigenesis.Front Immunol. 2018 May 31;9:1187. doi: 10.3389/fimmu.2018.01187. eCollection 2018.
• [410] Recent Advances in the Function of the 67 kDa Laminin Receptor and its Targeting for Personalized Therapy in Cancer.Curr Pharm Des. 2017;23(32):4745-4757. doi: 10.2174/1381612823666170710125332.
• [411] Addiction to Runx1 is partially attenuated by loss of p53 in the E-Myc lymphoma model.Oncotarget. 2016 Apr 26;7(17):22973-87. doi: 10.18632/oncotarget.8554.
• [412] Primary malignant lymphoma of the brain: frequent abnormalities and inactivation of p14 tumor suppressor gene.Cancer Sci. 2005 Jan;96(1):38-41. doi: 10.1111/j.1349-7006.2005.00003.x.
• [413] SUMOylation Confers Posttranslational Stability on NPM-ALK Oncogenic Protein.Neoplasia. 2015 Sep;17(9):742-754. doi: 10.1016/j.neo.2015.09.005.
• [414] Protein biomarker identification in the CSF of patients with CNS lymphoma.J Clin Oncol. 2008 Jan 1;26(1):96-105. doi: 10.1200/JCO.2007.12.1053. Epub 2007 Dec 3.
• [415] Angioedema due to acquired C1-inhibitor deficiency: spectrum and treatment with C1-inhibitor concentrate.Orphanet J Rare Dis. 2019 Mar 13;14(1):65. doi: 10.1186/s13023-019-1043-3.
• [416] Runx1 Orchestrates Sphingolipid Metabolism and Glucocorticoid Resistance in Lymphomagenesis.J Cell Biochem. 2017 Jun;118(6):1432-1441. doi: 10.1002/jcb.25802. Epub 2017 Jan 10.
• [417] The p27-Skp2 axis mediates glucocorticoid-induced cell cycle arrest in T-lymphoma cells.Cell Cycle. 2013 Aug 15;12(16):2625-35. doi: 10.4161/cc.25622. Epub 2013 Jul 9.
• [418] Collaboration of MYC and RUNX2 in lymphoma simulates T-cell receptor signaling and attenuates p53 pathway activity.J Cell Biochem. 2019 Oct;120(10):18332-18345. doi: 10.1002/jcb.29143. Epub 2019 Jun 30.
• [419] Targeting sphingosine kinase induces apoptosis and tumor regression for KSHV-associated primary effusion lymphoma.Mol Cancer Ther. 2014 Jan;13(1):154-64. doi: 10.1158/1535-7163.MCT-13-0466. Epub 2013 Oct 18.
• [420] STAT6 knockdown using multiple siRNA sequences inhibits proliferation and induces apoptosis of human colorectal and breast cancer cell lines.PLoS One. 2019 May 10;14(5):e0207558. doi: 10.1371/journal.pone.0207558. eCollection 2019.
• [421] STK38 is a critical upstream regulator of MYC's oncogenic activity in human B-cell lymphoma.Oncogene. 2013 Nov 7;32(45):5283-91. doi: 10.1038/onc.2012.543. Epub 2012 Nov 26.
• [422] EBV Negative Lymphoma and Autoimmune Lymphoproliferative Syndrome Like Phenotype Extend the Clinical Spectrum of Primary Immunodeficiency Caused by STK4 Deficiency.Front Immunol. 2018 Oct 16;9:2400. doi: 10.3389/fimmu.2018.02400. eCollection 2018.
• [423] Identification of Somatic Mutations in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type by Massive Parallel Sequencing. J Invest Dermatol. 2017 Sep;137(9):1984-1994. doi: 10.1016/j.jid.2017.04.010. Epub 2017 May 4.
• [424] The NF-B subunit c-Rel regulates Bach2 tumour suppressor expression in B-cell lymphoma.Oncogene. 2016 Jun 30;35(26):3476-84. doi: 10.1038/onc.2015.399. Epub 2015 Nov 2.
• [425] Gene dosage reductions of Trf1 and/or Tin2 induce telomere DNA damage and lymphoma formation in aging mice.Leukemia. 2017 Dec;31(12):2853. doi: 10.1038/leu.2017.224. Epub 2017 Nov 10.
• [426] Up-regulation of T-lymphoma and metastasis gene 1 in gastric cancer and its involvement in cell invasion and migration.Chin Med J (Engl). 2013 Feb;126(4):640-5.
• [427] TIRAP p.R81C is a novel lymphoma risk variant which enhances cell proliferation via NF-B mediated signaling in B-cells.Haematologica. 2019 Apr;104(4):766-777. doi: 10.3324/haematol.2018.201590. Epub 2018 Oct 31.
• [428] A sensitive and kinetically defined radiochemical assay for canine and human serum thymidine kinase 1 (TK1) to monitor canine malignant lymphoma.Vet J. 2012 Oct;194(1):40-7. doi: 10.1016/j.tvjl.2012.03.006. Epub 2012 Apr 18.
• [429] CD8-independent tumor cell recognition is a property of the T cell receptor and not the T cell.J Immunol. 2003 Mar 1;170(5):2582-9. doi: 10.4049/jimmunol.170.5.2582.
• [430] A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells.Leukemia. 2017 Jul;31(7):1611-1621. doi: 10.1038/leu.2016.352. Epub 2017 Nov 28.
• [431] Breast Cancer (18)F-ISO-1 Uptake as a Marker of Proliferation Status.J Nucl Med. 2020 May;61(5):665-670. doi: 10.2967/jnumed.119.232363. Epub 2019 Dec 13.
• [432] Development of a high-resolution melting method for the screening of TNFAIP3 gene mutations.Oncol Rep. 2016 May;35(5):2936-42. doi: 10.3892/or.2016.4662. Epub 2016 Mar 8.
• [433] Association of polymorphisms in TRAIL1 and TRAILR1 genes with susceptibility to lymphomas.Ann Hematol. 2014 Feb;93(2):243-7. doi: 10.1007/s00277-013-1864-4.
• [434] Genetic variants in interleukin-2 and risk of lymphoma among children in Korea.Asian Pac J Cancer Prev. 2012;13(2):621-3. doi: 10.7314/apjcp.2012.13.2.621.
• [435] CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies.Sci Transl Med. 2019 Sep 25;11(511):eaaw9414. doi: 10.1126/scitranslmed.aaw9414.
• [436] Enhancing immunotherapy of STING agonist for lymphoma in preclinical models.Blood Adv. 2018 Sep 11;2(17):2230-2241. doi: 10.1182/bloodadvances.2018020040.
• [437] Augmentation of CD134 (OX40)-dependent NK anti-tumour activity is dependent on antibody cross-linking.Sci Rep. 2018 Feb 2;8(1):2278. doi: 10.1038/s41598-018-20656-y.
• [438] CD137 deficiency causes immune dysregulation with predisposition to lymphomagenesis.Blood. 2019 Oct 31;134(18):1510-1516. doi: 10.1182/blood.2019000644.
• [439] A novel dual-cytokine-antibody fusion protein for the treatment of CD38-positive malignancies.Protein Eng Des Sel. 2018 May 1;31(5):173-179. doi: 10.1093/protein/gzy015.
• [440] Systemic lupus erythematosus and lymphoma: Incidence, pathogenesis and biology.Leuk Res. 2018 Dec;75:45-49. doi: 10.1016/j.leukres.2018.11.004. Epub 2018 Nov 12.
• [441] Genetic contributors and soluble mediators in prediction of autoimmune comorbidity.J Autoimmun. 2019 Nov;104:102317. doi: 10.1016/j.jaut.2019.102317. Epub 2019 Aug 20.
• [442] Adenovirus-mediated LIGHT gene modification in murine B-cell lymphoma elicits a potent antitumor effect.Cell Mol Immunol. 2010 Jul;7(4):296-305. doi: 10.1038/cmi.2010.15. Epub 2010 Apr 26.
• [443] Combined cellular and soluble mediator analysis for improved diagnosis of vitreoretinal lymphoma.Acta Ophthalmol. 2019 Sep;97(6):626-632. doi: 10.1111/aos.14036. Epub 2019 Jan 27.
• [444] In vivo detection of human TRPV6-rich tumors with anti-cancer peptides derived from soricidin. PLoS One. 2013;8(3):e58866.
• [445] Analysis of Aurora-A and hMPS1 mitotic kinases in mantle cell lymphoma.Int J Cancer. 2006 Jan 15;118(2):357-63. doi: 10.1002/ijc.21370.
• [446] Kinome profiling of non-Hodgkin lymphoma identifies Tyro3 as a therapeutic target in primary effusion lymphoma.Proc Natl Acad Sci U S A. 2019 Aug 13;116(33):16541-16550. doi: 10.1073/pnas.1903991116. Epub 2019 Jul 25.
• [447] Wiskott-Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma.Nat Med. 2019 Jan;25(1):130-140. doi: 10.1038/s41591-018-0262-9. Epub 2018 Dec 3.
• [448] Polymorphisms in DNA repair genes and risk of non-Hodgkin lymphoma among women in Connecticut.Hum Genet. 2006 Jul;119(6):659-68. doi: 10.1007/s00439-006-0177-2. Epub 2006 Apr 26.
• [449] X-linked lymphoproliferative syndrome in mainland China: review of clinical, genetic, and immunological characteristic.Eur J Pediatr. 2020 Feb;179(2):327-338. doi: 10.1007/s00431-019-03512-7. Epub 2019 Nov 21.
• [450] Influence of polymorphisms in ERCC5, XPA and MTR DNA repair and synthesis genes in B-cell lymphoma risk. A case-control study in Spanish population.J BUON. 2013 Apr-Jun;18(2):486-90.
• [451] ZAP-70 enhances B-cell-receptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells.Blood. 2007 Mar 1;109(5):2032-9. doi: 10.1182/blood-2006-03-011759. Epub 2006 Oct 12.
• [452] Rapid xenograft tumor progression in beta-arrestin1 transgenic mice due to enhanced tumor angiogenesis.FASEB J. 2008 Feb;22(2):355-64. doi: 10.1096/fj.07-9046com. Epub 2007 Sep 21.
• [453] Non-Hodgkin and Hodgkin Lymphomas Select for Overexpression of BCLW.Clin Cancer Res. 2017 Nov 15;23(22):7119-7129. doi: 10.1158/1078-0432.CCR-17-1144. Epub 2017 Aug 29.
• [454] Pharmacological inhibition of carbonic anhydrase XII interferes with cell proliferation and induces cell apoptosis in T-cell lymphomas.Cancer Lett. 2013 Jun 1;333(1):76-88. doi: 10.1016/j.canlet.2013.01.020. Epub 2013 Jan 21.
• [455] Oncogenic role of the chromobox protein CBX7 in gastric cancer.J Exp Clin Cancer Res. 2010 Aug 19;29(1):114. doi: 10.1186/1756-9966-29-114.
• [456] Expression and clinical significance of CXCR5/CXCL13 in human nonsmall cell lung carcinoma.Int J Oncol. 2014 Dec;45(6):2232-40. doi: 10.3892/ijo.2014.2688. Epub 2014 Sep 30.
• [457] Regulation of dipeptidyl peptidase 8 and 9 expression in activated lymphocytes and injured liver.World J Gastroenterol. 2013 May 21;19(19):2883-93. doi: 10.3748/wjg.v19.i19.2883.
• [458] Allorestricted T cells with specificity for the FMNL1-derived peptide PP2 have potent antitumor activity against hematologic and other malignancies.Blood. 2007 Oct 15;110(8):2931-9. doi: 10.1182/blood-2006-11-058750. Epub 2007 Jul 12.
• [459] Human T-leukemia and T-lymphoma express glutamate receptor AMPA GluR3, and the neurotransmitter glutamate elevates the cancer-related matrix-metalloproteinases inducer CD147/EMMPRIN, MMP-9 secretion and engraftment of T-leukemia in vivo.Leuk Lymphoma. 2009 Jun;50(6):985-97. doi: 10.1080/10428190902878448.
• [460] CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia.Haematologica. 2019 Apr;104(4):749-755. doi: 10.3324/haematol.2018.205252. Epub 2018 Oct 25.
• [461] A novel monoclonal antibody, KOR-SA3544 which reacts to Philadelphia chromosome-positive acute lymphoblastic leukemia cells with high sensitivity.Leukemia. 1995 Jul;9(7):1233-9.
• [462] Ribosomal Protein Rpl22 Controls the Dissemination of T-cell Lymphoma.Cancer Res. 2016 Jun 1;76(11):3387-96. doi: 10.1158/0008-5472.CAN-15-2698. Epub 2016 Apr 5.
• [463] A novel TRB@/NOTCH1 fusion gene in T-cell lymphoblastic lymphoma with t(7;9)(q34;q34).Eur J Haematol. 2013 Jan;90(1):68-75. doi: 10.1111/ejh.12019. Epub 2012 Nov 29.
• [464] Cell cycle arrest induced by engagement of B7-H4 on Epstein-Barr virus-positive B-cell lymphoma cell lines.Immunology. 2009 Nov;128(3):360-8. doi: 10.1111/j.1365-2567.2009.03111.x.
• [465] Metabolic targeting of oncogene MYC by selective activation of the proton-coupled monocarboxylate family of transporters.Oncogene. 2016 Jun 9;35(23):3037-48. doi: 10.1038/onc.2015.360. Epub 2015 Oct 5.
• [466] Cytogenetically unrelated clones in hematological neoplasms.Leukemia. 1989 Jan;3(1):6-8.
• [467] Epstein-Barr virus associated B-cell lymphoma of brain developing in myelodysplastic syndrome with c-kit mutation (Try-557 -->stop).Am J Hematol. 2000 Nov;65(3):234-8. doi: 10.1002/1096-8652(200011)65:3<234::aid-ajh10>3.0.co;2-e.
• [468] Expression of ABCB5 gene in hematological malignances and its significance.Leuk Lymphoma. 2012 Jun;53(6):1211-5. doi: 10.3109/10428194.2011.637214. Epub 2011 Dec 7.
• [469] Quantitative proteomics analysis of differentially expressed proteins in activated B-cell-like diffuse large B-cell lymphoma using quantitative proteomics.Pathol Res Pract. 2019 Sep;215(9):152528. doi: 10.1016/j.prp.2019.152528. Epub 2019 Jul 6.
• [470] A case-report of a pulmonary tuberculosis with lymphadenopathy mimicking a lymphoma.Int J Infect Dis. 2018 May;70:38-41. doi: 10.1016/j.ijid.2018.02.011. Epub 2018 Mar 1.
• [471] UGT1A1 *6 polymorphism predicts outcome in elderly patients with relapsed or refractory diffuse large B-cell lymphoma treated with carboplatin, dexamethasone, etoposide and irinotecan.Ann Hematol. 2015 Jan;94(1):65-9. doi: 10.1007/s00277-014-2170-5. Epub 2014 Jul 25.
• [472] Prognostic Value of Accumulative Expression of COX-2 and p53 in Small and Diffuse Large B Cell Lymphoma.Pathol Oncol Res. 2020 Apr;26(2):1183-1190. doi: 10.1007/s12253-019-00674-5. Epub 2019 Jun 11.
• [473] Uridine kinase: altered subunit size or enzyme expression as a function of cell type, growth stimulation, or mutagenesis.J Cell Biochem. 1987 Nov;35(3):217-29. doi: 10.1002/jcb.240350305.
• [474] Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial.Br J Haematol. 2018 Nov;183(4):601-607. doi: 10.1111/bjh.15585. Epub 2018 Sep 14.
• [475] Polymorphisms in xenobiotic metabolizing genes (EPHX1, NQO1 and PON1) in lymphoma susceptibility: a case control study.BMC Cancer. 2013 May 7;13:228. doi: 10.1186/1471-2407-13-228.
• [476] Unaccounted uncertainty from qPCR efficiency estimates entails uncontrolled false positive rates.BMC Bioinformatics. 2016 Apr 11;17:159. doi: 10.1186/s12859-016-0997-6.
• [477] N-acetyltransferase polymorphisms are associated with risk of lymphoma subtypes.Hematol Oncol. 2016 Jun;34(2):79-83. doi: 10.1002/hon.2193. Epub 2015 Feb 17.
• [478] The early variation of left ventricular twisting function in patients with lymphoma received anthracycline therapy assessed by three-dimensional speckle tracking echocardiography.Cardiol J. 2017;24(5):484-494. doi: 10.5603/CJ.a2017.0035. Epub 2017 Mar 29.
• [479] Lack of topoisomerase copy number changes in patients with de novo and relapsed diffuse large B-cell lymphoma.Exp Hematol. 2015 Jul;43(7):534-6. doi: 10.1016/j.exphem.2015.04.006. Epub 2015 Apr 27.
• [480] Human ACAP2 is a homolog of C. elegans CNT-1 that promotes apoptosis in cancer cells.Cell Cycle. 2015;14(12):1771-8. doi: 10.1080/15384101.2015.1026518.
• [481] A rare case of asynchronous bilateral B-cell lymphoma of the breast.Jpn J Clin Oncol. 1989 Dec;19(4):391-6.
• [482] The lymphocyte metalloprotease MDC-L (ADAM 28) is a ligand for the integrin alpha4beta1.J Biol Chem. 2002 Feb 1;277(5):3784-92. doi: 10.1074/jbc.M109538200. Epub 2001 Nov 27.
• [483] Red cell ABH antigens in leukaemias and lymphomas.Vox Sang. 1978 Sep;35(3):154-9. doi: 10.1111/j.1423-0410.1978.tb02915.x.
• [484] High incidence of monoclonal EBV episomes in Hodgkin's disease and anaplastic large-cell KI-1-positive lymphomas in HIV-1-positive patients.Int J Cancer. 1993 Apr 22;54(1):53-9. doi: 10.1002/ijc.2910540110.
• [485] Single and combined BTK and PI3K inhibition with acalabrutinib and ACP-319 in pre-clinical models of aggressive lymphomas.Br J Haematol. 2019 Dec;187(5):595-601. doi: 10.1111/bjh.16118. Epub 2019 Jul 29.
• [486] Five-year study assessing the clinical utility of anti-Mllerian hormone measurements in reproductive-age women with cancer.Reprod Biomed Online. 2019 Oct;39(4):712-720. doi: 10.1016/j.rbmo.2019.06.001. Epub 2019 Jun 11.
• [487] Clinicopathologic study of CD56 (NCAM)-positive angiocentric lymphoma occurring in sites other than the upper and lower respiratory tract.Am J Surg Pathol. 1995 Mar;19(3):284-96. doi: 10.1097/00000478-199503000-00006.
• [488] Identification of APOBEC3B as a potential target for the graft-versus-lymphoma effect by SEREX in a patient with mantle cell lymphoma.Br J Haematol. 2005 Aug;130(3):418-21. doi: 10.1111/j.1365-2141.2005.05604.x.
• [489] Aberrant expression of human achaete-scute homologue gene 1 in the gastrointestinal neuroendocrine carcinomas.Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):450-8.
• [490] Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis.Cell Death Dis. 2012 Jul 5;3(7):e342. doi: 10.1038/cddis.2012.83.
• [491] Concise Review: Cheating Death for a Better Transplant.Stem Cells. 2018 Nov;36(11):1646-1654. doi: 10.1002/stem.2901. Epub 2018 Oct 1.
• [492] An HDAC1-binding domain within FATS bridges p21 turnover to radiation-induced tumorigenesis.Oncogene. 2010 May 6;29(18):2659-71. doi: 10.1038/onc.2010.19. Epub 2010 Feb 15.
• [493] Loss of Dnmt3b function upregulates the tumor modifier Ment and accelerates mouse lymphomagenesis.J Clin Invest. 2012 Jan;122(1):163-77. doi: 10.1172/JCI57292. Epub 2011 Dec 1.
• [494] Efficacy of aprepitant for CHOP chemotherapy-induced nausea, vomiting, and anorexia.Curr Probl Cancer. 2017 Nov-Dec;41(6):419-425. doi: 10.1016/j.currproblcancer.2017.09.001. Epub 2017 Sep 23.
• [495] Overexpression of CCDC34 in colorectal cancer and its involvement in tumor growth, apoptosis and invasion.Mol Med Rep. 2018 Jan;17(1):465-473. doi: 10.3892/mmr.2017.7860. Epub 2017 Oct 24.
• [496] CCR8-dependent activation of the RAS/MAPK pathway mediates anti-apoptotic activity of I-309/ CCL1 and vMIP-I.Eur J Immunol. 2003 Feb;33(2):494-501. doi: 10.1002/immu.200310025.
• [497] CDK9/CYCLIN T1 expression during normal lymphoid differentiation and malignant transformation.J Pathol. 2004 Aug;203(4):946-52. doi: 10.1002/path.1588.
• [498] The phenotypic diversity of peripheral T-cell lymphomas: the Southeastern Cancer Study Group experience.Hum Pathol. 1986 Jun;17(6):567-74. doi: 10.1016/s0046-8177(86)80128-9.
• [499] Clinical significance of cancer specific methylation of the CDO1 gene in small bowel cancer.PLoS One. 2019 Jan 24;14(1):e0211108. doi: 10.1371/journal.pone.0211108. eCollection 2019.
• [500] The proliferation associated nuclear element (PANE1) is conserved between mammals and fish and preferentially expressed in activated lymphoid cells.Gene Expr Patterns. 2004 Jul;4(4):389-95. doi: 10.1016/j.modgep.2004.01.008.
• [501] Defective class II transactivator expression in a B lymphoma cell line.Leukemia. 2004 Apr;18(4):832-40. doi: 10.1038/sj.leu.2403315.
• [502] Metabolic changes associated with metformin potentiates Bcl-2 inhibitor, Venetoclax, and CDK9 inhibitor, BAY1143572 and reduces viability of lymphoma cells.Oncotarget. 2018 Apr 20;9(30):21166-21181. doi: 10.18632/oncotarget.24989. eCollection 2018 Apr 20.
• [503] ALK-positive diffuse large B-cell lymphoma of the stomach associated with a clathrin-ALK rearrangement.Hum Pathol. 2004 Oct;35(10):1285-8. doi: 10.1016/j.humpath.2004.06.001.
• [504] Reduced oncogenicity of p190 Bcr/Abl F-actin-binding domain mutants.Blood. 2000 Sep 15;96(6):2226-32.
• [505] Diagnosis of t(2;5)(p23;q35)-associated Ki-1 lymphoma with immunohistochemistry.Blood. 1994 Dec 1;84(11):3648-52.
• [506] Counterbalancing angiogenic regulatory factors control the rate of cancer progression and survival in a stage-specific manner.Proc Natl Acad Sci U S A. 2011 Jun 14;108(24):9939-44. doi: 10.1073/pnas.1105041108. Epub 2011 May 27.
• [507] Proposed rituximab biosimilar BCD-020 versus reference rituximab for treatment of patients with indolent non-Hodgkin lymphomas: An international multicenter randomized trial.Hematol Oncol. 2020 Feb;38(1):67-73. doi: 10.1002/hon.2693. Epub 2020 Jan 13.
• [508] Structural abnormalities of the X chromosome in non-Hodgkin's lymphoma.Leukemia. 1993 Jun;7(6):848-52.
• [509] VASA is a specific marker for both normal and malignant human germ cells.Lab Invest. 2002 Feb;82(2):159-66. doi: 10.1038/labinvest.3780408.
• [510] Interphase detection of BCL6/IgH fusion gene in non-Hodgkin lymphoma by fluorescence in situ hybridization.Cancer Genet Cytogenet. 1997 Dec;99(2):102-7. doi: 10.1016/s0165-4608(97)00203-3.
• [511] Expression of DHX32 in lymphoid tissues.Exp Mol Pathol. 2005 Dec;79(3):219-23. doi: 10.1016/j.yexmp.2005.07.002. Epub 2005 Sep 21.
• [512] Dependence of p53-deficient cells on the DHX9 DExH-box helicase.Oncotarget. 2017 May 9;8(19):30908-30921. doi: 10.18632/oncotarget.15889.
• [513] Correlation between decreased sensitivity of the Daudi lymphoma cells to VP-16-induced apoptosis and deficiency in DNAS1L3 expression.Biochem Biophys Res Commun. 2006 Mar 10;341(2):653-62. doi: 10.1016/j.bbrc.2006.01.014. Epub 2006 Jan 17.
• [514] BET Inhibition-Induced GSK3 Feedback Enhances Lymphoma Vulnerability to PI3K Inhibitors.Cell Rep. 2018 Aug 21;24(8):2155-2166. doi: 10.1016/j.celrep.2018.07.055.
• [515] Isolation and characterization of bovine and mouse terminal deoxynucleotidyltransferase cDNAs expressible in mammalian cells.Nucleic Acids Res. 1986 Jul 25;14(14):5777-92. doi: 10.1093/nar/14.14.5777.
• [516] Collapsin response mediator protein 4 promotor methylation level as a potential predictor for diagnosing primary malignant lymphoma of the prostate.Cancer Cell Int. 2018 Jan 4;18:3. doi: 10.1186/s12935-017-0484-9. eCollection 2018.
• [517] Methodology, Criteria, and Characterization of Patient-Matched Thyroid Cell Lines and Patient-Derived Tumor Xenografts.J Clin Endocrinol Metab. 2018 Sep 1;103(9):3169-3182. doi: 10.1210/jc.2017-01845.
• [518] Round cell tumours of bone.Pathol Res Pract. 1993 Dec;189(10):111-36.
• [519] Disturbed expression of the anti-apoptosis gene, survivin, and EPR-1 in hematological malignancies.Leuk Res. 2000 Nov;24(11):965-70. doi: 10.1016/s0145-2126(00)00065-5.
• [520] Berberine reinforces Sertoli cells niche and accelerates spermatogonial stem cells renewal in experimentally-induced varicocele condition in rats.Phytomedicine. 2018 Feb 1;40:68-78. doi: 10.1016/j.phymed.2017.12.036. Epub 2018 Jan 2.
• [521] The novel ETS factor TEL2 cooperates with Myc in B lymphomagenesis.Mol Cell Biol. 2005 Mar;25(6):2395-405. doi: 10.1128/MCB.25.6.2395-2405.2005.
• [522] Immunoglobulin superfamily receptor translocation associated 2 protein on lymphoma cell lines and hairy cell leukemia cells detected by novel monoclonal antibodies.Clin Cancer Res. 2005 Jan 1;11(1):87-96.
• [523] Expression of interleukin-9 in nasal natural killer/T-cell lymphoma cell lines and patients.Clin Cancer Res. 2005 Dec 1;11(23):8250-7. doi: 10.1158/1078-0432.CCR-05-1426.
• [524] The human placental growth hormone variant is mitogenic for rat lymphoma Nb2 cells.Endocrinology. 1990 Feb;126(2):971-6. doi: 10.1210/endo-126-2-971.
• [525] Granulysin, a novel marker for extranodal NK/T cell lymphoma, nasal type.Virchows Arch. 2018 Dec;473(6):749-757. doi: 10.1007/s00428-018-2434-x. Epub 2018 Aug 27.
• [526] GPC5 is a possible target for the 13q31-q32 amplification detected in lymphoma cell lines.J Hum Genet. 2003;48(6):331-335. doi: 10.1007/s10038-003-0026-2. Epub 2003 Apr 29.
• [527] Newcastle Disease Virus: Potential Therapeutic Application for Human and Canine Lymphoma.Viruses. 2015 Dec 23;8(1):3. doi: 10.3390/v8010003.
• [528] Overexpression of the receptor for hyaluronan-mediated motility (RHAMM) characterizes the malignant clone in multiple myeloma: identification of three distinct RHAMM variants.Blood. 1999 Mar 1;93(5):1684-96.
• [529] Haptoglobin-related protein as a serum marker in malignant lymphoma.Pathol Oncol Res. 1998;4(4):271-6. doi: 10.1007/BF02905217.
• [530] The adaptor protein HSH2 attenuates apoptosis in response to ligation of the B cell antigen receptor complex on the B lymphoma cell line, WEHI-231.J Biol Chem. 2005 Feb 4;280(5):3507-15. doi: 10.1074/jbc.M407690200. Epub 2004 Nov 29.
• [531] Expression of HYAL2 mRNA, hyaluronan and hyaluronidase in B-cell non-Hodgkin lymphoma: relationship with tumor aggressiveness.Int J Cancer. 2005 Jan 10;113(2):207-12. doi: 10.1002/ijc.20562.
• [532] Frequent DNA methylation but not mutation of the ID4 gene in malignant lymphoma.J Clin Exp Hematop. 2007 Apr;47(1):15-8. doi: 10.3960/jslrt.47.15.
• [533] Expression of the RNA-binding protein VICKZ in normal hematopoietic tissues and neoplasms.Haematologica. 2007 Feb;92(2):176-83. doi: 10.3324/haematol.10724.
• [534] Branched-chain in situ hybridization for and light chains: A powerful ancillary technique for determining B-cell clonality in cytology samples.Cancer Cytopathol. 2016 Mar;124(3):203-12. doi: 10.1002/cncy.21629. Epub 2015 Nov 2.
• [535] A variant Burkitt-type translocation (2p-;8q+) in a patient with diffuse large cell lymphoma.Cancer Genet Cytogenet. 1987 Feb;24(2):225-9. doi: 10.1016/0165-4608(87)90103-8.
• [536] T(11;18)-bearing pulmonary mucosa-associated lymphoid tissue lymphoma responding to cladribine.Int J Hematol. 2004 Jul;80(1):70-4. doi: 10.1532/ijh97.03170.
• [537] Primary gastric T-cell lymphoma with and without human T-lymphotropic virus type 1.Cancer. 1997 Jul 15;80(2):292-303. doi: 10.1002/(sici)1097-0142(19970715)80:2<292::aid-cncr18>3.0.co;2-p.
• [538] Epstein-Barr virus-negative extranodal "true" natural killer-cell lymphoma harbouring a KDM6A mutation.Hematol Oncol. 2018 Feb;36(1):328-335. doi: 10.1002/hon.2459. Epub 2017 Jul 10.
• [539] Galectin-9 induces atypical ubiquitination leading to cell death in PC-3 prostate cancer cells.Glycobiology. 2019 Jan 1;29(1):22-35. doi: 10.1093/glycob/cwy099.
• [540] Increased expression of germinal center-associated nuclear protein RNA-primase is associated with lymphomagenesis.Cancer Res. 2005 Jul 1;65(13):5925-34. doi: 10.1158/0008-5472.CAN-04-3259.
• [541] Chromosomal locations of human tissue plasminogen activator and urokinase genes.Science. 1985 Nov 8;230(4726):672-4. doi: 10.1126/science.3840278.
• [542] Methotrexate-associated lymphoproliferative disorder in the stomach and duodenum: a case report.BMC Gastroenterol. 2019 Apr 25;19(1):62. doi: 10.1186/s12876-019-0982-4.
• [543] Chromosome locations of the MYB related genes, AMYB and BMYB.Cancer Res. 1991 Jul 15;51(14):3821-4.
• [544] Constitutive NF-kappaB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas.Blood. 2006 Jun 1;107(11):4540-8. doi: 10.1182/blood-2005-10-4042. Epub 2006 Feb 23.
• [545] Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics.Nat Commun. 2016 Jun 14;7:11889. doi: 10.1038/ncomms11889.
• [546] No evidence for deletions of the NBS1 gene in lymphomas.Cancer Genet Cytogenet. 2001 Apr 1;126(1):60-2. doi: 10.1016/s0165-4608(00)00390-3.
• [547] Flow cytometry: its applications in hematology.Haematologica. 1995 Jan-Feb;80(1):69-81.
• [548] Systemic therapy in non-conventional cancers of the larynx.Oral Oncol. 2018 Jul;82:61-68. doi: 10.1016/j.oraloncology.2018.05.005. Epub 2018 May 26.
• [549] Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression.Eur J Immunol. 1995 May;25(5):1374-84. doi: 10.1002/eji.1830250536.
• [550] Aberrant methylation of HIN-1 (high in normal-1) is a frequent event in many human malignancies.Int J Cancer. 2005 Feb 10;113(4):600-4. doi: 10.1002/ijc.20622.
• [551] Enhanced expression of poly(ADP-ribose) synthetase gene in malignant lymphoma.Am J Hematol. 1991 Aug;37(4):223-7. doi: 10.1002/ajh.2830370402.
• [552] A novel diffuse large B-cell lymphoma-associated cancer testis antigen encoding a PAS domain protein.Br J Cancer. 2004 Jul 5;91(1):141-9. doi: 10.1038/sj.bjc.6601875.
• [553] POZ-, AT-hook-, and zinc finger-containing protein (PATZ) interacts with human oncogene B cell lymphoma 6 (BCL6) and is required for its negative autoregulation.J Biol Chem. 2012 May 25;287(22):18308-17. doi: 10.1074/jbc.M112.346270. Epub 2012 Apr 9.
• [554] The Rb tumor suppressor in stress responses and hematopoietic homeostasis.Cell Cycle. 2005 Jan;4(1):42-5. doi: 10.4161/cc.4.1.1337. Epub 2005 Jan 29.
• [555] Epigenetics and B-cell lymphoma.Curr Opin Hematol. 2011 Jul;18(4):293-9. doi: 10.1097/MOH.0b013e32834788cf.
• [556] PCDH10 promoter hypermethylation is frequent in most histologic subtypes of mature lymphoid malignancies and occurs early in lymphomagenesis.Genes Chromosomes Cancer. 2013 Nov;52(11):1030-41. doi: 10.1002/gcc.22098. Epub 2013 Aug 9.
• [557] Myeloid neoplasms with eosinophilia.Blood. 2017 Feb 9;129(6):704-714. doi: 10.1182/blood-2016-10-695973. Epub 2016 Dec 27.
• [558] Expression of protein gene product 9.5 and tyrosine hydroxylase in childhood small round cell tumors.Clin Cancer Res. 2000 Feb;6(2):551-8.
• [559] Deletion of the Miz-1 POZ Domain Increases Efficacy of Cytarabine Treatment in T- and B-ALL/Lymphoma Mouse Models.Cancer Res. 2019 Aug 15;79(16):4184-4195. doi: 10.1158/0008-5472.CAN-18-3038. Epub 2019 Jul 4.
• [560] Expression pattern of intracellular leukocyte-associated proteins in primary mediastinal B cell lymphoma.Leukemia. 2005 May;19(5):856-61. doi: 10.1038/sj.leu.2403702.
• [561] TAPP1 and TAPP2 are targets of phosphatidylinositol 3-kinase signaling in B cells: sustained plasma membrane recruitment triggered by the B-cell antigen receptor.Mol Cell Biol. 2002 Aug;22(15):5479-91. doi: 10.1128/MCB.22.15.5479-5491.2002.
• [562] Identification of highly methylated genes across various types of B-cell non-hodgkin lymphoma.PLoS One. 2013 Nov 19;8(11):e79602. doi: 10.1371/journal.pone.0079602. eCollection 2013.
• [563] Alterations of the PPP1R3 gene in hematological malignancies.Int J Oncol. 2000 Oct;17(4):717-21. doi: 10.3892/ijo.17.4.717.
• [564] A Noncanonical Function of Polycomb Repressive Complexes Promotes Human Cytomegalovirus Lytic DNA Replication and Serves as a Novel Cellular Target for Antiviral Intervention.J Virol. 2019 Apr 17;93(9):e02143-18. doi: 10.1128/JVI.02143-18. Print 2019 May 1.
• [565] Genome-wide analysis of immune system genes by expressed sequence Tag profiling.J Immunol. 2013 Jun 1;190(11):5578-87. doi: 10.4049/jimmunol.1203471. Epub 2013 Apr 24.
• [566] The expression and bioinformatic analysis of a novel gene C20orf14 associated with lymphoma.J Huazhong Univ Sci Technolog Med Sci. 2008 Feb;28(1):97-101. doi: 10.1007/s11596-008-0125-6.
• [567] New silicon compounds as resistance modifiers against multidrug-resistant cancer cells.Anticancer Res. 2004 Mar-Apr;24(2B):865-71.
• [568] Protein tyrosine phosphatase receptor-type O truncated (PTPROt) regulates SYK phosphorylation, proximal B-cell-receptor signaling, and cellular proliferation.Blood. 2006 Nov 15;108(10):3428-33. doi: 10.1182/blood-2006-03-013821. Epub 2006 Aug 3.
• [569] The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion.Blood. 1996 Feb 1;87(3):882-6.
• [570] Rare HRAS1 alleles outside the VTR region in lymph nodes from patients with malignant lymphoma.Cancer Genet Cytogenet. 1993 Aug;69(1):60-4. doi: 10.1016/0165-4608(93)90115-3.
• [571] Telomere dysfunction and inactivation of the p16(INK4a)/Rb pathway in pyothorax-associated lymphoma.Cancer Sci. 2007 Jul;98(7):978-84. doi: 10.1111/j.1349-7006.2007.00482.x. Epub 2007 Apr 12.
• [572] Genetic alterations disrupting the nuclear localization of the retinoblastoma-related gene RB2/p130 in human tumor cell lines and primary tumors.Cancer Res. 2000 Jan 15;60(2):383-9.
• [573] Translational repression of p53 by RNPC1, a p53 target overexpressed in lymphomas.Genes Dev. 2011 Jul 15;25(14):1528-43. doi: 10.1101/gad.2069311.
• [574] Hypermethylation-associated Inactivation of the Cellular Retinol-Binding-Protein 1 Gene in Human Cancer.Cancer Res. 2002 Oct 15;62(20):5902-5.
• [575] The regulator of calcineurin 1 (RCAN1) inhibits nuclear factor kappaB signaling pathway and suppresses human malignant glioma cells growth.Oncotarget. 2017 Feb 14;8(7):12003-12012. doi: 10.18632/oncotarget.14479.
• [576] Tumorigenic activity and therapeutic inhibition of Rheb GTPase.Genes Dev. 2008 Aug 15;22(16):2178-88. doi: 10.1101/gad.1690808.
• [577] Expression of the Rho-family GTPase gene RHOF in lymphocyte subsets and malignant lymphomas.Br J Haematol. 2005 May;129(4):531-3. doi: 10.1111/j.1365-2141.2005.05481.x.
• [578] Immunophenotypic Shifts in Primary Cutaneous T-Cell Lymphoma Suggest Antigenic Modulation: A Study of Sequential Biopsy Specimens.Am J Surg Pathol. 2017 Apr;41(4):431-445. doi: 10.1097/PAS.0000000000000786.
• [579] Expression of Myc target gene mina53 in subtypes of human lymphoma.Oncol Rep. 2007 Oct;18(4):841-8.
• [580] Homozygous deletions and point mutations of the Rit1/Bcl11b gene in gamma-ray induced mouse thymic lymphomas.Biochem Biophys Res Commun. 2003 Feb 7;301(2):598-603. doi: 10.1016/s0006-291x(02)03069-3.
• [581] Fusion of the SEC31L1 and ALK genes in an inflammatory myofibroblastic tumor.Int J Cancer. 2006 Mar 1;118(5):1181-6. doi: 10.1002/ijc.21490.
• [582] Notch signal transduction is not regulated by SEL1L in leukaemia and lymphoma cells in culture.Anticancer Res. 2002 Nov-Dec;22(6C):4211-4.
• [583] The effects of a growth-inhibiting tripeptide, acetylGlu-Ser-GlyNH2 (Ac-ESG), on gene expression and cell cycle progression of two lymphoma cell lines.Anticancer Res. 2003 Jul-Aug;23(4):3159-65.
• [584] Associations between polymorphisms in the thymidylate synthase and serine hydroxymethyltransferase genes and susceptibility to malignant lymphoma.Haematologica. 2003 Feb;88(2):159-66.
• [585] Fluorescence in situ hybridization and chromosomal organization of the human Sirtuin 7 gene.Int J Oncol. 2006 Apr;28(4):899-908.
• [586] The cellular homologue of the transforming gene of SKV avian retrovirus maps to human chromosome region 1q22----q24.Cytogenet Cell Genet. 1986;43(3-4):181-6. doi: 10.1159/000132318.
• [587] In vitro canine distemper virus infection of canine lymphoid cells: a prelude to oncolytic therapy for lymphoma.Clin Cancer Res. 2005 Feb 15;11(4):1579-87. doi: 10.1158/1078-0432.CCR-04-1944.
• [588] Ig VH gene expression among human follicular lymphomas.Blood. 1991 Sep 15;78(6):1561-8.
• [589] Evolving Strategies for the Treatment of T-Cell Lymphoma: A Systematic Review and Recent Patents.Recent Pat Anticancer Drug Discov. 2018;13(3):308-340. doi: 10.2174/1574892813666180517102801.
• [590] Different expressions of miR-125b and SOX30 in malignant lymphomas and their significance.J BUON. 2018 Jul-Aug;23(4):1179-1184.
• [591] Patterns of spectrin expression in B-cell lymphomas: loss of spectrin isoforms is associated with nodule-forming and germinal center-related lymphomas.Mod Pathol. 2007 Dec;20(12):1245-52. doi: 10.1038/modpathol.3800962. Epub 2007 Sep 21.
• [592] Purification, cDNA cloning, and expression of human sorcin in vincristine-resistant HOB1 lymphoma cell lines.Arch Biochem Biophys. 1996 Jan 15;325(2):217-26. doi: 10.1006/abbi.1996.0027.
• [593] Expression analysis of 0-series gangliosides in human cancer cell lines with monoclonal antibodies generated using knockout mice of ganglioside synthase genes.Glycobiology. 2016 Sep;26(9):984-998. doi: 10.1093/glycob/cww049. Epub 2016 Apr 21.
• [594] Epstein-Barr Virus Latent Membrane Protein-1 Induces the Expression of SUMO-1 and SUMO-2/3 in LMP1-positive Lymphomas and Cells.Sci Rep. 2019 Jan 18;9(1):208. doi: 10.1038/s41598-018-36312-4.
• [595] The HIV-1 transactivator protein Tat is a potent inducer of the human DNA repair enzyme beta-polymerase.AIDS. 2001 Mar 9;15(4):433-40. doi: 10.1097/00002030-200103090-00001.
• [596] Functional domains of chicken mitochondrial transcription factor A for the maintenance of mitochondrial DNA copy number in lymphoma cell line DT40.J Biol Chem. 2003 Aug 15;278(33):31149-58. doi: 10.1074/jbc.M303842200. Epub 2003 May 20.
• [597] Apoptosis stimulating protein of p53 (ASPP2) expression differs in diffuse large B-cell and follicular center lymphoma: correlation with clinical outcome.Leuk Lymphoma. 2002 Dec;43(12):2309-17. doi: 10.1080/1042819021000040017.
• [598] TRAF2 phosphorylation modulates tumor necrosis factor alpha-induced gene expression and cell resistance to apoptosis.Mol Cell Biol. 2009 Jan;29(2):303-14. doi: 10.1128/MCB.00699-08. Epub 2008 Nov 3.
• [599] TRIM11 promotes lymphomas by activating the -catenin signaling and Axin1 ubiquitination degradation.Exp Cell Res. 2020 Feb 15;387(2):111750. doi: 10.1016/j.yexcr.2019.111750. Epub 2019 Nov 28.
• [600] Cytogenetic findings in cell lines from cutaneous T-cell lymphoma.Dermatol Clin. 1994 Apr;12(2):295-304.
• [601] Effusion and solid lymphomas have distinctive gene and protein expression profiles in an animal model of primary effusion lymphoma.J Pathol. 2006 Aug;209(4):464-73. doi: 10.1002/path.2012.
• [602] Splenic marginal zone lymphoma: proposal of new diagnostic and prognostic markers identified after tissue and cDNA microarray analysis.Blood. 2005 Sep 1;106(5):1831-8. doi: 10.1182/blood-2004-10-3898. Epub 2005 May 24.
• [603] RGS1 and RGS13 mRNA silencing in a human B lymphoma line enhances responsiveness to chemoattractants and impairs desensitization.J Leukoc Biol. 2006 Jun;79(6):1357-68. doi: 10.1189/jlb.1105693. Epub 2006 Mar 24.
• [604] A new era for cutaneous CD30-positive T-cell lymphoproliferative disorders.Semin Diagn Pathol. 2017 Jan;34(1):22-35. doi: 10.1053/j.semdp.2016.11.005. Epub 2016 Nov 29.
• [605] Ectopic expression of transcription factor BATF3 induces B-cell lymphomas in a murine B-cell transplantation model.Oncotarget. 2018 Mar 23;9(22):15942-15951. doi: 10.18632/oncotarget.24639. eCollection 2018 Mar 23.
• [606] Stimulation of CD30 in anaplastic large cell lymphoma leads to production of nuclear factor-kappaB p52, which is associated with hyperphosphorylated Bcl-3.Cancer Sci. 2005 Aug;96(8):487-97. doi: 10.1111/j.1349-7006.2005.00078.x.
• [607] Exome sequencing identifies recurrent BCOR alterations and the absence of KLF2, TNFAIP3 and MYD88 mutations in splenic diffuse red pulp small B-cell lymphoma.Haematologica. 2017 Oct;102(10):1758-1766. doi: 10.3324/haematol.2016.160192. Epub 2017 Jul 27.
• [608] The SRC family kinase LYN redirects B cell receptor signaling in human SLP65-deficient B cell lymphoma cells.Oncogene. 2006 Aug 17;25(36):5056-62. doi: 10.1038/sj.onc.1209510. Epub 2006 Mar 27.
• [609] Expression of far upstream element binding protein1 in Bcell nonHodgkin lymphoma is correlated with tumor growth and celladhesion mediated drug resistance.Mol Med Rep. 2016 Oct;14(4):3759-68. doi: 10.3892/mmr.2016.5718. Epub 2016 Sep 6.
• [610] Expression profiling of T-cell lymphomas differentiates peripheral and lymphoblastic lymphomas and defines survival related genes.Clin Cancer Res. 2004 Aug 1;10(15):4971-82. doi: 10.1158/1078-0432.CCR-04-0269.
• [611] Protective effect of human serum amyloid P on CCl4-induced acute liver injury in mice.Int J Mol Med. 2017 Aug;40(2):454-464. doi: 10.3892/ijmm.2017.3028. Epub 2017 Jun 14.
• [612] Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors.Cancer Immunol Res. 2015 Jul;3(7):815-26. doi: 10.1158/2326-6066.CIR-15-0054. Epub 2015 May 4.
• [613] Molecular characterization of 9p21 deletions shows a minimal common deleted region removing CDKN2A exon 1 and CDKN2B exon 2 in diffuse large B-cell lymphomas.Genes Chromosomes Cancer. 2011 Sep;50(9):715-25. doi: 10.1002/gcc.20893. Epub 2011 Jun 2.
• [614] EBV latent membrane protein 2A orchestrates p27(kip1) degradation via Cks1 to accelerate MYC-driven lymphoma in mice.Blood. 2017 Dec 7;130(23):2516-2526. doi: 10.1182/blood-2017-07-796821. Epub 2017 Oct 26.
• [615] Human endogenous retrovirus K (HML-2) elements in the plasma of people with lymphoma and breast cancer.J Virol. 2008 Oct;82(19):9329-36. doi: 10.1128/JVI.00646-08. Epub 2008 Jul 16.
• [616] DLC-1 as a modulator of proliferation, apoptosis and migration in Burkitt's lymphoma cells.Mol Biol Rep. 2011 Mar;38(3):1915-20. doi: 10.1007/s11033-010-0311-z. Epub 2010 Oct 1.
• [617] Epigenetic silencing of the 3p22 tumor suppressor DLEC1 by promoter CpG methylation in non-Hodgkin and Hodgkin lymphomas.J Transl Med. 2012 Oct 11;10:209. doi: 10.1186/1479-5876-10-209.
• [618] Dlx5 Homeodomain:DNA Complex: Structure, Binding and Effect of Mutations Related to Split Hand and Foot Malformation Syndrome.J Mol Biol. 2016 Mar 27;428(6):1130-1141. doi: 10.1016/j.jmb.2016.01.023. Epub 2016 Jan 29.
• [619] The Transcription Factor ASCIZ and Its Target DYNLL1 Are Essential for the Development and Expansion of MYC-Driven B Cell Lymphoma.Cell Rep. 2016 Feb 16;14(6):1488-1499. doi: 10.1016/j.celrep.2016.01.012. Epub 2016 Jan 28.
• [620] DNA repair gene polymorphisms in B cell non-Hodgkin's lymphoma.Tumour Biol. 2015 Mar;36(3):2155-61. doi: 10.1007/s13277-014-2825-9. Epub 2014 Nov 18.
• [621] Suppression of Myc oncogenic activity by nucleostemin haploinsufficiency.Oncogene. 2012 Jul 12;31(28):3311-21. doi: 10.1038/onc.2011.507. Epub 2011 Nov 14.
• [622] Strong association of the HLA-DP6 supertype with childhood leukaemia is due to a single allele, DPB1*0601.Leukemia. 2009 May;23(5):863-9. doi: 10.1038/leu.2008.374. Epub 2009 Jan 15.
• [623] Gene polymorphisms in Toll-like receptors, interleukin-10, and interleukin-10 receptor alpha and lymphoma risk.Genes Immun. 2006 Dec;7(8):615-24. doi: 10.1038/sj.gene.6364337. Epub 2006 Sep 14.
• [624] Mapping of transcription factor motifs in active chromatin identifies IRF5 as key regulator in classical Hodgkin lymphoma.Proc Natl Acad Sci U S A. 2014 Oct 21;111(42):E4513-22. doi: 10.1073/pnas.1406985111. Epub 2014 Oct 6.
• [625] Expression of interferon regulatory factor 7 correlates with the expression of Epstein-Barr Virus latent membrane protein 1 and cervical lymph node metastasis in nasopharyngeal cancer.Pathol Int. 2017 Sep;67(9):461-466. doi: 10.1111/pin.12561. Epub 2017 Jul 16.
• [626] Killer cell immunoglobulin-like receptor 2DL4 is expressed in and suppresses the cell growth of Langerhans cell histiocytosis.Oncotarget. 2017 Jun 6;8(23):36964-36972. doi: 10.18632/oncotarget.16936.
• [627] Galectin-1-mediated cell adhesion, invasion and cell death in human anaplastic large cell lymphoma: regulatory roles of cell surface glycans.Int J Oncol. 2014 May;44(5):1433-42. doi: 10.3892/ijo.2014.2319. Epub 2014 Mar 4.
• [628] Increased galectin-7 gene expression in lymphoma cells is under the control of DNA methylation.Biochem Biophys Res Commun. 2009 Sep 25;387(3):425-9. doi: 10.1016/j.bbrc.2009.07.015. Epub 2009 Jul 9.
• [629] LIMD1 is induced by and required for LMP1 signaling, and protects EBV-transformed cells from DNA damage-induced cell death.Oncotarget. 2017 Dec 26;9(5):6282-6297. doi: 10.18632/oncotarget.23676. eCollection 2018 Jan 19.
• [630] Latexin is down-regulated in hematopoietic malignancies and restoration of expression inhibits lymphoma growth.PLoS One. 2012;7(9):e44979. doi: 10.1371/journal.pone.0044979. Epub 2012 Sep 27.
• [631] Functional screen of human MCM2-7 variant alleles for disease-causing potential.Mutat Res. 2009 Jun 18;666(1-2):74-8. doi: 10.1016/j.mrfmmm.2009.03.006. Epub 2009 Mar 27.
• [632] CALM/AF10-positive leukemias show upregulation of genes involved in chromatin assembly and DNA repair processes and of genes adjacent to the breakpoint at 10p12.Leukemia. 2012 May;26(5):1012-9. doi: 10.1038/leu.2011.307. Epub 2011 Nov 8.
• [633] Identification of MNDA as a new marker for nodal marginal zone lymphoma.Leukemia. 2009 Oct;23(10):1847-57. doi: 10.1038/leu.2009.108. Epub 2009 May 28.
• [634] An epigenetic chromatin remodeling role for NFATc1 in transcriptional regulation of growth and survival genes in diffuse large B-cell lymphomas.Blood. 2010 Nov 11;116(19):3899-906. doi: 10.1182/blood-2009-12-257378. Epub 2010 Jul 27.
• [635] The role of centrosomal Nlp in the control of mitotic progression and tumourigenesis.Br J Cancer. 2011 May 10;104(10):1523-8. doi: 10.1038/bjc.2011.130. Epub 2011 Apr 19.
• [636] OPCML is a broad tumor suppressor for multiple carcinomas and lymphomas with frequently epigenetic inactivation.PLoS One. 2008 Aug 20;3(8):e2990. doi: 10.1371/journal.pone.0002990.
• [637] Pol deficiency induces moderate shortening of P53(-/-) mouse lifespan and modifies tumor spectrum.DNA Repair (Amst). 2017 Jun;54:40-45. doi: 10.1016/j.dnarep.2017.04.001. Epub 2017 Apr 10.
• [638] Gcet1 (centerin), a highly restricted marker for a subset of germinal center-derived lymphomas.Blood. 2008 Jan 1;111(1):351-8. doi: 10.1182/blood-2007-06-094151. Epub 2007 Sep 26.
• [639] Acquired STAT4 deficiency as a consequence of cancer chemotherapy.Blood. 2011 Dec 1;118(23):6097-106. doi: 10.1182/blood-2011-03-341867. Epub 2011 Oct 13.
• [640] Concurrent inhibition of MYC and BCL2 is a potentially effective treatment strategy for double hit and triple hit B-cell lymphomas.Leuk Res. 2015 Jul;39(7):730-8. doi: 10.1016/j.leukres.2015.04.003. Epub 2015 Apr 17.
• [641] Epigenetic inactivation of the Groucho homologue gene TLE1 in hematologic malignancies.Cancer Res. 2008 Jun 1;68(11):4116-22. doi: 10.1158/0008-5472.CAN-08-0085.
• [642] Expression of a soluble decoy receptor 3 in patients with diffuse large B-cell lymphoma predicts clinical outcome.Int J Oncol. 2008 Sep;33(3):549-54.
• [643] Hypoxia-microRNA-16 downregulation induces VEGF expression in anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphomas.Leukemia. 2011 Dec;25(12):1882-90. doi: 10.1038/leu.2011.168. Epub 2011 Jul 22.
• [644] Highly potent anti-CD20-RLI immunocytokine targeting established human B lymphoma in SCID mouse.MAbs. 2014 Jul-Aug;6(4):1026-37. doi: 10.4161/mabs.28699.
• [645] ACOX1 destabilizes p73 to suppress intrinsic apoptosis pathway and regulates sensitivity to doxorubicin in lymphoma cells.BMB Rep. 2019 Sep;52(9):566-571. doi: 10.5483/BMBRep.2019.52.9.094.
• [646] The CBFA2T3/ACSF3 locus is recurrently involved in IGH chromosomal translocation t(14;16)(q32;q24) in pediatric B-cell lymphoma with germinal center phenotype.Genes Chromosomes Cancer. 2012 Apr;51(4):338-43. doi: 10.1002/gcc.21919.
• [647] TFG, a target of chromosome translocations in lymphoma and soft tissue tumors, fuses to GPR128 in healthy individuals.Haematologica. 2010 Jan;95(1):20-6. doi: 10.3324/haematol.2009.011536. Epub 2009 Oct 1.
• [648] AHI-1: a novel signaling protein and potential therapeutic target in human leukemia and brain disorders.Oncotarget. 2011 Dec;2(12):918-34. doi: 10.18632/oncotarget.405.
• [649] The clastogenicity of 4NQO is cell-type dependent and linked to cytotoxicity, length of exposure and p53 proficiency.Mutagenesis. 2016 Mar;31(2):171-80. doi: 10.1093/mutage/gev069. Epub 2015 Sep 11.
• [650] Aryl Hydrocarbon Receptor Interacting Protein Maintains Germinal Center B Cells through Suppression of BCL6 Degradation.Cell Rep. 2019 Apr 30;27(5):1461-1471.e4. doi: 10.1016/j.celrep.2019.04.014.
• [651] Overexpression of proto-oncogene FBI-1 activates membrane type 1-matrix metalloproteinase in association with adverse outcome in ovarian cancers.Mol Cancer. 2010 Dec 21;9:318. doi: 10.1186/1476-4598-9-318.
• [652] Crucial Role of Increased Arid3a at the Pre-B and Immature B Cell Stages for B1a Cell Generation.Front Immunol. 2019 Mar 15;10:457. doi: 10.3389/fimmu.2019.00457. eCollection 2019.
• [653] HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies.Blood. 2014 Aug 21;124(8):1266-76. doi: 10.1182/blood-2014-03-563742. Epub 2014 Jun 26.
• [654] Sensitisation of c-MYC-induced B-lymphoma cells to apoptosis by ATF2.Oncogene. 2014 Feb 20;33(8):1027-36. doi: 10.1038/onc.2013.28. Epub 2013 Feb 18.
• [655] Case for diagnosis. Infective dermatitis associated with HTLV-1: differential diagnosis of atopic dermatitis.An Bras Dermatol. 2017 Jul-Aug;92(4):573-574. doi: 10.1590/abd1806-4841.20176684.
• [656] Inhibition of BCL11B expression leads to apoptosis of malignant but not normal mature T cells.Oncogene. 2007 May 31;26(26):3797-810. doi: 10.1038/sj.onc.1210152. Epub 2006 Dec 18.
• [657] BAM conditioning before autologous transplantation for lymphoma: a study on behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC).Ann Hematol. 2019 Aug;98(8):1973-1980. doi: 10.1007/s00277-019-03704-z. Epub 2019 May 20.
• [658] Mutations of the BIK gene in human peripheral B-cell lymphomas.Genes Chromosomes Cancer. 2003 Sep;38(1):91-6. doi: 10.1002/gcc.10245.
• [659] Germline Genetic Predisposition to Hematologic Malignancy.J Clin Oncol. 2017 Mar 20;35(9):1018-1028. doi: 10.1200/JCO.2016.70.8644. Epub 2017 Feb 13.
• [660] CART cell therapy for prostate cancer: status and promise.Onco Targets Ther. 2019 Jan 3;12:391-395. doi: 10.2147/OTT.S185556. eCollection 2019.
• [661] Targeting a mitochondrial potassium channel to fight cancer.Cell Calcium. 2015 Jul;58(1):131-8. doi: 10.1016/j.ceca.2014.09.006. Epub 2014 Oct 18.
• [662] Age-Related Gliosis Promotes Central Nervous System Lymphoma through CCL19-Mediated Tumor Cell Retention.Cancer Cell. 2019 Sep 16;36(3):250-267.e9. doi: 10.1016/j.ccell.2019.08.001.
• [663] Enhanced Anti-lymphoma Activity of CAR19-iNKT Cells Underpinned by Dual CD19 and CD1d Targeting.Cancer Cell. 2018 Oct 8;34(4):596-610.e11. doi: 10.1016/j.ccell.2018.08.017.
• [664] CD2-Associated Protein Contributes to Hepatitis C, Virus Propagation and Steatosis by Disrupting Insulin Signaling.Hepatology. 2018 Nov;68(5):1710-1725. doi: 10.1002/hep.30073.
• [665] Signalling pathways identified in salivary glands from primary Sjgren's syndrome patients reveal enhanced adipose tissue development.Autoimmunity. 2018 May;51(3):135-146. doi: 10.1080/08916934.2018.1446525. Epub 2018 Mar 5.
• [666] p53 expression in large B-cell lymphomas with MYC extra copies and CD99 expression in large B-cell lymphomas in relation to MYC status.Hum Pathol. 2019 Apr;86:21-31. doi: 10.1016/j.humpath.2018.11.015. Epub 2018 Nov 26.
• [667] Common variants on 14q32 and 13q12 are associated with DLBCL susceptibility.J Hum Genet. 2011 Jun;56(6):436-9. doi: 10.1038/jhg.2011.35. Epub 2011 Apr 7.
• [668] CDCA7 finely tunes cytoskeleton dynamics to promote lymphoma migration and invasion.Haematologica. 2020 Mar;105(3):730-740. doi: 10.3324/haematol.2018.215459. Epub 2019 Jun 20.
• [669] The Transitional Endoplasmic Reticulum ATPase p97 Regulates the Alternative Nuclear Factor NF-B Signaling via Partial Degradation of the NF-B Subunit p100.J Biol Chem. 2015 Aug 7;290(32):19558-68. doi: 10.1074/jbc.M114.630061. Epub 2015 Jun 25.
• [670] Congenital heart disease complexity and childhood cancer risk.Birth Defects Res. 2018 Oct 16;110(17):1314-1321. doi: 10.1002/bdr2.1390. Epub 2018 Oct 16.
• [671] A novel protein CMTM1-v5 specifically induced human lymphoma cells apoptosis in vitro and in vivo.Exp Cell Res. 2019 Dec 1;385(1):111623. doi: 10.1016/j.yexcr.2019.111623. Epub 2019 Sep 19.
• [672] The extent of B-cell activation and dysfunction preceding lymphoma development in HIV-positive people.HIV Med. 2018 Feb;19(2):90-101. doi: 10.1111/hiv.12546. Epub 2017 Aug 31.
• [673] Epstein-Barr virus-associated natural killer/T-cell lymphomas.Best Pract Res Clin Haematol. 2013 Mar;26(1):15-21. doi: 10.1016/j.beha.2013.04.002. Epub 2013 May 25.
• [674] Frequent aberrant promoter hypermethylation of O6-methylguanine-DNA methyltransferase and death-associated protein kinase genes in immunodeficiency-related lymphomas.Br J Haematol. 2003 Nov;123(3):475-8. doi: 10.1046/j.1365-2141.2003.04644.x.
• [675] Prognostic significance of DAPK promoter methylation in lymphoma: A meta-analysis.PLoS One. 2019 Jan 25;14(1):e0210943. doi: 10.1371/journal.pone.0210943. eCollection 2019.
• [676] Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical.Blood. 2007 Oct 1;110(7):2569-77. doi: 10.1182/blood-2006-12-062927. Epub 2007 Apr 17.
• [677] Efficacy of dose-adjusted EPOCH plus rituximab/R-CHOP regimens and the prognosis analysis in patients with MYC, BCL2/BCL6 gene copy number gain lymphoma and double-hit lymphoma: results from a single institution retrospective clinical study.Cancer Manag Res. 2019 Feb 11;11:1363-1372. doi: 10.2147/CMAR.S192143. eCollection 2019.
• [678] Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy.Int J Oncol. 2018 Sep;53(3):1193-1203. doi: 10.3892/ijo.2018.4456. Epub 2018 Jun 27.
• [679] DIXDC1 promotes tumor proliferation and cell adhesion mediated drug resistance (CAM-DR) via enhancing p-Akt in Non-Hodgkin's lymphomas.Leuk Res. 2016 Nov;50:104-111. doi: 10.1016/j.leukres.2016.09.011. Epub 2016 Sep 8.
• [680] Serological identification of HSP105 as a novel non-Hodgkin lymphoma therapeutic target.Blood. 2011 Oct 20;118(16):4421-30. doi: 10.1182/blood-2011-06-364570. Epub 2011 Aug 22.
• [681] Integrated analysis of 10 lymphoma datasets identifies E2F8 as a key regulator in Burkitt's lymphoma and mantle cell lymphoma.Am J Transl Res. 2019 Jul 15;11(7):4382-4396. eCollection 2019.
• [682] Overexpression of the immediate-early genes Egr1, Egr2, and Egr3 in two strains of rodents susceptible to audiogenic seizures.Epilepsy Behav. 2017 Jun;71(Pt B):226-237. doi: 10.1016/j.yebeh.2015.12.020. Epub 2016 Jan 14.
• [683] Inhibiting CARD11 translation during BCR activation by targeting the eIF4A RNA helicase.Blood. 2014 Dec 11;124(25):3758-67. doi: 10.1182/blood-2014-07-589689. Epub 2014 Oct 15.
• [684] Expression and activity of eIF6 trigger malignant pleural mesothelioma growth in vivo.Oncotarget. 2015 Nov 10;6(35):37471-85. doi: 10.18632/oncotarget.5462.
• [685] The oncogenic role of the ETS transcription factors MEF and ERG.Cell Cycle. 2010 Sep 1;9(17):3457-9. doi: 10.4161/cc.9.17.13000. Epub 2010 Sep 13.
• [686] Selective expression of the transcription elongation factor ELL3 in B cells prior to ELL2 drives proliferation and survival.Mol Immunol. 2017 Nov;91:8-16. doi: 10.1016/j.molimm.2017.08.016. Epub 2017 Aug 31.
• [687] NSE from diffuse large B-cell lymphoma cells regulates macrophage polarization.Cancer Manag Res. 2019 May 17;11:4577-4595. doi: 10.2147/CMAR.S203010. eCollection 2019.
• [688] Rothmund-Thomson syndrome and osteoma cutis in a patient previously diagnosed as COPS syndrome.Eur J Pediatr. 2017 Feb;176(2):279-283. doi: 10.1007/s00431-016-2834-3. Epub 2016 Dec 30.
• [689] Epm2a suppresses tumor growth in an immunocompromised host by inhibiting Wnt signaling.Cancer Cell. 2006 Sep;10(3):179-90. doi: 10.1016/j.ccr.2006.08.008.
• [690] Expression of syncytin in leukemia and lymphoma cells.Leuk Res. 2010 Sep;34(9):1195-202. doi: 10.1016/j.leukres.2010.03.016. Epub 2010 Apr 2.
• [691] Lymphomagenic properties of a HIV p17 variant derived from a splenic marginal zone lymphoma occurred in a HIV-infected patient.Hematol Oncol. 2019 Apr;37(2):176-184. doi: 10.1002/hon.2562. Epub 2018 Nov 6.
• [692] A new monoclonal antibody which binds to the cytoplasm of large cell lymphomas.Hematol Oncol. 1992 Mar-Apr;10(2):95-104. doi: 10.1002/hon.2900100205.
• [693] FcRL4(+) B-cells in salivary glands of primary Sjgren's syndrome patients.J Autoimmun. 2017 Jul;81:90-98. doi: 10.1016/j.jaut.2017.03.012. Epub 2017 Apr 6.
• [694] Pipeline for large-scale microdroplet bisulfite PCR-based sequencing allows the tracking of hepitype evolution in tumors.PLoS One. 2011;6(7):e21332. doi: 10.1371/journal.pone.0021332. Epub 2011 Jul 5.
• [695] Angioimmunoblastic T-cell lymphoma and hypereosinophilic syndrome with FIP1L1/PDGFRA fusion gene effectively treated with imatinib: A case report.Medicine (Baltimore). 2017 Sep;96(36):e8001. doi: 10.1097/MD.0000000000008001.
• [696] Novel flavagline-like compounds with potent Fli-1 inhibitory activity suppress diverse types of leukemia.FEBS J. 2018 Dec;285(24):4631-4645. doi: 10.1111/febs.14690. Epub 2018 Nov 20.
• [697] The role of fibromodulin in cancer pathogenesis: implications for diagnosis and therapy.Cancer Cell Int. 2019 Jun 10;19:157. doi: 10.1186/s12935-019-0870-6. eCollection 2019.
• [698] FOXO4 expression is related to stem cell-like properties and resistance to treatment in diffuse large B-cell lymphoma.Oncotarget. 2017 Jan 10;8(2):2466-2476. doi: 10.18632/oncotarget.13690.
• [699] MicroRNA-376a regulates cell proliferation and apoptosis by targeting forkhead box protein P2 in lymphoma.Oncol Lett. 2018 Sep;16(3):3169-3176. doi: 10.3892/ol.2018.9012. Epub 2018 Jun 22.
• [700] miR-155 regulates HGAL expression and increases lymphoma cell motility.Blood. 2012 Jan 12;119(2):513-20. doi: 10.1182/blood-2011-08-370536. Epub 2011 Nov 16.
• [701] From cytopenia to leukemia: the role of Gfi1 and Gfi1b in blood formation.Blood. 2015 Dec 10;126(24):2561-9. doi: 10.1182/blood-2015-06-655043. Epub 2015 Oct 7.
• [702] NKL homeobox gene activities in B-cell development and lymphomas.PLoS One. 2018 Oct 11;13(10):e0205537. doi: 10.1371/journal.pone.0205537. eCollection 2018.
• [703] Loss of signalling via G13 in germinal centre B-cell-derived lymphoma.Nature. 2014 Dec 11;516(7530):254-8. doi: 10.1038/nature13765. Epub 2014 Sep 28.
• [704] Cooperative STAT/NF-B signaling regulates lymphoma metabolic reprogramming and aberrant GOT2 expression.Nat Commun. 2018 Apr 17;9(1):1514. doi: 10.1038/s41467-018-03803-x.
• [705] Acidosis decreases c-Myc oncogene expression in human lymphoma cells: a role for the proton-sensing G protein-coupled receptor TDAG8.Int J Mol Sci. 2013 Oct 11;14(10):20236-55. doi: 10.3390/ijms141020236.
• [706] Glutathione peroxidase 4 overexpression inhibits ROS-induced cell death in diffuse large B-cell lymphoma.Lab Invest. 2018 May;98(5):609-619. doi: 10.1038/s41374-017-0008-1. Epub 2018 Feb 20.
• [707] Epigenetic control via allosteric regulation of mammalian protein arginine methyltransferases.Proc Natl Acad Sci U S A. 2017 Sep 19;114(38):10101-10106. doi: 10.1073/pnas.1706978114. Epub 2017 Sep 5.
• [708] Heterogeneous epigenetic regulation of HACE1 in Burkitt- Lymphoma-derived cells.Leuk Res. 2017 Sep;60:53-57. doi: 10.1016/j.leukres.2017.06.006. Epub 2017 Jun 16.
• [709] The TP53-Induced Glycolysis and Apoptosis Regulator mediates cooperation between HTLV-1 p30(II) and the retroviral oncoproteins Tax and HBZ and is highly expressed in an in vivo xenograft model of HTLV-1-induced lymphoma.Virology. 2018 Jul;520:39-58. doi: 10.1016/j.virol.2018.05.007. Epub 2018 May 26.
• [710] Adoptive transfer of murine T cells expressing a chimeric-PD1-Dap10 receptor as an immunotherapy for lymphoma.Immunology. 2017 Nov;152(3):472-483. doi: 10.1111/imm.12784. Epub 2017 Jul 27.
• [711] HLA Polymorphism in Algerian Children With Lymphomas.J Pediatr Hematol Oncol. 2015 Nov;37(8):e458-61. doi: 10.1097/MPH.0000000000000419.
• [712] Uncovering the Role of RNA-Binding Protein hnRNP K in B-Cell Lymphomas.J Natl Cancer Inst. 2020 Jan 1;112(1):95-106. doi: 10.1093/jnci/djz078.
• [713] The role of HRK gene in human cancer.Oncogene. 2008 Dec;27 Suppl 1:S105-13. doi: 10.1038/onc.2009.48.
• [714] Polymorphism in the tumor necrosis factor-alpha promotor region and in the heat shock protein 70 genes associated with malignant tumors.Cancer. 1997 Oct 15;80(8):1489-96. doi: 10.1002/(sici)1097-0142(19971015)80:8<1489::aid-cncr17>3.0.co;2-1.
• [715] Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma.Blood. 2017 Jan 26;129(4):473-483. doi: 10.1182/blood-2016-07-729954. Epub 2016 Nov 14.
• [716] IBTK contributes to B-cell lymphomagenesis in E-myc transgenic mice conferring resistance to apoptosis.Cell Death Dis. 2019 Apr 11;10(4):320. doi: 10.1038/s41419-019-1557-6.
• [717] ID3 mutations are recurrent events in double-hit B-cell lymphomas.Anticancer Res. 2013 Nov;33(11):4771-8.
• [718] Expression of IL-34 correlates with macrophage infiltration and prognosis of diffuse large B-cell lymphoma.Clin Transl Immunology. 2019 Aug 13;8(8):e1074. doi: 10.1002/cti2.1074. eCollection 2019.
• [719] Interleukin-9 promotes cell survival and drug resistance in diffuse large B-cell lymphoma.J Exp Clin Cancer Res. 2016 Jul 1;35(1):106. doi: 10.1186/s13046-016-0374-3.
• [720] Establishment and characterization of a novel VEGF-producing HHV-8-unrelated PEL-like lymphoma cell line, OGU1.Eur J Haematol. 2016 Feb;96(2):144-51. doi: 10.1111/ejh.12559. Epub 2015 Apr 21.
• [721] An RNA Aptamer-Based Biomarker Platform Demonstrates High Soluble CD25 Occupancy by IL2 in the Serum of Follicular Lymphoma Patients.Cancer Immunol Res. 2019 Sep;7(9):1511-1522. doi: 10.1158/2326-6066.CIR-18-0821. Epub 2019 Aug 5.
• [722] ISL-1 is overexpressed in non-Hodgkin lymphoma and promotes lymphoma cell proliferation by forming a p-STAT3/p-c-Jun/ISL-1 complex.Mol Cancer. 2014 Jul 29;13:181. doi: 10.1186/1476-4598-13-181.
• [723] The ITM2B (BRI2) gene is a target of BCL6 repression: Implications for lymphomas and neurodegenerative diseases.Biochim Biophys Acta. 2015 May;1852(5):742-8. doi: 10.1016/j.bbadis.2014.12.018. Epub 2014 Dec 31.
• [724] Tip60 is a haplo-insufficient tumour suppressor required for an oncogene-induced DNA damage response.Nature. 2007 Aug 30;448(7157):1063-7. doi: 10.1038/nature06055.
• [725] Pro-apoptotic and antiproliferative activity of human KCNRG, a putative tumor suppressor in 13q14 region.Tumour Biol. 2010 Jan;31(1):33-45. doi: 10.1007/s13277-009-0005-0. Epub 2009 Dec 18.
• [726] Genetic diversity of the KIR/HLA system and susceptibility to hepatitis C virus-related diseases.PLoS One. 2015 Feb 20;10(2):e0117420. doi: 10.1371/journal.pone.0117420. eCollection 2015.
• [727] Mutations in a gene encoding a midbody kelch protein in familial and sporadic classical Hodgkin lymphoma lead to binucleated cells. Proc Natl Acad Sci U S A. 2009 Sep 1;106(35):14920-5. doi: 10.1073/pnas.0904231106. Epub 2009 Aug 12.
• [728] Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified.Haematologica. 2018 Apr;103(4):679-687. doi: 10.3324/haematol.2017.182444. Epub 2018 Jan 5.
• [729] Safety study of culinary-medicinal Royal Sun Agaricus, Agaricus brasiliensis S. Wasser et al. KA21 (higher Basidiomycetes) assessed by prokaryotic as well as eukaryotic systems.Int J Med Mushrooms. 2012;14(2):135-48. doi: 10.1615/intjmedmushr.v14.i2.20.
• [730] Stage-specific expression of Clast6/E3/LAPTM5 during B cell differentiation: elevated expression in human B lymphomas.Int J Oncol. 2003 Feb;22(2):301-4.
• [731] miR-155 Controls Lymphoproliferation in LAT Mutant Mice by Restraining T-Cell Apoptosis via SHIP-1/mTOR and PAK1/FOXO3/BIM Pathways.PLoS One. 2015 Jun 29;10(6):e0131823. doi: 10.1371/journal.pone.0131823. eCollection 2015.
• [732] A gene panel, including LRP12, is frequently hypermethylated in major types of B-cell lymphoma.PLoS One. 2014 Sep 16;9(9):e104249. doi: 10.1371/journal.pone.0104249. eCollection 2014.
• [733] Transcript profiling in peripheral T-cell lymphoma, not otherwise specified, and diffuse large B-cell lymphoma identifies distinct tumor profile signatures.Mol Cancer Ther. 2005 Dec;4(12):1867-79. doi: 10.1158/1535-7163.MCT-05-0146.
• [734] Treatment with mRNA coding for the necroptosis mediator MLKL induces antitumor immunity directed against neo-epitopes.Nat Commun. 2018 Aug 24;9(1):3417. doi: 10.1038/s41467-018-05979-8.
• [735] Different incidence and pattern of p15INK4b and p16INK4a promoter region hypermethylation in Hodgkin's and CD30-Positive non-Hodgkin's lymphomas.Am J Pathol. 2002 Sep;161(3):1007-13. doi: 10.1016/S0002-9440(10)64261-7.
• [736] Mice deficient in MIM expression are predisposed to lymphomagenesis.Oncogene. 2012 Jul 26;31(30):3561-8. doi: 10.1038/onc.2011.509. Epub 2011 Nov 14.
• [737] Multidrug resistance protein expression of adult T-cell leukemia/lymphoma.Leuk Res. 2007 Apr;31(4):465-70. doi: 10.1016/j.leukres.2006.10.012. Epub 2006 Nov 28.
• [738] B-cell activating factor and v-Myc myelocytomatosis viral oncogene homolog (c-Myc) influence progression of chronic lymphocytic leukemia.Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):18956-60. doi: 10.1073/pnas.1013420107. Epub 2010 Oct 18.
• [739] Aberrant expression of napsin A in a subset of malignant lymphomas.Histol Histopathol. 2016 Feb;31(2):213-21. doi: 10.14670/HH-11-669. Epub 2015 Sep 24.
• [740] Unique morphological spectrum of lymphomas in Nijmegen breakage syndrome (NBS) patients with high frequency of consecutive lymphoma formation.J Pathol. 2008 Nov;216(3):337-44. doi: 10.1002/path.2418.
• [741] An NKp30-based chimeric antigen receptor promotes T cell effector functions and antitumor efficacy in vivo.J Immunol. 2012 Sep 1;189(5):2290-9. doi: 10.4049/jimmunol.1103495. Epub 2012 Jul 30.
• [742] The B7 Family Member B7-H6: a New Bane of Tumor.Pathol Oncol Res. 2018 Oct;24(4):717-721. doi: 10.1007/s12253-017-0357-5. Epub 2017 Oct 31.
• [743] Nfe2l3 (Nrf3) deficiency predisposes mice to T-cell lymphoblastic lymphoma.Blood. 2011 Feb 10;117(6):2005-8. doi: 10.1182/blood-2010-02-271460. Epub 2010 Dec 8.
• [744] Small cell lung cancer mimicking lymphoma in CT and 68Ga-DOTA-NOC PET/CT: A case report.Medicine (Baltimore). 2018 Jun;97(25):e11159. doi: 10.1097/MD.0000000000011159.
• [745] Cyclic Cystine-Bridged Peptides from the Marine Sponge Clathria basilana Induce Apoptosis in Tumor Cells and Depolarize the Bacterial Cytoplasmic Membrane.J Nat Prod. 2017 Nov 22;80(11):2941-2952. doi: 10.1021/acs.jnatprod.7b00477. Epub 2017 Nov 2.
• [746] Expression of splice variants of cancer-testis genes ODF3 and ODF4 in the testis of a prostate cancer patient.Genet Mol Res. 2012 Oct 4;11(4):3642-8. doi: 10.4238/2012.October.4.11.
• [747] Collagen prolyl hydroxylase 3 has a tumor suppressive activity in human lung cancer.Exp Cell Res. 2018 Feb 1;363(1):121-128. doi: 10.1016/j.yexcr.2017.12.020. Epub 2017 Dec 23.
• [748] The JAK inhibitor antcin H exhibits direct anticancer activity while enhancing chemotherapy against LMP1-expressed lymphoma.Leuk Lymphoma. 2019 May;60(5):1193-1203. doi: 10.1080/10428194.2018.1512709. Epub 2018 Oct 2.
• [749] A Phase 1 Study to Assess the Relative Bioavailability of Two Capsule Formulations of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma.J Clin Pharmacol. 2018 Jan;58(1):114-121. doi: 10.1002/jcph.987. Epub 2017 Aug 7.
• [750] The prohibitin protein complex promotes mitochondrial stabilization and cell survival in hematologic malignancies.Oncotarget. 2017 Jul 1;8(39):65445-65456. doi: 10.18632/oncotarget.18920. eCollection 2017 Sep 12.
• [751] Reduced expression of the tumor suppressor PHLPP1 enhances the antiapoptotic B-cell receptor signal in chronic lymphocytic leukemia B-cells.Leukemia. 2010 Dec;24(12):2063-71. doi: 10.1038/leu.2010.201. Epub 2010 Sep 23.
• [752] The novel CALM interactor CATS influences the subcellular localization of the leukemogenic fusion protein CALM/AF10.Oncogene. 2006 Jul 6;25(29):4099-109. doi: 10.1038/sj.onc.1209438. Epub 2006 Feb 20.
• [753] Profiling the expression pattern of GPI transamidase complex subunits in human cancer.Mod Pathol. 2008 Aug;21(8):979-91. doi: 10.1038/modpathol.2008.76. Epub 2008 May 16.
• [754] Prep1 (pKnox1)-deficiency leads to spontaneous tumor development in mice and accelerates EmuMyc lymphomagenesis: a tumor suppressor role for Prep1.Mol Oncol. 2010 Apr;4(2):126-34. doi: 10.1016/j.molonc.2010.01.001. Epub 2010 Jan 7.
• [755] Silencing of CKIP-1 promotes tumor proliferation and cell adhesion-mediated drug resistance via regulating AKT activity in non-Hodgkin's lymphoma.Oncol Rep. 2017 Jan;37(1):622-630. doi: 10.3892/or.2016.5233. Epub 2016 Nov 8.
• [756] Transgenic expression of human MGMT blocks the hypersensitivity of PMS2-deficient mice to low dose MNU thymic lymphomagenesis.Carcinogenesis. 1999 Sep;20(9):1667-73. doi: 10.1093/carcin/20.9.1667.
• [757] Germline variation in the 3'-untranslated region of the POU2AF1 gene is associated with susceptibility to lymphoma.Mol Carcinog. 2017 Aug;56(8):1945-1952. doi: 10.1002/mc.22652. Epub 2017 Apr 19.
• [758] Female GADD34 mice develop age-related inflammation and hepatocellular carcinoma.Geriatr Gerontol Int. 2017 Dec;17(12):2593-2601. doi: 10.1111/ggi.13080. Epub 2017 Jun 21.
• [759] Downregulation of PRDM1 promotes cellular invasion and lung cancer metastasis.Tumour Biol. 2017 Apr;39(4):1010428317695929. doi: 10.1177/1010428317695929.
• [760] Spectrum of Atypical Clinical Presentations in Patients with Biallelic PRF1 Missense Mutations.Pediatr Blood Cancer. 2015 Dec;62(12):2094-100. doi: 10.1002/pbc.25646. Epub 2015 Jul 16.
• [761] IFR4/MUM1-positive lymphoma in Waldeyer ring with co-expression of CD5 and CD10.Pediatr Blood Cancer. 2017 Feb;64(2):311-314. doi: 10.1002/pbc.26236. Epub 2016 Sep 12.
• [762] In vivo RNAi screening identifies regulators of actin dynamics as key determinants of lymphoma progression.Nat Genet. 2009 Oct;41(10):1133-7. doi: 10.1038/ng.451. Epub 2009 Sep 27.
• [763] Mutations of a novel human RAD54 homologue, RAD54B, in primary cancer.Oncogene. 1999 Jun 3;18(22):3422-6. doi: 10.1038/sj.onc.1202691.
• [764] CBP/p300 acetyltransferases regulate the expression of NKG2D ligands on tumor cells.Oncogene. 2017 Feb 16;36(7):933-941. doi: 10.1038/onc.2016.259. Epub 2016 Aug 1.
• [765] RAG1/2 induces genomic insertions by mobilizing DNA into RAG1/2-independent breaks.J Exp Med. 2017 Mar 6;214(3):815-831. doi: 10.1084/jem.20161638. Epub 2017 Feb 8.
• [766] A Rapid Embryonic Stem Cell-Based Mouse Model for B-cell Lymphomas Driven by Epstein-Barr Virus Protein LMP1.Cancer Immunol Res. 2015 Jun;3(6):641-9. doi: 10.1158/2326-6066.CIR-15-0058. Epub 2015 May 1.
• [767] An RCOR1 loss-associated gene expression signature identifies a prognostically significant DLBCL subgroup.Blood. 2015 Feb 5;125(6):959-66. doi: 10.1182/blood-2013-06-507152. Epub 2014 Nov 13.
• [768] Interaction between hepatitis C virus core protein and translin protein--a possible molecular mechanism for hepatocellular carcinoma and lymphoma caused by hepatitis C virus.World J Gastroenterol. 2003 Feb;9(2):300-3. doi: 10.3748/wjg.v9.i2.300.
• [769] Alternative and canonical NF-kB pathways DNA-binding hierarchies networks define Hodgkin lymphoma and Non-Hodgkin diffuse large B Cell lymphoma respectively.J Cancer Res Clin Oncol. 2019 Jun;145(6):1437-1448. doi: 10.1007/s00432-019-02909-z. Epub 2019 Apr 2.
• [770] Influence of MTHFR and RFC1 polymorphisms on toxicities during maintenance chemotherapy for childhood acute lymphoblastic leukemia or lymphoma. J Pediatr Hematol Oncol. 2008 May;30(5):347-52.
• [771] R-RAS2 overexpression in tumors of the human central nervous system.Mol Cancer. 2013 Oct 23;12(1):127. doi: 10.1186/1476-4598-12-127.
• [772] Body size and obesity during adulthood, and risk of lympho-haematopoietic cancers: an update of the WCRF-AICR systematic review of published prospective studies.Ann Oncol. 2019 Apr 1;30(4):528-541. doi: 10.1093/annonc/mdz045.
• [773] Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomas.Blood. 2013 Apr 11;121(15):2964-74. doi: 10.1182/blood-2012-08-446096. Epub 2013 Feb 12.
• [774] The role of a newly identified SET domain-containing protein, SETD3, in oncogenesis.Haematologica. 2013 May;98(5):739-43. doi: 10.3324/haematol.2012.066977. Epub 2012 Oct 12.
• [775] Novel mutations in ataxia telangiectasia and AOA2 associated with prolonged survival.J Neurol Sci. 2013 Dec 15;335(1-2):134-8. doi: 10.1016/j.jns.2013.09.014. Epub 2013 Sep 17.
• [776] CREB targets define the gene expression signature of malignancies having reduced levels of the tumor suppressor tristetraprolin.PLoS One. 2014 Dec 26;9(12):e115517. doi: 10.1371/journal.pone.0115517. eCollection 2014.
• [777] Targeting of SMAD5 links microRNA-155 to the TGF-beta pathway and lymphomagenesis.Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):3111-6. doi: 10.1073/pnas.0910667107. Epub 2010 Feb 1.
• [778] Smarcal1 and Zranb3 Protect Replication Forks from Myc-Induced DNA Replication Stress.Cancer Res. 2019 Apr 1;79(7):1612-1623. doi: 10.1158/0008-5472.CAN-18-2705. Epub 2019 Jan 4.
• [779] Epigenetic regulator Smchd1 functions as a tumor suppressor.Cancer Res. 2013 Mar 1;73(5):1591-9. doi: 10.1158/0008-5472.CAN-12-3019. Epub 2012 Dec 26.
• [780] Colorectal cancer DNA methylation marker panel validated with high performance in Non-Hodgkin lymphoma.Epigenetics. 2014 Mar;9(3):428-36. doi: 10.4161/epi.27554. Epub 2013 Dec 20.
• [781] SPIB is a novel prognostic factor in diffuse large B-cell lymphoma that mediates apoptosis via the PI3K-AKT pathway.Cancer Sci. 2016 Sep;107(9):1270-80. doi: 10.1111/cas.13001. Epub 2016 Sep 6.
• [782] Expression of pancreatic secretory trypsin inhibitor gene in human colorectal tumor.Cancer. 1990 Nov 15;66(10):2144-9. doi: 10.1002/1097-0142(19901115)66:10<2144::aid-cncr2820661017>3.0.co;2-#.
• [783] Identification of trypsin-inhibitory site and structure determination of human SPINK2 serine proteinase inhibitor.Proteins. 2009 Oct;77(1):209-19. doi: 10.1002/prot.22432.
• [784] STAT4, TRAF3IP2, IL10, and HCP5 Polymorphisms in Sjgren's Syndrome: Association with Disease Susceptibility and Clinical Aspects.J Immunol Res. 2019 Feb 10;2019:7682827. doi: 10.1155/2019/7682827. eCollection 2019.
• [785] Expression of SSX genes in human tumors.Int J Cancer. 1998 Jul 3;77(1):19-23. doi: 10.1002/(sici)1097-0215(19980703)77:1<19::aid-ijc4>3.0.co;2-2.
• [786] Signal transducer and activator of transcription (STAT)-5: an opportunity for drug development in oncohematology.Oncogene. 2019 Jun;38(24):4657-4668. doi: 10.1038/s41388-019-0752-3. Epub 2019 Feb 19.
• [787] Development of classical Hodgkin's lymphoma in an adult with biallelic STXBP2 mutations.Haematologica. 2013 May;98(5):760-4. doi: 10.3324/haematol.2012.073098. Epub 2012 Oct 25.
• [788] The Oncogenic Potential of SUV39H2: A Comprehensive and Perspective View.J Cancer. 2019 Jan 1;10(3):721-729. doi: 10.7150/jca.28254. eCollection 2019.
• [789] Silencing P2X7 receptor downregulates the expression of TCP-1 involved in lymphoma lymphatic metastasis.Oncotarget. 2015 Dec 8;6(39):42105-17. doi: 10.18632/oncotarget.5870.
• [790] Association between lymphoma prognosis and aberrant methylation of ID4 and ZO-1 in bone marrow and paraffin-embedded lymphoma tissues of treatment-naive patients.Oncol Rep. 2013 Jul;30(1):455-61. doi: 10.3892/or.2013.2450. Epub 2013 May 10.
• [791] Transient responses to NOTCH and TLX1/HOX11 inhibition in T-cell acute lymphoblastic leukemia/lymphoma.PLoS One. 2011 Feb 4;6(2):e16761. doi: 10.1371/journal.pone.0016761.
• [792] Pro-death and pro-survival properties of ouabain in U937 lymphoma derived cells.J Exp Clin Cancer Res. 2012 Nov 15;31(1):95. doi: 10.1186/1756-9966-31-95.
• [793] Abnormal accumulation of human transmembrane (TMEM)-176A and 176B proteins is associated with cancer pathology.Acta Histochem. 2012 Nov;114(7):705-12. doi: 10.1016/j.acthis.2011.12.006. Epub 2012 Jan 12.
• [794] Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types.Int J Cancer. 2004 May 1;109(5):786-92. doi: 10.1002/ijc.20041.
• [795] Need for an improved molecular/genetic classification for CD30+ lymphomas involving the skin.Cancer Control. 2007 Apr;14(2):124-32. doi: 10.1177/107327480701400205.
• [796] Recurrent deletions of the TNFSF7 and TNFSF9 genes in 19p13.3 in diffuse large B-cell and Burkitt lymphomas.Int J Cancer. 2012 Sep 1;131(5):E830-5. doi: 10.1002/ijc.27416. Epub 2012 Jan 31.
• [797] Immunocytochemical p63 expression discriminates between primary cutaneous follicle centre cell and diffuse large B cell lymphoma-leg type, and is of the TAp63 isoform.Histopathology. 2016 Jul;69(1):11-9. doi: 10.1111/his.12855. Epub 2016 Mar 1.
• [798] The Upregulation of TRAF1 Induced by Helicobacter pylori Plays an Antiapoptotic Effect on the Infected Cells.Helicobacter. 2016 Dec;21(6):554-564. doi: 10.1111/hel.12311. Epub 2016 Apr 6.
• [799] Signaling mechanisms of bortezomib in TRAF3-deficient mouse B lymphoma and human multiple myeloma cells.Leuk Res. 2016 Feb;41:85-95. doi: 10.1016/j.leukres.2015.12.005. Epub 2015 Dec 19.
• [800] TREX1 variants in Sjogren's syndrome related lymphomagenesis.Cytokine. 2020 Aug;132:154781. doi: 10.1016/j.cyto.2019.154781. Epub 2019 Jul 18.
• [801] TRIM65 is a potential oncogenic protein via ERK1/2 on Jurkat and Raji cells: A therapeutic target in human lymphoma malignancies.Cell Biol Int. 2018 Nov;42(11):1503-1510. doi: 10.1002/cbin.11035. Epub 2018 Sep 11.
• [802] TRRAP is essential for regulating the accumulation of mutant and wild-type p53 in lymphoma.Blood. 2018 Jun 21;131(25):2789-2802. doi: 10.1182/blood-2017-09-806679. Epub 2018 Apr 13.
• [803] TSPAN33 is a novel marker of activated and malignant B cells.Clin Immunol. 2013 Dec;149(3):388-99. doi: 10.1016/j.clim.2013.08.005. Epub 2013 Aug 15.
• [804] Aberrant localization of apoptosis protease activating factor-1 in lipid raft sub-domains of diffuse large B cell lymphomas.Oncotarget. 2016 Dec 20;7(51):83964-83975. doi: 10.18632/oncotarget.13336.
• [805] A proliferation-inducing ligand mediates follicular lymphoma B-cell proliferation and cyclin D1 expression through phosphatidylinositol 3-kinase-regulated mammalian target of rapamycin activation.Blood. 2009 May 21;113(21):5206-16. doi: 10.1182/blood-2008-09-179762. Epub 2009 Mar 25.
• [806] Gene expression profiling in lymphoma diagnosis and management.Best Pract Res Clin Haematol. 2009 Jun;22(2):191-210. doi: 10.1016/j.beha.2009.05.001.
• [807] HOXC4, HOXC5, and HOXC6 expression in non-Hodgkin's lymphoma: preferential expression of the HOXC5 gene in primary cutaneous anaplastic T-cell and oro-gastrointestinal tract mucosa-associated B-cell lymphomas.Blood. 1997 Nov 15;90(10):4116-25.
• [808] Overexpression of a transcription factor LYL1 induces T- and B-cell lymphoma in mice.Oncogene. 2007 Oct 18;26(48):6937-47. doi: 10.1038/sj.onc.1210494. Epub 2007 May 7.
• [809] Differential expression of the human MIXL1 gene product in non-Hodgkin and Hodgkin lymphomas.Hum Pathol. 2007 Mar;38(3):500-7. doi: 10.1016/j.humpath.2006.09.020.
• [810] Anaplastic plasmacytoma of mouse--establishing parallels between subtypes of mouse and human plasma cell neoplasia.J Pathol. 2010 Jul;221(3):242-7. doi: 10.1002/path.2714.
• [811] Defects of FA/BRCA pathway in lymphoma cell lines.Int J Hematol. 2008 Dec;88(5):543-550. doi: 10.1007/s12185-008-0199-8. Epub 2008 Nov 15.
• [812] The CALM and CALM/AF10 interactor CATS is a marker for proliferation.Mol Oncol. 2008 Dec;2(4):356-67. doi: 10.1016/j.molonc.2008.08.001. Epub 2008 Sep 4.
• [813] Gene amplification and associated loss of 5' regulatory sequences of CoAA in human cancers.Oncogene. 2007 Feb 8;26(6):822-35. doi: 10.1038/sj.onc.1209847. Epub 2006 Jul 31.
• [814] Molecular profiling of CD3-CD4+ T cells from patients with the lymphocytic variant of hypereosinophilic syndrome reveals targeting of growth control pathways.Blood. 2009 Oct 1;114(14):2969-83. doi: 10.1182/blood-2008-08-175091. Epub 2009 Jul 16.
• [815] Expression of sprouty2 inhibits B-cell proliferation and is epigenetically silenced in mouse and human B-cell lymphomas.Blood. 2009 Mar 12;113(11):2478-87. doi: 10.1182/blood-2008-05-156943. Epub 2009 Jan 15.
• [816] Defects of the mismatch repair gene MSH2 are implicated in the development of murine and human lymphoblastic lymphomas and are associated with the aberrant expression of rhombotin-2 (Lmo-2) and Tal-1 (SCL).Blood. 1997 Apr 1;89(7):2276-82.